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ABSTRACT 
 JULIE C. LAUFFENBURGER: Dabigatran and warfarin for stroke prevention in atrial 
fibrillation: Use, switching, and clinical effects following new market entry in real-world patients 
(Under the direction of Gang Fang) 
 
 
 Patients with atrial fibrillation frequently benefit from anticoagulation to prevent stroke 
and systemic embolism. For decades, warfarin was the primary oral anticoagulant option despite 
its narrow therapeutic index requiring monitoring and drug-drug interactions. Dabigatran’s 
recent availability provides practical advantages including no monitoring and fewer interactions; 
however, it lacks a convenient reversal agent for bleeding events. Currently, it is unclear what 
factors have driven anticoagulant utilization since dabigatran’s introduction, and little real-world 
evidence on the agents’ comparative effectiveness and safety is available. The objectives were to 
describe dabigatran and warfarin’s utilization and switching patterns and assess their 
comparative effectiveness and safety. 
  A cohort of non-valvular atrial fibrillation patients  initiating anticoagulation from a 
large US database of commercial and Medicare supplement claims from 2009-2012 was 
extracted. We first examined factors associated with anticoagulant selection using a retrospective 
cohort design and multivariable regression. We then evaluated the effectiveness and safety of 
dabigatran compared with warfarin using multivariable Cox proportional hazards regression and 
propensity score weighting. Finally, we evaluated the clinical effects of switching anticoagulants 
compared with non-switching using a time-varying exposure design and multivariable Cox 
proportional hazards regression. 
 iv 
 
Of the 64,935 patients included in the cohort, 32.5% used dabigatran. Dabigatran users 
were less likely to have high ischemic stroke or bleeding risk or other clinical comorbidities. 
Switching anticoagulation was also less frequent among patients with higher ischemic stroke or 
bleeding risk. Dabigatran was associated with a lower risk of ischemic stroke or venous 
thromboembolism, and no relation was seen between anticoagulant and harmful outcomes 
including bleeding events or acute myocardial infarction. However, dabigatran was also 
associated with a higher risk of gastrointestinal bleeding. Compared with non-switchers, no 
relation was seen between switching anticoagulants and an increased risk of stroke, systemic 
embolism, bleeding events, or myocardial infarction. 
Despite the rapid uptake of dabigatran, these results highlight that patients initiating 
dabigatran were generally healthier than those initiating warfarin. Dabigatran may be considered 
a safe and possibly more effective alternative to warfarin in patients with atrial fibrillation; 
despite encouraging results from the observed lack of increased adverse outcomes from 
switching anticoagulants, caution is still recommended. 
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CHAPTER 1:  INTRODUCTION 
 
1.1.  OVERVIEW 
Atrial fibrillation (AF), a heartbeat irregularity, is typically managed by oral 
anticoagulants to prevent clot formation in the upper atria chambers of the heart when blood is 
pumped inefficiently.
1
 To prevent ischemic stroke and thromboembolism in atrial fibrillation, 
current clinical guidelines support the use of warfarin, a Vitamin K antagonist which has been 
available since the 1950s; however, recently newly-approved oral anticoagulants (known as 
“novel oral anticoagulants” or “target-specific oral anticoagulants”) have been recommended as 
alternatives and as even first-line options.
2-5
 Use of warfarin in atrial fibrillation has been shown 
to prevent up to 68% of ischemic stroke and lead to a significant reduction in mortality risk.
6,7
 
Despite its effectiveness, warfarin has a narrow therapeutic index, leading to some safety issues 
and potential drug-drug interactions, requiring frequent monitoring.
8-10
 Initiation of warfarin and 
subsequent medication adherence, the extent to which patients take their medications as 
prescribed, to warfarin has also been shown to be low, possibly because of the high perceived 
risk of bleeding.
11,12
  Maintaining patients on chronic warfarin therapy has its challenges, and 
alternatives to warfarin have been sought for easier monitoring and management.  
Since 2010, newer oral anticoagulants have emerged as potential treatment options for 
atrial fibrillation. Dabigatran etexilate
13,14
, a direct thrombin inhibitor that entered the US market 
in October 2010, has shown superior or similar efficacy in stroke prevention over warfarin in 
treatment naïve patients with AF in randomized-controlled clinical trials, depending on the dose 
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studied.
14-16
 Moreover, dabigatran requires less frequent monitoring, may have fewer drug-drug 
interactions, and may be easier for patients to manage.
17,18
 However, dabigatran has also been 
thought lead to higher risk of dyspepsia, bleeding, and myocardial infarction than warfarin.
19
 
Uncertainty also remains about its relative safety, because, unlike warfarin, dabigatran lacks a 
direct reversal agent in the event of bleeding complications.
20
 Regardless, the utilization and 
clinical effectiveness of dabigatran in the management of atrial fibrillation compared with 
warfarin is unclear in real-world clinical practice, despite current clinical guidelines offering 
dabigatran as a possible anticoagulant alternative to warfarin.  
First and foremost, to examine the comparative effectiveness of anticoagulants 
necessitates the understanding of factors associated with the choice of a particular treatment, 
especially new pharmaceuticals. If certain characteristics are significantly associated with use of 
one therapy versus another, the apparent comparative effectiveness could be affected, 
particularly if these characteristics cannot be fully measured. Secondly, optimal treatment 
selection may differ in specific patient populations; understanding the risk of clinical outcomes 
among subgroups can help patients and providers in decision making when managing AF. The 
factors associated with the uptake of novel pharmaceuticals have been studied in other 
contexts.
21-23
 Certain providers have been shown to be more likely to prescribe therapies with a 
new mechanism of action or those used for chronic illnesses; both of these situations apply to 
dabigatran.
24
  
Switching to a new medication may also carry an increased risk of therapeutic failure and 
toxicity
25
, especially for a therapy with a narrow therapeutic window, such as warfarin. Early 
case reports of patients switching from dabigatran to warfarin suggest an overall increased risk of 
bleeding on dabigatran.
26,27
 Yet, the clinical effects of switching between warfarin and an 
anticoagulant of a different drug class are still somewhat unclear, as most guidelines have 
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recommended that patients stabilized on warfarin generally should remain on warfarin.
5
 Expert 
opinion suggests that if switching is necessary, additional monitoring is warranted.
28
 By 
comparison, even switching between warfarin product formulations (e.g., brand to generic) has 
been studied and is thought to be potentially problematic.
28-32
 Studies have suggested that 
switching between warfarin formulations may be possible without avoiding any major adverse 
consequences while others have found a slight increased risk of bleeding.
31-33
  Given this 
underlying controversy, it is possible that switching between entirely different anticoagulants 
may lead to an increased risk of adverse events, especially in the absence of validated dosing 
conversion standards between anticoagulants. Regardless, there is still minimal evidence 
regarding the factors and consequences associated with switching between warfarin and a 
different anticoagulant (or vice versa), particularly among patients in the US.
34,35
 
 
1.2.  SIGNIFICANCE AND INNOVATION 
More than 460,000 individuals in the United States are newly-diagnosed with AF 
annually. Meanwhile, AF is only increasing in prevalence and incidence as the population ages.
36
 
An estimated $26 billion dollars is spent by the US health care system annually on the 
management of AF.
37
 As the use and effects of dabigatran in the management of atrial fibrillation 
are unknown outside of small clinical trials with limited patient diversity, further examination of 
possible clinical and safety effects is needed. Optimizing anticoagulation in atrial fibrillation is a 
critical public health need. 
Understanding the factors associated with the use of anticoagulants may also help further 
future patient-centered research by examining areas where treatment effect heterogeneity may 
exist. Comparative effectiveness research has also been thought to be affected by changing 
patterns of use in newly-launched therapies.
38,39
 While the factors associated with use of 
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dabigatran versus warfarin for anticoagulation management are still unclear, particularly in the 
US, some limited evidence is suggesting some channeling away from dabigatran for patients 
with higher comorbidity burden.
40,41
 
Furthermore, the effectiveness and safety of dabigatran compared with warfarin in AF 
has not been studied extensively outside of randomized-clinical trials (RCTs) or meta-analyses of 
these RCTs. Concerns have been raised about an increased excess risk of bleeding and 
myocardial infarction in patients with AF treated with dabigatran, but once adjusted for renal 
impairment, dabigatran may not carry the same risk.
42,43
 Moreover, the Food and Drug 
Administration (FDA) approved dabigatran at doses of 150mg or 75mg (renally-adjusted) twice 
daily for AF; however, dabigatran has not been studied at the 75mg dose – either in RCTs or 
observational studies.
43
 Given the potential for many patients being placed on this dose, using 
secondary data from real-world settings can provide additional evidence for this previously 
unstudied strength.  
Moreover, the introduction of these new anticoagulants may carry increased risks of 
bleeding or ischemic stroke and have implications for patients and providers in the management 
of transitioning patients from warfarin to dabigatran. In practice, many patients may not be 
treatment-naïve to anticoagulants, and the actual effectiveness and safety of transitioning AF 
patients between drug products should be examined. The clinical effects of switching between 
warfarin to an entire different drug product in AF patients in the period following the medication 
transition is still largely unclear, and switching from dabigatran to warfarin is even less studied. 
The goal of this study is to investigate the factors associated with new use and switching 
between anticoagulants, comparative effectiveness of new use of anticoagulants, and the clinical 
effects of switching anticoagulants following new market entry of dabigatran. The contribution 
of the proposed research is expected to help inform patients, clinicians, researchers, and third-
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party payers of the real-world utilization, comparative effectiveness and safety of dabigatran 
compared to warfarin, to help improve clinical practice. Because of the increasing prevalence of 
AF and the rapid introduction of new anticoagulants, understanding their comparative 
effectiveness and safety is of imperative importance. 
 
1.3.  SPECIFIC AIMS AND HYPOTHESES 
Specific Aim #1: Assess and investigate patient factors associated with new use of either 
warfarin or dabigatran and switching between anticoagulants in patients with atrial fibrillation. 
Hypothesis 1: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will not 
differ between new users of warfarin compared with dabigatran.  
Hypothesis 2: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will not 
differ between new users who switch anticoagulants within 12 months compared with those who 
do not switch. 
Proposed contribution to the literature: This aim is designed to describe the clinical and 
demographic characteristics associated with use of anticoagulants in the setting of 
dabigatran market introduction while focusing on ischemic stroke and bleeding risk 
predictions. Because new users are by definition naïve to anticoagulation, individuals 
using warfarin therapy post-dabigatran approval may be markedly different than those 
using dabigatran. Previous users of warfarin who switched to dabigatran post-approval 
may be those more likely to have had adverse events, but these characteristics have not 
been studied. Examining for potential differences may lend additional insight into real-
world drug utilization patterns. 
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Specific Aim #2: Investigate the comparative clinical outcomes (risk of harm and clinical 
effectiveness) following new use of either warfarin or dabigatran, adjusting for baseline patient 
factors. 
3.6.3.1 Hypothesis 
Hypothesis 3: There are no significant differences in the risk of clinical effectiveness 
outcomes or harm outcomes or acute myocardial infarction in new users of warfarin 
compared with users of dabigatran. 
Proposed contribution to the literature: The comparative effectiveness and safety of 
dabigatran versus warfarin have not yet been examined outside of RCTs for newly-
initiating patients. By examining clinical effectiveness outcomes (such as ischemic stroke 
or venous thromboembolism), safety outcomes (such as bleeding events) and acute 
myocardial infarction, this research is expected to provide insights on real-world 
outcomes to inform clinical practice. 
 
Specific Aim #3: Explore the comparative clinical outcomes (risk of harm and clinical 
effectiveness) of switching from warfarin to dabigatran or dabigatran to warfarin compared with 
non-switchers, adjusting for patient clinical and demographic factors. 
Hypothesis 4: Switching from warfarin to dabigatran will not be associated with increased risk of 
harm or clinical effectiveness outcomes compared with those who remain on warfarin. 
Hypothesis 5: Switching from dabigatran to warfarin will not be associated with an increased 
risk of harm or clinical effectiveness outcomes compared with those who remain on dabigatran. 
Proposed Contribution to the Literature: Because many warfarin patients may not be 
treatment-naïve and may have different clinical risk profiles than new users, examining 
the clinical effects of switching oral anticoagulants would provide additional insight on 
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the role of dabigatran post-approval. Said another way, the comparative effectiveness and 
safety of switching anticoagulants may differ than initiating therapy for the first time. 
 
1.4. SUMMARY 
Retrospective, observational examination of the use and outcomes of dabigatran 
compared with warfarin will allow for understanding the generalizability of findings from RCTs 
to patients in the US health care system. Previous research has been narrowly focused on specific 
patient populations due to limitations in randomized-controlled designs, such as small sample 
sizes, restrictive inclusion and exclusion criteria, and the inability to measure real-world 
utilization. Understanding the utilization of each drug in patients with atrial fibrillation may 
allow a better approach to managing such patients.  
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CHAPTER 2: LITERATURE REVIEW 
 
 The following chapter outlines the background of atrial fibrillation (AF) as follows: how 
AF is diagnosed, risk factors for developing AF and outcomes of atrial fibrillation to explain 
which types of AF will be examined in this research. The pharmacologic and non-pharmacologic 
management of AF is also discussed through published randomized-controlled trials (RCTs), 
observational studies of anticoagulation use to prevent ischemic stroke, and recent guideline 
recommendations. These findings will be used to outline which dependent variables, covariates 
and potential confounders will need to be measured as part of this research in Chapter 3. Any 
published literature about the uptake of dabigatran is also discussed, along with controversies 
which currently exist in using dabigatran for AF to highlight the types of studies which have 
already been conducted and underscore what knowledge gaps currently exist which this research 
will help address. 
 
2.1.  ATRIAL FIBRILLATION 
2.1.1. Definition and diagnosis 
 Atrial fibrillation, the most common arrhythmia seen clinically, is characterized by 
irregular electrical impulses which generate irregular heartbeats.
44
 AF may be discovered by 
measuring a pulse on clinical exam, but clinicians generally confirm AF using an 
electrocardiogram (ECG).
45
 On the ECG, the replacement of consistent P waves with rapid 
oscillations or fibrillatory waves of irregular, frequently rapid ventricular responses identifies an 
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AF diagnosis.
3,46
 Pathogenically, AF is initiated by a “trigger”, an abnormal automaticity arising 
from non-cardiac sites, including most commonly pulmonary veins, but also other venous sites 
or autonomic ganglia.
47
 While the exact mechanism causing potential “triggers” is unknown, 
these automaticities may eventually lead to atrial remodeling, causing a permanent change in 
atrial function or structure.
48
 Correspondingly, AF may be considered reversible or irreversible, 
depending on the atrial “substrate” etiology, other electrophysiological factors, and other clinical 
conditions. The goal of many treatments for AF is to prevent triggers and control this atrial 
modeling – to ultimately reduce the likelihood of adverse outcomes.46  
Major clinical guidelines have generally recognized four different classifications of AF: 
first detected AF, paroxysmal AF, persistent AF and permanent AF.
3,46,49
 First detected AF is 
often characterized by only one diagnosed episode. If the first detected AF terminates 
spontaneously but a second episode occurs, then the patient is considered to have paroxysmal 
AF, whereby most cases are still short and self-limiting. However, if the paroxysmal AF episode 
is sustained longer than 7 days, then the patient is classified as having persistent AF, which 
generally requires cardioversion to terminate. If a patient has undergone cardioversion 
unsuccessfully or is not a candidate for one, then the patient is considered to have permanent 
AF.
49
 
In addition to the above definitions, AF has also been classified by clinical guidelines as 
lone atrial fibrillation, indicating the absence of other clinical findings or other cardiovascular 
disease, non-valvular AF, whereby AF occurs in the absence of other mitral valve disease or 
prosthetic heart valves, and secondary AF, in which AF occurs secondarily from another primary 
condition including acute myocardial infarction, previous surgery, pulmonary embolism, 
pneumonia, hyperthyroidism or other pulmonary disease.
49
 AF etiology may also differ broadly 
between those with primary AF versus secondary AF. Thus, many studies incorporate baseline 
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factors prior to AF diagnosis when examining treatment outcomes or study those patients with 
primary AF or those patients with non-reversible causes of AF.
45,46
 For instance, long-term 
treatment goals of AF may differ when patients develop AF post-operatively versus those 
without any acute perturbations or illness. When a patient has 2 or more episodes, regardless of 
classification, the patient is considered to have recurrent AF.
46
  
While these categories are not considered to be mutually exclusive, the duration of AF 
seems to be particularly important in determining the management for AF. Pharmacologic or 
non-pharmacologic management is not considered to clinically change the classification of a 
patient’s AF, though in some cases the AF episodes may terminate permanently.44,49 Clinicians 
can often diagnose AF within a single inpatient or outpatient encounter, where thyroid, renal, and 
hepatic functions are also measured as part of the evaluation.
46,50
 As will be discussed in later 
sections, anticoagulation is typically reserved for cases of persistent, permanent, or recurrent AF, 
while dabigatran specifically is indicated by the FDA for non-valvular AF only.
3,4
 Thus, the 
proposed research will focus on patients with irreversible persistent or permanent non-valvular 
AF classifications.  
By comparison, atrial flutter, may occur via similar mechanisms, but is pathogenically 
and prognostically different even though the atrial fibrillation and atrial flutter may convert back 
and forth to each other.
3,4,46
 Atrial flutter is usually distinguishable from atrial fibrillation based 
ECG patterns and is often not treated indefinitely with anticoagulation. For this reason, atrial 
flutter will not be examined in the context of the proposed research. 
 
2.1.2. Epidemiology, costs, and quality of life 
Developing atrial fibrillation is associated with an increased risk of ischemic stroke and 
thromboembolism through emboli from the atria.
1
 AF primarily affects middle aged adults and 
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older. Thought to impact 3 million Americans, more than 460,000 individuals are newly-
diagnosed with AF annually.
36
 This number is only expected to grow as the population ages. The 
lifetime risk is 1 in 4 for persons over the age of 40 years in the United States, and the median 
age of AF patients is thought to be about 75 years.  
Managing atrial fibrillation can also be expensive and burdensome to individuals. The US 
health care system spends an estimated $26 billion dollars annually on care related to AF.
37
 One 
study found that approximately 350,000 hospitalizations, 5 million office visits, and 276,000 
emergency room visits are annually attributable to AF and its complications.
51
 Having atrial 
fibrillation and developing one of its complications can also lead to a decreased quality of life. 
Measured in quality-adjusted life-years [QALYs], AF can decrease quality of life by up to 
20%.
52
 Moreover, ischemic stroke, a complication of AF and a main reason for the use of 
anticoagulation in AF, results in estimated QALYs of 0.87, 0.68, and 0.52 for major ischemic 
stroke, moderate ischemic stroke, and minor ischemic stroke, respectively, compared with a 
QALY of 1.0 for those in perfect health.
53
 
 
2.1.3. Risk factors 
A number of cardiovascular risk factors have been associated with the development of 
atrial fibrillation. Commonly-cited cardiovascular risk factors include hypertension, valvular 
disease, coronary artery disease, cardiomyopathy/heart failure, congenital heart disease, 
myocardial infarction, post-surgical complications, pulmonary embolism, and use of a 
pacemaker.
54,55
 Of these, congestive heart failure (CHF), hypertension, valvular disease, and 
previous myocardial infarction appear to be the most studied risk factors. CHF has been 
associated with odds ratios of 4.5 in men and 5.9 in women compared with patients without 
CHF, suggesting a vastly increased likelihood of developing AF with CHF.
50
 Valvular disease 
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has been associated with odds ratios of 1.8 in men and 3.4 in women, while previous myocardial 
infarction has also been shown to increase the risk of developing AF by 40%.
50
 Concomitant 
hypertension increases the AF risk by approximately 50% compared with those without 
hypertension.
50
 Because of its sheer prevalence, hypertension is thought to contribute to a greater 
AF burden than any other risk factor.
56
 
However, some patients with AF have no underlying cardiovascular disease – in fact, as 
many as 12% of all diagnosed AF patients have no identifiable history of cardiovascular disease. 
45,57
 Published literature has identified diabetes mellitus, hyperthyroidism, chronic lung disease, 
chronic kidney disease, alcohol withdrawal, pharmacologic agents (e.g., stimulants, digoxin 
toxicity, and illicit drugs), smoking, excessive physical exertion, and recent surgery as 
commonly-cited non-cardiovascular causes contributing to AF.
54,55,58
  Though not considered to 
be independent causal factors, male sex, elevated inflammatory markers, advanced age, sleep 
apnea, and obesity have also been thought to increase the likelihood of developing AF.
57
 The 
odds ratio of developing AF has been shown to be 2.1 for men and 2.2 for women for each 
additional decade of life.
50
 Having diabetes mellitus doubly increases one’s risk, with differences 
in risks between sexes. Men have a 1.5 times the likelihood of developing AF compared with 
women.
50,56
 In addition, obesity and smoking are associated with a 50%and 40% greater risk of 
AF, respectively.
59
  
While many risk factors for AF have been elucidated, some recent efforts have focused 
on identifying additional risk factors. Some patients with AF have none of the aforementioned 
risk factors. Approximately 30-45% of cases of paroxysmal AF and 20-25% of cases of 
persistent AF occur in patients without underlying disease (e.g., “lone AF”).45 As a result, 
researchers are continuing to search for other underlying reasons for developing AF. 
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2.1.4. Outcomes 
Having atrial fibrillation is primarily associated with an increased risk of systemic 
embolism leading to ischemic stroke. While less common due to the physiologic nature of 
developing acute myocardial infarction (AMI), atrial fibrillation may be associated with an 
increased risk of AMI. Congestive heart failure (CHF) is also thought to be exacerbated by AF, 
due to the increased potential for clot formation in general.
60,61
 While AF is most often 
associated with the aforementioned cardiovascular causes, AF may also lead to a significantly 
increased risk of hyperthyroidism
54
  and dementia
62
. Studies have also shown associations with 
increased risk of mortality through multiple intermediate outcomes, including ischemic stroke, 
congestive heart failure, and myocardial infarction.
47,63
 In particular, the mortality rate of AF 
patients has been estimated to be twice that of patients with normal sinus rhythm.
60
 These 
outcomes will be discussed further in subsequent sections. 
 
2.1.4.1. Systemic Embolism/Ischemic Stroke 
One of the most serious adverse complications of AF is systemic thromboembolism 
leading to ischemic stroke, which is a distinct consequence from either deep vein thrombosis 
(DVT) or pulmonary embolism (PE). While treatments for AF are similar for these other embolic 
conditions, AF itself mechanistically does not lead to an increased risk of either DVT or PE, 
because these clots form in different locations than the atria.
64
 This will be discussed more in the 
management section below. 
Atrial fibrillation increases the risk of developing ischemic stroke, mechanistically 
occurring through blood vessel obstruction to the brain. The rate of ischemic stroke among 
patients with non-valvular AF averages approximately 5% per year, which is thought to be 2 to 7 
times that of the general US population.
7
 In fact, 1 out of every 6 ischemic strokes in the US 
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occurs in patients with AF.
65
 Compared with those with normal sinus rhythm, patients with AF 
have at least twice the increased risk of developing systemic embolism than those without AF – 
independent of other cardiac risk factors for AF.
6
  
 In patients with non-valvular atrial fibrillation, common risk factors for developing 
ischemic stroke also include: congestive heart failure or ejection fraction ≤35%, hypertension, 
advanced age, diabetes, stroke, transient ischemic attack (TIA), or systemic emboli.
36,44
 In 
patients with AF, prior stroke or TIA has been shown to be the strongest independent factor in 
developing ischemic stroke (Relative Risk [RR]: 3.0) in patients with non-valvular AF.
46
 
Diabetes mellitus significantly increases the risk of ischemic stroke and systemic embolism (RR: 
1.7). By comparison, hypertension (RR: 1.6), heart failure (RR: 1.4), and advanced age (RR: 1.4) 
can also significantly increase the risk of systemic embolism.
46
 An AF event lasting greater than 
5.5 hours on any given day in the last 30 days has also been associated with a 2-fold increase in 
the risk of thromboembolism.
66
 While the risk of embolic stroke in AF can also be enhanced by 
other AF risk factors, the risk is higher in patients with AF relative to other causes. Worse, 
ischemic stroke may spontaneously devolve into conditions leading even to death.
6
 The risk of 
ischemic stroke also increases with age, as demonstrated by the Framingham Heart Study. In this 
study, the annual risk of stroke attributable to AF increased from 1.5% in those 50-59 years to 
23.5% in those aged 80-89 years.
47,60
 Age has also been shown to be a modifier of the 
relationship between hypertension and female gender with ischemic stroke, again increasing the 
risk of ischemic stroke in these individuals.
47
  
 
2.1.4.2. Congestive heart failure 
 Another serious complication of AF is the development of or worsening of CHF. 
Mechanistically, AF can disrupt cardiac contractility, exacerbating congestive heart failure.
60
 As 
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a result, AF can lead to tachycardia-induced heart failure (HF). The co-occurrence of AF and HF 
has been shown to be increasing in incidence and consequence in the population, especially 
among older adults.
67
  In fact, as many as 39.7% of hospitalized CHF patients had a history of 
AF.
61
 The proportion of heart failure with concomitant AF has been shown to increase over time 
from 1995 to 2004. The prognosis in AF and CHF together is also thought to be grim.
67
 The 
conditions’ co-occurrence also been shown to reduce survival and decrease health-related 
quality-of-life.
67-69
 Patients with HF and AF together are at an increased risk of in-hospital and 
post-discharge mortality.
61
 Consequently, guidelines suggest taking co-occurrence of CHF into 
consideration when treating AF patients, but anticoagulation management is unlikely to have any 
major beneficial effect on this condition.
67
 
 
2.1.4.3. Acute myocardial infarction  
While less-commonly considered a direct outcome of AF, patients with newly-diagnosed 
atrial fibrillation are thought to be especially prone to AMI, possibly through excess cardiac 
demand.
70
 New-onset atrial fibrillation may increase oxygen demand over the short term, 
potentially explaining the increased propensity to develop AMI.
70
 The  resulting irregular heart 
rhythms may also further hamper coronary circulation and left ventricular function or lead to 
severe ventricular tachyarrthymias.
71,72
 Concomitant AF diagnoses have been difficult to 
quantify, but studies have reported that 2.3-21.0% of patients experiencing AMI also had a 
concomitant AF diagnosis. 
72
  One study found that AF was newly-diagnosed within 2 weeks 
prior to 7.1% of index AMI hospitalizations, which was higher than expected. 
70
  
In addition, patients with AF developing AMI appear to have a different risk profile than 
general patients experiencing AMI. Patients with atrial fibrillation experiencing AMI are more 
likely to be of advanced age, produce heart failure symptoms, increased heart rate upon AMI 
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admission, and have left ventricular dysfunction compared with those without AF.
69,72
 
Guidelines recommend accounting for risk of AMI during treatment for the prevention of 
ischemic stroke in atrial fibrillation.
46,73
 On the other hand, despite the possible cardiac 
worsening from AF, anticoagulation treatment for stroke prevention may have beneficial a 
secondary effects in providing overall emboli prevention advantageous to reducing AMI risk.
74
 
Thus, risk of AMI should be considered when considering management options for AF. 
 
2.2. MANAGEMENT OF ATRIAL FIBRILLATION 
2.2.1. Overview 
Management of AF patients usually involves a 3-pronged approach: 1) prevention of 
thromboembolism; 2) rate control; and 3) consideration of rhythm control.
44,46
 The strategy for 
managing AF primarily includes therapies to prevent thromboembolism and other related 
complications, such as ischemic stroke or death, as rate and rhythm control alone will not 
decrease these risks. 
44
The rate control strategies often include management of the ventricular 
rate without regard to efforts to maintain regular sinus rhythm. The goal of rhythm control 
therapies is to restore or maintain sinus rhythm itself based on severity of symptoms.
45
  
Regardless of strategy, pharmacologic therapies usually do not fully correct the 
underlying rhythm disorder, but are intended to reduce the likelihood of adverse outcomes.
46
 
Beyond these strategies, in managing AF, electrical cardioversion is often considered to attempt 
to restore sinus rhythm by “reseting” the heart to a normal rhythm.44,75 Patient selection for 
cardioversion depends on several factors including: type, severity and duration of AF, 
concomitant cardiovascular and non-cardiovascular conditions, patient age, treatment goals, and 
available treatment options.
44
 Ultimately, catheter ablations may be considered when 
pharmacologic strategies or electrical cardioversion are either ineffective or contraindicated.
76
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These other therapies and strategies used for AF are discussed because they will help 
guide covariate selection for Chapter 3. These covariates will be used to control potential 
confounders during the study of anticoagulation effectiveness and safety. Because rate control is 
generally regarded first as a management option for AF, it is discussed first in this overview, 
followed by a discussion of rate versus rhythm control and anticoagulation management. All of 
these approaches in AF will be discussed more thoroughly in subsequent sections. 
 
2.2.2. Rate control strategies 
Initial treatment of atrial fibrillation is usually directed at controlling ventricular heart 
rate. Evidence-based rate control strategies include the use of either digoxin, a beta-blocker, or a 
calcium channel blocker (particularly a non-dihydropyridine such as diltiazem and verapamil).
44
 
These therapies are recommended for patients with persistent or permanent AF.
44
 Digoxin can be 
effective but is now considered a second-line agent, especially in patients with concomitant heart 
failure, left ventricular dysfunction or sedentary individuals.
44,77
 Factors favoring rate control 
strategy alone over rhythm control include patients with less symptomatic AF or concomitant 
hypertension, while the presence of concomitant systolic dysfunction (heart failure) and potential 
for adverse effects would hinder a preference for rate control.
55, 44
 Rate control strategies are 
usually continued indefinitely or until cardioversion is successful. 
 
2.2.3. Rate vs. rhythm control 
Clinical guidelines recommend rate control as the first-line strategy especially in older 
adults with concomitant heart conditions.
45,46
 However, published studies have found conflicting 
results.
55
 The RACE (Rate Control vs. Electrical cardioversion for persistent atrial fibrillation) 
study found no differences in rate control versus rhythm control for all adverse outcomes and 
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mortality.
75
 The AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) 
study also found no differences in the rate of ischemic stroke between patients assigned rate 
versus rhythm control. However, overall mortality (26.7% vs. 25.9%, p=0.08) and frequency of 
hospitalizations were higher among those assigned rhythm control.
78
 When stratifying on age, 
older adults were found to have a significantly higher mortality burden in those using rhythm 
control strategies compared with rate control strategies.
78
 However, a recent population-based 
study found that rhythm control was associated with a lower rate of ischemic stroke compared 
with rate control (Hazard Ratio [HR]: 0.80, 95% CI: 0.74-0.87).
77
 Considering patient quality of 
life, patients have reported no differences in quality of life in rate versus rhythm control 
strategies.
75,79
  
 
2.2.4. Rhythm control strategies  
Once the ventricular rate is controlled, restoration of an appropriate sinus rhythm is the 
next AF management goal.
44
 In patients with newly-diagnosed atrial fibrillation, restoration of 
sinus rhythm can be considered immediately in patients experiencing symptoms of AF, such as 
shortness of breath or fatigue. However, rhythm control strategies have not demonstrated long-
term benefits on reducing mortality or ischemic stroke risk. Furthermore, anticoagulation for 
ischemic stroke prevention and rate control therapies are still generally required. 
 
2.2.4.1 Electrical Cardioversion 
Direct-current cardioversion can be considered a treatment choice to restore sinus 
rhythm, especially if within 48 hours of onset of the AF episode. If the 48-hour window has 
passed, a transesophageal echocardiography may be ordered to ensure no emboli formation and 
then cardioversion can be performed. Regardless of specific strategy, anticoagulation is 
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recommended for at least 4 weeks after cardioversion, depending on whether the causation of AF 
is considered to be reversible or irreversible. Guidelines also recommend vigilance for 
thromboemboli immediately following cardioversion. In addition to an increased risk of 
embolism from the AF, cardioversion itself can also increase embolism risk, but occurrence is 
almost always within the first 3-10 days following the procedure.
44
 
 
2.2.4.2 Role of Anti-arrhythmic therapies 
 Pharmacologic rhythmic control therapies can be considered as chemical cardioversion, 
especially in younger adults, those with paroxysmal lone AF, newly-detected AF and those 
currently not preferred for electrical cardioversion.
55
 However, medication strategies are thought 
to be less effective than electrical cardioversion. Ibutilide is the most commonly used 
antiarrythmic drug to emergently restore heart rhythm. Once adequate heart rhythm has been 
restored, pharmacologic therapies may also be used to maintain normal rhythm.
46
 These 
therapies include flecanide, amiodarone, dronedarone, sotalol, propafenone and dofetilide, and 
the choice of therapy typically depends on presence of concomitant heart conditions such as CHF 
and coronary disease.  Pharmacologic cardioversion is usually continued indefinitely until 
clinical need for discontinuation due to adverse effects or clinical need subsides. As a second-
line option in the event of antiarrhythmic drug failure, catheter ablation is often considered. 
 
2.2.4.3 Ablation measures 
Other ablation strategies are considered as possible curative measures. Radiofrequency 
catheter ablation (RFCA) or pulmonary vein isolation are recommended as treatment options 
particularly in patients with recurrent AF or patients not able to tolerate antiarrhythmic therapies. 
Catheter ablation is thought to better reduce AF recurrence compared with antiarrhythmics with 
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one meta-analysis finding a 23% recurrence after RFCA versus a 77% recurrence with 
therapies.
80
 Another meta-analysis found that RCFA significantly inhibited recurrence of AF 
(RR: 0.27; 95% CI: 0.18, 0.41) but with limited effect on reducing mortality (RR: 0.50, 95% CI: 
0.04-5.65), complications (e.g., ischemic stroke) (RR: 1.01, 95% CI: 0.18-5.68), or death from 
thromboembolic events (RR: 3.04, 95% CI: 0.13-73.43).
76
  
Ablation of the AV node or accessory pathway to control heart rate appears to be 
warranted when pharmacological therapy is insufficient or associated with undue adverse effects. 
However, caution has been suggested in patients of advanced age (≥ 80 years).81 While discussed 
more broadly in subsequent sections, anticoagulation may be used to manage patients either post-
electrical conversion or post-ablation until successful restoration of sinus rhythm is 
demonstrated.
48
 Two recent studies examined the comparative incidence of bleeding 
complications in the first week following RFCA in patients using dabigatran and warfarin, 
finding no differences in bleeding risk, ischemic strokes, TIAs or emboli.
82,83
 Future research is 
warranted in this area. 
 
2.2.5. Overview: Antithrombotic therapies 
Regardless of rhythm or rate control strategy, guidelines recommend the use of an oral 
antithrombotic agent in patients with AF to prevent ischemic stroke, except for patients with lone 
AF or contraindications.
48
 Oral antithrombotic agents consist of two therapy classes: antiplatelets 
(e.g., aspirin) and oral anticoagulants (OACs) (e.g., warfarin or dabigatran). When prescribing a 
therapy, clinicians are largely recommended to weigh the benefit of preventing emboli versus the 
risks of bleeding from the therapies using stroke and bleeding clinical prediction risk scores.
1,45
 
More detail on these clinical prediction scores will be provided in subsequent sections.  
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2.2.5.1. Antiplatelet therapy 
Antiplatelet therapies examined for the prevention of ischemic stroke in atrial fibrillation 
have primarily consisted of two medications: aspirin and clopidogrel. Evidence from a widely-
disseminated meta-analysis suggested that aspirin reduces the risk of ischemic stroke by 22% 
(95% CI: 2%-38%).
84
 The absolute risk reductions were 1.5% per year for primary prevention 
and 2.5% per year for secondary prevention of ischemic stroke.
84
 Another meta-analysis found a 
34% reduced likelihood of ischemic stroke in patients with atrial fibrillation using aspirin 
compared with no therapy (RR: 0.66, 95% CI: 0.44-0.88).
85
 Dual antiplatelet therapy with 
clopidogrel has seen mixed results.
4,86-88
 The ACTIVE W Trial (The Atrial Fibrillation 
Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) found that anticoagulant 
therapy was statistically superior to dual antiplatelet therapy with aspirin and clopidogrel in 
preventing ischemic stroke in patients with AF (RR: 0.56, 95% CI: 0.39-0.82).
87
 Among patients 
deemed inappropriate for anticoagulation, another study found a decreased ischemic stroke risk 
(RR: 0.72, 95% CI: 0.61-0.85) but increased bleeding risk (RR: 1.50, 95% CI: 1.18-1.89) among 
dual platelet therapy users compared with aspirin alone. These findings suggest that risk for 
ischemic stroke should determine use of antiplatelet therapy, if any, but be balanced with 
bleeding risk.
4
 
For patients at low risk of ischemic stroke, clinical guidelines recommend aspirin only or 
combination therapy with aspirin and clopidogrel rather than anticoagulation to balance risks of 
bleeding from anticoagulation.
4
 More discussion in the choice of antiplatelet versus 
anticoagulant therapies will be discussed in upcoming sections. 
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2.2.5.2. Anticoagulation  
Prior to late 2010, the only FDA-approved anticoagulant for the prevention of ischemic 
stroke in atrial fibrillation consisted of an oral vitamin K factor inhibitor (warfarin), which has 
served as the cornerstone therapy for years.  
More recently, oral direct thrombin inhibitors and oral Factor Xa inhibitors have been 
studied and considered as possible alternatives.
45,89,90
 The first seemingly viable alternative to 
warfarin was considered in the early 2000’s but was subsequently revoked: ximelagatran, the 
first oral direct thrombin inhibitor, was studied into Phase III trials but was removed from 
consideration for FDA approval in 2006.
91,92
 These Phase III RCTs suggested that ximelagatran 
was similarly efficacious to alternatives in preventing deep vein thrombosis
93,94
 and non-inferior 
to warfarin for ischemic stroke prevention.
91,94
 Ultimately, ximelagatran was withdrawn from the 
FDA approval process in 2006 following reports of hepatotoxicity and elevated liver enzymes in 
approximately 5-6% of patients.
95
  The next viable oral direct thrombin inhibitor alternative to 
warfarin was FDA-approved in October 2010; dabigatran (Pradaxa
TM
) will be discussed more 
thoroughly in subsequent sections.  
Oral Factor Xa inhibitors have also been developed to prevent ischemic stroke in atrial 
fibrillation patients. Current FDA-approved therapies include rivaroxaban (approved Nov 2011) 
and apixaban (approved Dec 2012).
15,19
 Edoxaban, a third Factor Xa inhibitor, is currently 
undergoing FDA-approval, and betrixaban is currently undergoing Phase III clinical trials.
96,97
 
RCTs and meta-analyses of RCTs have largely shown similar or better efficacy of these agents in 
preventing ischemic stroke in patients with AF compared with warfarin, but the extent of 
efficacy appears to differ somewhat across agents.
15,18,89,90,98-102
 These agents have also generally 
been shown to lead to less or equal risk of bleeding compared with warfarin, but concerns have 
been raised about a potentially increased risk of gastrointestinal bleeding compared with 
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warfarin.
18,89,90,98-100
 It is anticipated that the literature will continue to robustly evolve in this 
area. The evidence related to these therapies has currently been generally restricted to the 
randomized-controlled trial setting or meta-analyses of these RCTs; broad observational studies 
in real-world patients of these Factor Xa inhibitors have not yet been published  
More discussion on warfarin and dabigatran will be provided in Section 2.2.6 “Specific 
Anticoagulants and Atrial Fibrillation”. These therapies were the main focus of the dissertation 
as more longitudinal data were available on them.  
 
2.2.5.3 Bleeding risk from use of antithrombotic therapies 
When prescribing antithrombotic therapies for patients with AF, practitioners must weigh 
the risk of ischemic stroke with the risk of bleeding resulting from the therapies. Hemorrhagic 
and gastrointestinal bleeding are notable adverse effects from using antithrombotic 
pharmacotherapy for prevention of ischemic stroke.
84,103
 Without using anticoagulants, the 
baseline risk of hemorrhagic stroke or bleeding in patients with atrial fibrillation has not been 
shown to be independently elevated compared with those without atrial fibrillation.
4
 The risk of 
hemorrhagic stroke or bleeding while using warfarin and dabigatran will be further discussed in 
the following section examining pharmacotherapy in atrial fibrillation. 
 
2.2.5.4 Tools to determine antithrombotic therapy 
2.2.5.4.1 Stroke clinical prediction risk scores 
In clinical practice, providers determine the need for anticoagulation for ischemic stroke 
prevention in atrial fibrillation through the use of clinical risk prediction scores.
4
 The two most 
common ischemic stroke risk scores used in clinical practice are CHADS2
104
 and CHAD2S2-
VASc
105
 and are described in Table 1.
103
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Table 1. Stroke risk scores used in atrial fibrillation 
Risk Score Use Characteristics Points Comment 
CHADS2 Stroke C: Congestive Heart Failure 
H: Hypertension above 140/90mmHg 
A: Age ≥ 75 years 
D: Diabetes Mellitus 
S: Prior Stroke/TIA 
1 
1 
1 
1 
2 
Maximum 6 points 
 
CHA2DS2-
VASc 
Stroke C: Congestive Heart Failure 
H: Hypertension above 140/90mmHg 
A: Age ≥ 75 years 
D: Diabetes Mellitus 
S: Prior Stroke/TIA 
V: Vascular disease 
A: Age 65-74 years 
Sc: Sex category (Gender) 
1 
1 
2 
1 
2 
1 
1 
1 
Maximum 9 points 
 
Of these, clinicians have most frequently used the CHADS2 risk score to help select 
anticoagulation or antiplatelet therapy.
105,106
 While the CHADS2 score has been around for much 
longer, the CHA2DS2-VASc risk score is becoming more commonly used due to better 
stratification of low-risk patients and better predictive ability for thromboembolism.
105,107
 
European guidelines have recommended its use for the last few years, and the most recent US 
clinical guidelines from the American Heart Association/American College of Cardiology/Heart 
Rhythm Society (AHA/ACC/HRS) recommend the use of the CHA2DS2-VASc to estimate 
ischemic stroke risk.
5
  
However, the CHADS2 Score has been most frequently used in observational studies of 
medical claims, but the CHA2DS2-VASc has been increasingly validated in observational 
data.
108-110
 For either score, anticoagulation therapy is recommended in patients with patients 
with a CHADS2 or CHA2DS2-VASc score of 1 or greater and strongly recommended in patients 
with scores of 2 or greater. Of note, these clinical prediction scores have been validated in 
warfarin users; however, to our knowledge, neither score to date has been explicitly validated in 
users of newer anticoagulants.  
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2.2.5.4.2 Bleeding clinical prediction risk scores 
When prescribing antithrombotic therapies, providers also need to consider the risk of 
bleeding in which clinical risk prediction scores are recommended.
4
 Three major bleeding risk 
scores are used in for AF patients in clinical practice (HAS-BLED
111
, HEMORR2HAGES
103
, and 
ATRIA
112
). These tools are described in Table 2 below.
103
  
 
  
 26 
 
Table 2. Bleeding risk scores used in atrial fibrillation 
Risk Score Use Characteristics Points Comment 
ATRIA Bleeding Anemia 
Severe Renal Disease 
Age ≥ 75 years 
Any prior hemorrhage 
Hypertension 
3 
3 
2 
1 
1 
Maximum 10 points 
HAS-BLED Bleeding H: Hypertension 
A: Abnormal Renal and liver function 
S: Stroke 
B: Bleeding 
L: Labile INRs 
E: Elderly (age > 65 yrs) 
D: Drugs or alcohol 
1 
1 or 2 
1 
1 
1 
1 
1 or 2 
Maximum 9 points 
HEMORR2HAGES Bleeding H: Hepatic or renal disease 
E: Ethanol abuse 
M: Malignancy 
O: Older age 
R: Reduced platelet count or function 
R: Re-bleeding risk (i.e., prior bleed) 
A: Anemia 
G: Genetic factors (CYP2C9 variant) 
E: Excessive fall risk 
S: Stroke 
1 
1 
1 
1 
1 
2 
1 
1 
1 
1 
Maximum 11 points 
 
Of the validated bleeding risk scores, the HAS-BLED score has been the most 
recommended in clinical guidelines; however, using the ATRIA score for observational studies 
in medical claims has been thought to be the most accurate, because some of the criteria in the 
HAS-BLED score cannot be directly or accurately measured in claims, such as labile INRs or 
drug/alcohol use.
107,113
 Of note, these clinical prediction scores have been validated in a strictly 
warfarin-taking population.  
Published literature suggests that combining a bleeding risk score with a stroke clinical 
prediction rule can help clinicians maximize the risk and benefit tradeoff of prescribing an 
anticoagulant versus an antiplatelet therapy in patients with atrial fibrillation.
103
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2.2.6. Specific Anticoagulants and Atrial Fibrillation 
2.2.6.1. Warfarin: Uses, Efficacy, and Adverse Effects 
2.2.6.1.1. Uses 
Warfarin, an oral Vitamin K antagonist, is FDA-approved for prevention of ischemic 
stroke and venous thromboembolism.
73
 Until very recently, ACC clinical guidelines favored the 
use of chronic warfarin for patients without mechanical heart valves (non-valvular AF) at 
moderate to high risk of stroke; however, more recent AHA/ACC/HRS clinical guidelines 
released in March 2014 have offered no major preference between warfarin and the other novel 
oral anticoagulants.
1,4,70,73
  
To manage warfarin dosing, patients are monitored regularly in provider visits or self-
monitoring using international normalized ratio (INR) tests, because warfarin has a narrow 
therapeutic index.
45,46
 In non-valvular AF, patients receive titrated warfarin doses to a target INR 
of 2.0 to 3.0, monitored and adjusted through these INR tests.
45
 When first beginning warfarin, 
patients generally start on doses of 5.0mg and increase or decrease doses as needed. INRs are 
generally monitored at least weekly during the initiation of therapy and are recommended to be 
conducted monthly once anticoagulation is stabilized.
45,46
 The use of laboratory tests has 
historically been a drawback to using warfarin due to the added inconvenience to patients and 
costs to the health system, but is recommended for chronic therapy.
114
 
 
2.2.6.1.2. Efficacy and Effectiveness 
A wide body of literature is available on warfarin and its use in prevention of stroke in 
atrial fibrillation. Warfarin has a strong history of demonstrated effectiveness in ischemic stroke 
prevention.
115
 Long-term anticoagulation therapy with warfarin has been shown to reduce the 
risk of ischemic stroke in patients with non-valvular AF in RCTs by up to 68%.
6,7,115,116
 Meta-
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analyses have suggested that the annual incidence of stroke or systemic embolism in AF patients 
using warfarin is approximately 1.66% (95% CI: 1.41-1.91).
9
 However, the risk of ischemic 
stroke on warfarin can also vary based on underlying risk factors. Ischemic stroke risk has been 
shown to increase when taken in elderly patients, female patients, patients with a history of 
stroke, and newly-initiated users (e.g., patients never having taken vitamin K antagonists 
before).
9
 Renal impairment (OR: 1.54, 95% CI: 1.30-1.81), previous aspirin use (OR: 1.19, 95% 
CI: 1.04-1.37), and higher CHADS2 score (1.64, 95% CI: 1.18-2.27) are also associated with a 
higher risk of stroke on warfarin, even in more recent RCTs.
117
  
Because warfarin has been available for decades, older RCTs were conducted when the 
quality of care for AF patients was worse. 
9,32,117
 In addition, the time in therapeutic range (TTR) 
has been shown to not only vary widely across clinical practice settings but also is strongly 
related to warfarin’s effectiveness.118,119 More recently, home monitoring for INRs has become 
available, further mudding the picture.
120
 Thus, the debate regarding the effectiveness of warfarin 
continues and still remains relevant today. 
 
2.2.6.1.3. Adverse Effects 
Because of its narrow therapeutic index, warfarin has been linked with a number of 
adverse effects, the most serious being a high risk of bleeding. 
45,46
 An observational cohort of 
AF patients beginning warfarin found the rate of major hemorrhage was 7.2 years per 100 
person-years (95% CI: 4.9-10.6) and rate of intracranial hemorrhage of 2.5% (95% CI: 1.1-4.7) 
among those newly initiating warfarin.
121
 Anticoagulation therapy has been shown to increase 
the annual risk for intracranial bleeding by 0.2% to 0.3% in RCTs.
85
 In particular, the first 90 
days has been associated with a 3-fold increased risk of bleeding.
85
 However, the study reporting 
this finding was conducted at a single site in specifically older adults, and the authors were 
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concerned that the bleeding risk may even have been underestimated.
121
 Warfarin has also been 
linked to osteoporosis, purple toe syndrome, and warfarin necrosis.
73
 Warfarin also has other 
drug-drug and drug-lab interactions, which lead to many additional adjusted dosing 
requirements.  
 
2.2.6.2. Dabigatran: Uses, Efficacy, and Adverse Effects 
2.2.6.2.1. Uses 
Dabigatran, a direct thrombin inhibitor, has been FDA-approved since October 2010 for 
prevention of stroke and embolism in non-valvular atrial fibrillation and for venous 
thromboembolism prophylaxis.
122
 Dabigatran has not been approved for any mechanical valve 
ischemic stroke prophylaxis. Importantly, patients with mechanical heart valves or significant 
mitral stenosis were excluded from RCTs used for FDA-approval, and a more recent study 
indicated dabigatran’s increased risk of bleeding compared with warfarin patients with valvular 
AF.
123
 In the US, the FDA approved two doses of dabigatran for the prevention of stroke in atrial 
fibrillation: 75mg twice daily and 150mg twice daily, while the 110mg dose was studied in 
RCTs.
19
 The 75mg twice daily dose is specifically indicated for patients with renal impairment 
(CrCl <30mL/min). Notably, no RCTs have been done to study the 75mg dose. 
 
2.2.6.2.2. Efficacy and Effectiveness 
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial has 
provided most of the current evidence surrounding the efficacy of dabigatran for ischemic stroke 
prevention in patients with AF. This study found a decreased risk of stroke or systemic embolism 
in patients using dabigatran 110mg or 150mg twice daily versus INR adjusted-dose warfarin.
13
 In 
this study, the rates of stroke or systemic embolism varied from 1.7% in the warfarin group to 
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1.5% per year in the group receiving dabigatran 110mg (RR: 0.91, 95% CI: 0.74-1.11, p<0.001 
for non-inferiority) and 1.1% per year in the group receiving 150mg dabigatran (RR: 0.66, 95% 
CI: 0.53-0.82, p<0.001 for superiority).
13
  
Some sub-analyses of the overall RE-LY trial have also been published. One sub-analysis 
has found that the risk of ischemic stroke or systemic embolism was significantly higher in 
patients from Asian countries than from non-Asian countries, though geographic treatment 
variation is thought to have influenced these differences.
124
 Another RE-LY sub-analysis of 
patients receiving concomitant anti-platelet therapy found that dabigatran was still non-inferior 
to warfarin in reducing ischemic stroke or systemic embolism, regardless of receipt of anti-
platelet therapy.
88
 Another third RE-LY sub-analysis following 5,851 patients who had not 
discontinued dabigatran (with no warfarin comparator) found approximately 1.5% and 1.6%/year 
rates of ischemic stroke or systemic embolism.
125
 These findings were largely similar to the 
original RCT findings. Whether patients were adequately anticoagulated with warfarin 
(measured by time in the therapeutic range) in the RE-LY trial was also found to slightly 
influence the apparent efficacy of dabigatran.
14
 Additional post-hoc analyses have been 
conducted on patients using anticoagulation for secondary prevention versus primary prevention 
and found similar findings. Overall, these sub-analyses have been useful at elucidating potential 
areas for further study, but are no substitution for large real-world studies. In addition, a number 
of meta-analyses summarizing the clinical trials have been published – many of them combining 
the novel oral anticoagulants together. These meta-analyses have largely found superiority of the 
novel oral anticoagulants but also caution about possible increased risk of myocardial infarction 
or gastrointestinal bleeding risk with dabigatran.
18,126,127
 
To our knowledge, three observational studies to date have been published to begin to 
examine the effectiveness of dabigatran in preventing ischemic stroke in AF patients.
128
 The 
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first, a cross-sectional study, followed 103 patients treated with dabigatran for at least 3 months 
at a single-center anticoagulation clinic without a comparator group. In this study, only 1 
ischemic stroke was reported; the authors found no statistically significant difference between 
treatment-naïve patients and patients previously treated with warfarin. Of the 99 patients they 
had prescription fill records for, 12% of patients had inadequate adherence over the study period 
(defined as <80% adherence). The second study, a registry-based study of patients in Denmark, 
followed 4,978 dabigatran-treated patients against 8,936 propensity-score matched warfarin 
patients using time-to-event analysis.
129
 This study found that while risk of stroke and systemic 
embolism was not statistically different between the two groups, mortality and risk of AMI was 
significantly lower in dabigatran patients. However, this study examined dabigatran at a dose of 
110mg and 150mg, because the 75mg dose is not used in Europe. This study also exclusively 
followed new users of anticoagulants. The third study examined the medication adherence and 
the association between non-adherence to dabigatran and clinical outcomes in a cohort of 5,376 
Veterans Affairs patients.
130
 They found high medication adherence among this VA population 
(Mean proportion of days covered [PDC] 94%). Patients with low medication adherence (<80% 
PDC) were associated with an increased risk for all-cause mortality and stroke (HR: 1.13, 95% 
CI: 1.07-1.19) per 10% decrease in PDC, but adherence was not associated with increased risk of 
non-fatal bleeding or myocardial infarction.  
In summary, dabigatran has shown relative improved efficacy over warfarin in 
randomized-controlled clinical trials, though the generalizability of the findings has been 
questioned, because of the narrow inclusion criteria used in the trials. Specifically, the population 
included in RE-LY tended to be younger and with fewer comorbidities than has been seen in 
previous observational studies examining warfarin use.
119,131
 In addition, the RE-LY trial 
excluded patients with renal impairment or hepatic disease, which could be important sub-groups 
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to analyze in real-world settings. Lastly, patients who were non-adherent were excluded from 
RE-LY analyses. Using our knowledge about low medication adherence in actual clinical 
practice suggests that further observational research is continued to be needed. 
 
2.2.6.2.3. Adverse Effects 
While dabigatran has fewer monitoring requirements and easier dosing arrangements, its 
use has also been suggested to lead to higher risk of dyspepsia, potentially higher risk of 
bleeding, and myocardial infarction than warfarin.
19
 Uncertainty also remains about its relative 
safety, because, unlike warfarin, dabigatran lacks a direct reversal agent in the event of bleeding 
complications, even though some are under development.
20
  
Major randomized-controlled trials have shown that dabigatran is associated with 
decreased intracerebral hemorrhage (ICH) compared with warfarin whether or not patients have 
prior stroke/TIA and are using anticoagulation for secondary prevention.
13,132,133
 The RE-LY trial 
found that major bleeding was 3.36% per year in the warfarin group compared with 2.71% per 
year in those receiving dabigatran 110mg (p=0.003) and 3.11% per year those receiving 
dabigatran 150mg (p=0.31).
13
 In addition, the reported rate of hemorrhagic stroke was 0.38%, 
0.12%, and 0.10% per year in the warfarin, dabigatran 110mg (p<0.001), and dabigatran 150mg 
(p<0.001) groups, respectively.
13
 Mortality did not differ significantly between the groups.
13
  
Other RE-LY sub-analyses and case reports have found an increased risk of bleeding in 
dabigatran, mainly in older adults.
19,42,134
 Some RE-LY sub-analyses have found a slightly 
increased risk of bleeding on dabigatran versus warfarin, while others did not.
14,88,124,125
 Case 
studies suggest that the risk of bleeding in dabigatran may be among those that did not 
appropriately receive renally-adjusted dosing or among older adults.
27,117,135-137
 The FDA has 
reported a greater proportion of adverse events reported to their MEDWATCH program for 
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dabigatran than warfarin since dabigatran market entry
138
; however, a Mini-Sentinel analysis 
found in an unadjusted cohort of patients that the risk of bleeding was not significantly greater 
than warfarin.
26
 Consensus opinion suggests that bleeding complications may be much more 
difficult to manage, and that those that occur may also be much more severe.
139
 Another study 
examined 2,391 atrial fibrillation patients admitted with intracranial bleeding and their 
comparative risk of mortality among patients treated with dabigatran compared with warfarin 
using the TruvenHealth MarketScan® database.
140
 They found similar in-hospital mortality and 
no differences in propensity-score adjusted risk ratios. Overall, much less is known about the 
comparative efficacy of dabigatran compared with warfarin in real-world use, and even more 
questions regarding dabigatran’s comparative safety remain unanswered.20  
Dabigatran used for the prevention of stroke in atrial fibrillation has also been thought to 
lead to increased risk of myocardial infarction, but data examining this outcome have been 
primarily aggregation of the large randomized, controlled trials.
99,141,142
 In addition, the RE-LY 
trial also found significantly increased risk of dyspepsia-like symptoms compared with 
warfarin.
13
 Sub-analyses have found that gastroesophageal reflux disease (GERD)-related non-
bleeding adverse events occurred in 16.9% of those receiving dabigatran and 9.4% of those 
receiving warfarin (RR: 1.81 [95% CI: 1.66-1.97], p<0.001).
143
 In this sub-analysis, 
discontinuation occurred in 4% of patients receiving warfarin due to non-bleeding adverse 
events.
143
  
 
2.2.7. Guidelines for Anticoagulation in AF 
Clinical guidelines recommend tailoring antithrombotic therapy to individual patient’s 
risk of ischemic stroke and other side effects. The following sections discuss the recommended 
treatment algorithms in patients with AF with regard to antithrombotic therapy. While either 
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aspirin or warfarin have been shown to reduce stroke risk in patients with atrial fibrillation, 
warfarin is considered to be significantly more effective than aspirin, but carries increased risk of 
hemorrhage and other side effects.
3,45
 
For either the CHADS2 or the CHA2DS2-VASc, a risk score of 0 indicates a low risk of 
ischemic stroke, whereby no anticoagulation or aspirin use is suggested. A CHADS2 risk score of 
1 suggests a moderate risk of ischemic stroke, whereby either aspirin or anticoagulation are 
indicated based on patient preference.
104,105
 A CHADS2 risk score of 2 or greater suggests a 
moderate or high risk of stroke, whereby anticoagulation is warranted. Anticoagulation with a 
vitamin K antagonist is recommended for patients with at least 1 moderate risk factor, including 
age > 75 years, hypertension, heart failure, impaired left ventricular systolic function, and 
diabetes mellitus (e.g., CHADS2 Score – see previous discussion on this topic).
104
 Recently, the 
guidelines have incorporated equivalencies of the new oral anticoagulant (e.g., dabigatran) or 
well-controlled warfarin at INR 2.0-3.0 for risk scores of 1 or greater.
3,19,45
 
As is discussed in the following sub-sections, the clinical guidelines by the various 
associations appear to have reached some degree of consensus. Generally, dabigatran is 
recommended as an alternative to warfarin for clinically-indicated patients, but these guidelines 
caution against its use in patients with renal impairment and advanced age. As this is a rapidly-
growing area, other guidelines are possible, but the major relevant ones have been summarized 
below. 
 
2.2.7.1. American College of Chest Physicians (ACCP) 2012 Guidelines Update 
The American College of Chest Physicians in February 2012 summarized antithrombotic 
recommendations in a supplement to their 9
th
 edition of clinical practice guidelines.
4
 These 
recommendations for patients with non-valvular irreversible AF are summarized in Table 3. 
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These guidelines use the GRADE approach which classifies recommendations as strong (Grade 
1) or weak (Grade 2) based on expert consensus about the overall risks and benefits of 
therapy.
144,145
 The quality of the evidence is also synthesized into high (Grade A), moderate 
(Grade B), or low (Grade C) according to the overall validity and risk of bias inherent in the 
available studies.
144
 
Notable changes to the ACCP guidelines include an active suggestion towards dabigatran 
150mg twice daily rather than adjusted-dose warfarin therapy in patients with CHADS2≥2, but 
the evidence supporting this recommendation currently is considered to be “weak”. In addition, 
at lower risk levels, other treatment decisions are considered on an individualized basis. All of 
these include patients with paroxysmal AF. 
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Table 3. American College of Chest Physicians 2012 Antithrombotic Guidelines Update 
Recommendation Grade 
For patients with AF at low risk of stroke (CHADS2: 0), no antithrombotic therapy recommended 
- If therapy chosen, aspirin 75mg or 325mg once daily recommended 
2B 
2B 
For patients with AF at intermediate risk of stroke (CHADS2: 1), oral anticoagulation 
recommended rather than no therapy 
- Oral anticoagulation preferred over aspirin or aspirin + clopidogrel 
- If precautions against oral anticoagulation, then aspirin + clopidogrel 
1B 
 
2B 
2B 
For patients with AF at high risk of stroke (CHADS2: 2), oral anticoagulation recommended rather 
than no therapy, or 
- Aspirin (75mg or 325mg), or 
- Aspirin + clopidogrel 
- If precautions against oral anticoagulation, then aspirin + clopidogrel 
1A 
 
1B 
1B 
1B 
For patients with AF with oral anticoagulation recommended, dabigatran 150mg twice daily 
recommended rather than adjusted-dose warfarin 
2B 
For patients with AF and stable coronary artery disease with oral anticoagulation recommended, 
adjusted dose warfarin alone rather than adjusted-dose warfarin + aspirin  
2C 
 
2.2.7.2. 2012 Focused Update: Recommendations for Prevention of Thromboembolism in Non-
valvular AF
3
 
The European Society of Cardiology (ESC) convened an update to practice guidelines for 
atrial fibrillation published in August 2012. Their recommendations related to dabigatran are 
summarized in Table 4 below. These guidelines incorporated ratings using the Class and Level 
of Evidence (LOE) system. Class I indicates that good-quality RCTs are available. Lower levels 
(up to III) suggest that poor quality evidence is available (such as case series or other studies 
with no control group). The Level of Evidence ratings suggest how consistent the underlying 
studies are. Overall, these guidelines provided similar recommendations as the ACCP guidelines, 
based here on the CHA2DS2-VASc score. These guidelines seemed to suggest clinical equipoise 
between dabigatran and warfarin depending on various risk factors, but that further evidence 
would be needed to discern differences. These guidelines recommend that selection of therapy be 
based on risk factors, cost, tolerability, patient preference, drug-drug interactions, TTR, and other 
clinical risk factors. 
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Table 4. 2012 European Society of Cardiology (ESC) Focused Update 
Recommendation Class Level of Evidence 
Antithrombotic therapy to prevent thromboembolism is recommended for all 
patients with AF, except in those patients (both male and female) who are at 
low risk (aged < 65 years and lone AF) or with contraindications 
I A 
In patients with a CHA2DS2-VASc score ≥2, OAC therapy with: 
- Adjusted-dose VKA (INR 2-3); or 
- A direct thrombin inhibitor (dabigatran); or 
- An oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) 
… is recommended, unless contraindicated 
I A 
In patients with a CHA2DS2-VASc score = 1, OAC therapy with: 
- Adjusted-dose VKA (INR 2-3); or 
- A direct thrombin inhibitor (dabigatran); or 
- An oral factor Xa inhibitor (e.g., rivaroxaban, apixaban) 
… should be considered, based upon an assessment of the risk of bleeding 
complications and patient preferences 
IIa A 
When patients refuse the use of any OAC, antiplatelet therapy should be 
considered, using combination therapy with aspirin 75-100mg plus clopidogrel 
75mg daily (where there is a low risk of bleeding), or, less effectively, aspirin 
75-325mg daily 
IIa B 
  Abbreviations: AF, Atrial Fibrillation; OAC, Oral anticoagulant; VKA, Vitamin K Antagonist; INR, International 
Normalized Ratio 
 
 
2.2.7.3. American Heart Association (AHA)/American Stroke Association (ASA) Science 
Advisory Committee 2012 recommendations 
 The AHA/ASA Science Advisory committee published recommendations even more 
recently than the ACCP guidelines in December 2012 using expert consensus. These guidelines 
suggested that selection of OACs should be individualized and based on risk factors, cost, 
tolerability, patient preference, drug interaction potential and INR time in the therapeutic range.
2
 
Notably, this committee also recommended that dabigatran 150mg twice daily is an efficacious 
alternative to warfarin (Class I; Level of Evidence (LOE) B). Dabigatran 75mg twice daily may 
be considered for patients with CrCl 15-30 ml/min but with a caution that safety and efficacy 
have not been established in renal-insufficient patients (Class IIb; LOE C). The committee did 
not, however, recommend dabigatran in patients with CrCl < 15ml/min (Class III; LOE C).  
 Their overall recommendations related to dabigatran are summarized in Table 5 below. 
Prior to this update, these guidelines had previously separated out explicit recommendations 
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based on whether antithrombotic therapy is being used for primary versus secondary prevention 
of ischemic stroke. However, the committee has generally recommended dabigatran as an 
efficacious alternative to warfarin for both primary and secondary prevention in patients with at 
least a moderate risk of ischemic stroke but recommended caution in renal insufficiency. 
 
  
 39 
 
Table 5. American Heart Association/American Stroke Association 2012 Guidelines Update 
Recommendation Class (LOE) 
For prevention of first and recurrent stroke in patients with non-valvular AF, one of the 
following antithrombotic agents can be considered based on individualized factors: 
- Warfarin 
- Dabigatran 
- Rivaroxaban 
- Apixaban 
 
 
I (A) 
I (B) 
IIa (B) 
I (B) 
Dabigatran 150mg twice daily is an efficacious alternative to warfarin for prevention of first 
and recurrent stroke in patients with non-valvular AF and ≥1 other risk factor and CrCl 
>30mL/min 
I (B) 
Dabigatran 75mg twice daily may be considered for prevention of first and recurrent stroke in 
patients with non-valvular AF and and ≥1 other risk factor and CrCl 15-30mL/min 
IIb (C) 
Dabigatran is not recommended in patients with CrCl <15mL/min III (C) 
  Abbreviations: LOE, Level of Evidence; AF, Atrial Fibrillation; CrCl, Creatinine clearance 
 
2.2.7.4. American Heart Association (AHA)/American College of Cardiology (ACC)/Heart 
Rhythm Society 2014 Guidelines 
 The AHA/ASA/HRS Science Advisory committee released recommendations in late 
March 2014 regarding the management of atrial fibrillation.
5
 Similar to guidelines released in 
2012, antithrombotic therapy is still recommended to be individualized based on shared decision-
making and recommended for patients with high ischemic stroke risk. In this 2014 version, 
patients with non-valvular AF are recommended to use warfarin, dabigatran, rivaroxaban or 
apixaban, with no noted preference among the agents. However, again, patients with end-stage 
chronic kidney disease or on hemodialysis are not recommended to use one of the novel oral 
anticoagulants. The largest difference between these guidelines and previous guidelines are that 
the oral anticoagulants are considered as equal options in newly-initiating patients. 
 
2.2.8. Other adjunctive therapies used in atrial fibrillation 
 Angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers 
(ARBs), and HMG Co-A-reductase inhibitors (statins) are also under investigation as adjunctive 
therapies to the 3-pronged approach in managing AF. ACEIs/ARBs have been thought to play a 
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potential role in decreasing both the incidence of AF and the rate of relapse following 
cardioversion in patients with AF. These drugs are hypothesized to work by reducing P-wave 
duration, but their overall primary use in AF is still being evaluated.
146
 A recent meta-analysis 
found that ACEIs and ARBs significantly lowered the risk of incident AF compared with no use 
(OR: 0.65, 95% CI: 0.55-0.76).
146
 Compared with non-users, users of ACEIs and ARBs were 
also found to have a significantly reduced recurrence of sinus rhythm disturbances (OR: 0.45, 
95% CI: 0.31-0.65).
146
 However, the included RCTs heavily relied on post-hoc analyses for their 
conclusions. Statins have also been thought to play a role in maintaining sinus rhythm in patients 
with persistent lone AF, but their role as a primary agent in AF is still being evaluated and only 
hypothesized in commentaries.
55
 The literature examining the role of adjunctive therapies 
beyond the 3-pronged approach currently recommended is still evolving, and no strong 
recommendation for their uses in AF has been given.
55
 
 
2.3. CLINICAL CONTROVERSIES  
As previously discussed, dabigatran has shown similar efficacy in stroke prevention over 
warfarin in treatment naïve patients with AF in randomized-controlled clinical trials.
14-16
  While 
dabigatran requires less frequent monitoring and may lead to decreased intracerebral 
hemorrhage, it may also lead to higher risk of dyspepsia, other types of bleeding, and myocardial 
infarction than warfarin.
19
 In addition, dabigatran lacks a direct agent in the event of bleeding 
complications, which may decrease its overall safety.
20
 This section explores the clinical 
controversies surrounding the use of warfarin and dabigatran and identifies the literature 
available in this area.  
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2.3.1. Warfarin: Clinical controversies 
Despite warfarin’s longevity on the market, some clinical controversies remain, 
especially around patient-centered outcomes and effectiveness. Long-term therapy with warfarin 
has been shown to decrease quality of life in patients with AF by as much as a mean 1.3% 
decrease in utility.
52,147
 Other studies have also reported that some patients thought their quality 
of life would be increased with the use of aspirin versus oral anticoagulants.
52,148
 In addition, the 
extent to which warfarin’s effectiveness is affected by non-adherence and INR control is still not 
fully established.
119
 INR control is directly related to the TTR for warfarin.
119,149
 This issue is 
particularly important because patients’ TTR has been shown to vary widely among warfarin 
users in not only observational studies but also Phase III RCTs examining the novel oral 
anticoagulants (NOACs) (including dabigatran).
14,15,118,150
 Because TTR has been shown to be 
related to clinical effectiveness of warfarin, the adequacy of the comparator groups in these 
settings has been called into question.
14
 
Research is also still examining rates and effects of warfarin initiation and 
discontinuation, despite indications for chronic use, especially given perceived risks of bleeding. 
Despite knowledge about its effectiveness, patients also have been shown to be fairly non-
adherent with using warfarin.
151,152
 In addition, research is still assessing long-term outcomes of 
warfarin use, even years after initiating therapy.
11,153
 
9
  
 
2.3.2. Dabigatran: Clinical controversies 
While the FDA-approved dabigatran at 75mg twice daily, this dose was not studied in 
Phase III clinical trials.
43
 Instead, the RE-LY trial compared dose-adjusted warfarin against 
dabigatran 110mg (along with the FDA-approved dose of dabigatran 150mg). Other countries 
did, however, approve dabigatran at 110mg. The fact that dabigatran has not been studied at the 
 42 
 
75mg dose has implications for patients, as much further study is warranted to ensure 
comparative effectiveness of dabigatran at that dose. The lack of current information about the 
dabigatran110mg dose has raised considerable controversy, underlying the need for 
observational studies to assess this dose. 
There is also interest in the apparent effectiveness of dabigatran in patients with mild-
moderate ischemic stroke – with a CHADS2 or CHA2DSs-VASc score of 1. Previously, these 
patients would be treated with antiplatelet therapy. However, some commentaries suggest that 
dabigatran may be useful in these marginal patients – ones where the decision to anticoagulate 
had been primarily preference-driven prior to dabigatran’s availability.17,154 Thus, more research 
will be needed to resolve whether dabigatran can be used in a wider degree of patients than 
warfarin previously had been. 
In addition, providers have raised some concerns regarding the apparent increased risk of 
bleeding on dabigatran. A recent theheart.org analysis surveyed physicians regarding their 
concerns of dabigatran use in AF patients.
155
 On a scale of 1-6 (6 being very concerned), 
physicians were asked about intracranial hemorrhage, gastrointestinal (GI) bleeding and left 
atrial enlargement, renal dysfunction, and recurrent stroke yielding average ratings of 4.11, 4.07, 
3.45, 4.04, and 3.85, respectively.
155
 By comparison, physician asked about burden of INR 
monitoring, difficulty maintaining INR, managing multiple medications, side effects, quality of 
life and compliance in warfarin used yielded average ratings of 4.36, 4.22, 4.13, 4.13, 3.98, and 
4.10, respectively.
155
 
Management of dabigatran is simultaneously easier and more difficult. Currently, no 
laboratory monitoring for chronic therapy is recommended; INR testing is neither useful nor 
determinative.
156
 Thrombin time and ecarin clotting time, directly measuring thrombin activity 
from the plasma, may be used to estimate anticoagulant effect in a concentration-dependent 
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linear relationship.
135,157
 However, no studies have yet been conducted examining the real-world 
utility of these tests. The fixed-dosing arrangements of dabigatran have also been widely 
marketed as treatment advancement from INR dose-adjusted warfarin. 
Moreover, in the event of over-anticoagulation (e.g., bleeding), no reversal agent exists to 
stop the bleeding, unlike warfarin whereby phytonadione (vitamin K), among others such as 
dialysis, factor, and fresh frozen plasma, can be used to reverse warfarin toxicity.
156,157
 This lack 
of antidote for dabigatran has clinical implications, because while the drug is easier to take and 
easier to dose, adverse outcomes may be more difficult to manage, and costs of managing 
bleeding outcomes may be much higher than warfarin.
158
 Current recommendations for treatment 
of bleeding include supportive care, activated prothrombin complex concentrate, activated factor 
VIIs, or dialysis.
19
 A recent survey of 221 vascular neurologists found large variations in 
recommended treatment modalities for bleeding events on dabigatran among these providers.
157
 
Clearly, much more research is needed in this area as well. 
 
2.3.3. Other controversies in choice of anticoagulation 
While not the focus of this research, the use of dabigatran versus warfarin in the setting 
of catheter ablation is also undergoing strenuous evaluations. Even when undergoing catheter 
ablation, anticoagulation is still considered a recommended course of therapy as some patients 
may still experience inconsistent sinus rhythms. Currently, it is still not clear whether dabigatran 
is as safe and effective compared with warfarin during catheter ablation.
159
 One case-control 
study examining the risk during radiofrequency catheter ablation found no significant difference 
in perioperative acute risk in terms of major and minor bleeding events.
160
 Another study found a 
decreased risk in rebleeding occurring from dabigatran patients compared with warfarin (20% vs. 
44%, p =0.01).
161
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 Recent research has also uncovered the challenges of prescribing antithrombotic therapy 
in patients with new-onset acute myocardial infarction and previous anticoagulation therapy to 
prevent stroke. While long-term oral anticoagulation is important for the prevention of stroke in 
atrial fibrillation, the combination of warfarin and antiplatelet medications following AMI 
creates challenges for such patients. A sub-analysis of the RE-LY trial found that 38.4% of 
included patients received clopidogrel and aspirin simultaneously along with warfarin or 
dabigatran in the study.
88
 Both doses of dabigatran studied (110mg and 150mg) were found to be 
non-inferior to warfarin in terms of stroke or systemic embolism risk regardless of platelet use.
88
 
Major bleeding was also similar to warfarin among those using concomitant antiplatelet therapies 
(HR: 0.80, 95% CI: 0.70-1.25). Dual antiplatelet therapy (clopidogrel + aspirin) increased the 
risk of bleeding as well (HR: 1.60, 95% CI: 1.42-1.82). Fewer than 50% of these patients have 
been shown to use warfarin at discharge, even with CHADS2 greater than 2, and triple therapy 
(with antiplatelet medications) is used in only 14.6% of patients.
70
 Literature has suggested a 
further research need in this area.  
 Because of the difficulty in attaining and maintaining an INR in the recommended 
therapeutic ranges in treatment with warfarin, pharmacogenetic testing for variants in the 
cytochrome P450 2C9 gene has been developed. Interindividual dose variability has been shown 
to derive from coding variations and polymorphisms on this gene.
10,162,163
 While the uptake of 
the testing is still limited to some health settings, warfarin dosing can be affected by the results 
of the test.
164
 The cost-effectiveness of the test in determining warfarin dosing has affected its 
uptake in clinical practice despite recommendations.
163
 This potential for better identification of 
genetic differences in response to warfarin has relevance for comparisons to dabigatran, as 
researchers better understand idiosyncratic differences in response to warfarin dosing. 
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2.4. ISSUES IN USE OF ANTICOAGULATION IN REAL-WORLD PRACTICE 
The previous section summarizes the published research examining clinical differences 
between anticoagulants under optimal clinical conditions. However, selection between available 
treatment options may also be influenced by additional factors frequently studied in health 
services research related to health behavior, patient/provider preferences, and willingness and 
ability to pay. Examining how these factors affect anticoagulant use and outcomes in the real-
world is just as important as under optimal clinical conditions and settings to help improve 
evidence-based clinical practice. This section explores the research related to use of 
anticoagulants in the management of AF and related contexts. 
 
2.4.1. Andersen’s Behavioral Model of Health Services Use 
The Andersen’s Behavioral Model of Health Services Uses can be used to help illustrate 
factors associated with the use of anticoagulants in patients with atrial fibrillation. Briefly, the 
Andersen’s Model describes multiple levels of factors that have been historically associated with 
use of health care services – individual, provider and health-system factors.165 The first model, 
created in the 1960s, described that the use of health services is primarily driven by individual 
predisposition, factors that affect use, and need for the services.
166
 More recent models have 
incorporated system factors that all influence health services, including processes of care and 
provider interactions as part of health behavior affecting service use.
165-167
 More discussion on 
the Andersen’s model and its application to this proposed research will be provided in Chapter 3. 
The most recent version of the Andersen model is displayed below in Figure 1.  
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Figure 1. Andersen's Behavioral Model of Health Services Use
166
 
 
 
 
 
 
 
 
 
 
In Figure 1 above, predisposing, enabling and need characteristics are illustrated on 
multiple levels, including contextual and individual. These factors influence health behaviors and 
ultimately outcomes, such as perceived health, evaluated (clinical) health, and satisfaction.
165-167
 
Predisposing demographic characteristics (e.g., age, gender) and social characteristics (e.g., 
education, race/ethnicity) occur on multiple levels as well. Enabling characteristics (e.g., 
financial, access to care) may also occur on multiple levels. Need characteristics often 
encompass both an individual’s perceived and evaluated (clinical) need for services. In the 
setting of this dissertation, evaluated need will serve as the primary measurement for need 
factors. Because much contextual information is not available in the data source for the study, 
the dissertation focuses on those variables primarily describing the individual level. The 
Andersen’s Model has also been successfully used in a number of settings examining factors 
associated with pharmaceutical use.
165
 Chapter 3 illustrates the proposed adaption of the model 
for the dissertation, given the available data and ultimate study questions.  
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2.4.2. Real-world uptake of anticoagulation in AF 
To examine factors associated with the use of anticoagulants, the overall uptake of 
anticoagulants also needs to be examined. Historically, utilization of anticoagulants in the setting 
of atrial fibrillation has been shown to be remarkably low, largely because of concerns over 
perceived risk of bleeding.
121,168,169
 Before the introduction of direct thrombin inhibitors and 
Factor Xa antagonists, the use of warfarin in AF patients  has ranged widely in observational 
studies (9.1%-79.8% across 28 studies; median=49.1%).
168
 Other reviews suggest that of eligible 
patients without contraindications (as indicated by CHADS2 score), only 15-44% are prescribed 
warfarin.
7
 While over time utilization has increased, without alternatives to warfarin in patients 
with high CHADS2 scores, patients with contraindications to warfarin may have gone 
undertreated.
95,168
 One study found a strong correlation between proportion of patients using 
warfarin and the year the study was conducted, suggesting some increased initiation of warfarin 
over time (r=0.60; p=0.002).
168
 
Despite being chronic therapy, discontinuation and medication non-adherence has also 
been high in patients treated with warfarin. In a population-based cohort of AF patients starting 
warfarin, 8.9% of patients did not fill a second prescription, 31.8% discontinued therapy within 1 
year, and 61.3% discontinued therapy within 5 years with a median time to discontinuation of 2.9 
years.
11
 
The real-world uptake of dabigatran has been examined in a few, small studies. A study 
by Kirley et al in 2012 examining the proportion of office visits in the US in IMS Health data 
from 2007-2011 for AF resulting in anticoagulation prescriptions found that visits attributed to 
warfarin declined from 2.1 million in 2007 to 1.6 million in 2011.
170
 The number of office visits 
resulting in a dabigatran prescription increased from 0.062 million in quarter 4 of 2010 to 0.363 
million visits in quarter 4 of 2011 (3.1% to 18.9% share of visits resulting in oral anticoagulants). 
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However, the proportion of office visits resulting in warfarin decreased from 60.5% to 44.4% 
over the same interval. Pharmacy sales for dabigatran also increased from 0.8% to 8.1%. Despite 
the uptake of dabigatran, the treatment rates of high-risk patients still ranged from 20-80%, 
depending on the population under study.
170
 A very recent study of Medco claims of 41,805 non-
valvular patients indicated that patients using dabigatran were less likely to have comorbidities 
and higher ischemic stroke risk between patients initiating anticoagulation from Feb 2011 to 
April 2012.
40
  
 
2.4.3. Factors associated with anticoagulant use 
Factors associated with real-world use of dabigatran for the prevention of stroke in atrial 
fibrillation patients are still being elucidated. Characteristics of users of warfarin by comparison 
have been studied, but primarily in cohorts prior to the introduction of these novel oral 
anticoagulants though additional research is being released.
171
 The Andersen’s Behavioral Model 
of Health Services Use was used to help guide the factors examined for inclusion in the study, as 
will be described in Chapter 3. Because fewer health-system level factors can be directly 
measured in the insurance claims data used for the dissertation, the focus of this section is 
primarily on individual-level factors. 
While the use of warfarin is part of the 3-pronged approach for ischemic stroke 
prevention in atrial fibrillation and overall use has been shown to be less than adequate, some 
contraindications to therapy do exist.
148,172
 The initiation of anticoagulants often depends on 
precautions or relative contraindications to therapy (e.g., history of bleeding, alcohol use, 
dementia, falls, cancer or use of nonsteroidal anti-inflammatory medications).
116,172
 The need 
predicted by the stroke prediction scale (e.g., CHADS2 score) can also influence the decision of 
prescribing anticoagulation.
116,172
 Of these factors in the CHADS2 score, advanced age has been 
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repeatedly cited as one of the largest barriers to anticoagulation.
7,116
 History of stroke has also 
been shown to better predict more aggressive and consistent anticoagulation.
173
 
Previous research has also uncovered individual factors associated with the use of 
warfarin. A widely-cited chart review of 707 patients found that use of warfarin was significantly 
higher among patients who were younger, had prior stroke or TIA, and concomitantly used beta-
blockers, ACEIs, or diuretics.
116
 Those with lower activities of daily living or used aspirin were 
associated with a lower rate of warfarin use.
116
 Other studies have corroborated the association of 
these factors with use of warfarin.
7,116,169,173
 Patients with coronary artery disease also trended 
towards higher use of warfarin.
174
 Patient geographic location has also been shown to influence 
anticoagulation, with patients in the South being shown to be less likely to receive warfarin than 
other geographic regions, even after adjusting for other measured covariates.
169,173
  
Discontinuation after initiation has also been shown to depend on several factors. 
Younger adult men with lower stroke risk have also been shown to be more likely to discontinue 
warfarin therapy.
11
 However, this study was conducted in Canada with a strictly older adult-
based cohort where all patients had comprehensive drug coverage.  
The type of physician has also been found to affect initiation of warfarin for 
anticoagulation.
169,175
 Cardiologists or internists were more likely to prescribe anticoagulation 
compared with antiplatelet therapy (e.g., aspirin) for stroke prevention in atrial fibrillation 
compared with general and family practitioners.
173
 
Only one study using IMS health physician-level data has examined provider-level 
factors in the use of dabigatran (or any other new anticoagulant since 2010). In the study by 
Kirley et al examining the proportion of office visits attributable to warfarin versus dabigatran, 
cardiologists were found to contribute to most of the uptake.
170
 Additional literature on the 
provider-level factors associated with the use of the new anticoagulants is warranted. 
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2.4.4. Medication switching 
2.4.4.1. Switching between generic and brand warfarin products 
Because of warfarin’s narrow therapeutic index, substitution of generic warfarin for 
brand warfarin (Coumadin®) clinically has been discouraged in clinical practice guidelines.
4,176
 
Previous research has largely found minimal effects of switching, but caution that additional 
monitoring is warranted. In particular, switching between warfarin products has been thought to 
lead to increased risk of bleeding and other adverse outcomes. Out of 265 patients, Milligan et al 
saw no statistically significant differences in adverse effects or bleeding between those who 
switched to generic warfarin from brand over a 1-year period.
177
 In a multiple n-of-1 study 
between generic warfarin and Coumadin and vice versa over 30 weeks, Pereira et al saw no 
differences in mean INR or number of dosage adjustments required between groups.
33
 In an 
observational study of 2,299 patients, the INR control changed by <10% in 28.0% of patients, 
where 33.1% experienced a 10% improvement in INR and 38.9% experienced INR control that 
worsened by greater than 10%. The study authors found these differences to be statistically 
significant but not clinically significant. A major meta-analysis found strong evidence of clinical 
equivalence between brand and generic warfarin formulations (5 of 5 RCTs) but did not 
comment on safety of switching.
25
 Overall, switching between warfarin formulations is 
discouraged but still remains an area of study. 
 
2.4.4.2. Switching between anticoagulants 
Compared with switching between warfarin products, the published literature examining 
switching between warfarin and dabigatran (or any other new anticoagulant) is thin. Most of the 
literature in non-naïve patients exists solely in the setting of randomized-controlled trials. In the 
clinical trial RE-LY trial, 50% of the patients enrolled were “warfarin-experienced” resulting in a 
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0.40 reduction in ICH (p≤0.001).13 However, the exact outcomes immediately following the 
switch to dabigatran were not elucidated.  
Some recent literature is emerging via primary data collection methods. A recent study 
using patient-administered written surveys from Sept to Dec 2010 in one warfarin clinic in 155 
chronically warfarin-treated patients studied  willingness to switch from warfarin to 
dabigatran.
178
 Of the examined factors, this study found that women were less willing to switch 
than men (44% vs. 69%, p=0.003) and that patients ≥ 70 years versus ≤ 70 years were less 
willing to switch (71% v. 51%, p=0.017).
178
 Overall, the actual rate of switching and factors 
associated with switching have yet to be thoroughly examined empirically. 
 
2.4.5. Concerns associated with newly-approved products 
One final issue in examining factors associated with the use of dabigatran versus warfarin 
lies in the nature of dabigatran being a newly-approved product. Research has suggested that 
examining the effectiveness of newly-approved products may be difficult for a number of 
reasons. Some theorize that it may take up to 5-10 years for significant adverse effects to be 
identified in new drugs until a sufficient number of patients have encountered new medicines.
179
 
Phase II and III studies often do not have sufficient patients included with comorbidities and 
complexity of drug regimens that patients in real-world settings typically have; such patients are 
frequently excluded in clinical trials.
180
 It is also difficult to mimic routine clinical care and study 
every relevant sub-group in head-to-head RCTs.
181
 In addition, newly-diagnosed new users of 
medications may experience different harms and benefits than patients who have been previous 
users of alternative therapy options.
182
  
Related to dabigatran specifically, commentaries examining the generalizability of the 
RE-LY trial have suggested that dabigatran may be less useful in patients previously stabilized 
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on warfarin (defined by a high TTR for the INRs).
182,183
 Thus, examining the factors associated 
with patients who are switching from warfarin and the types of outcomes these patients may be 
experiencing has particular usefulness. 
In addition, new pharmaceuticals are usually not adopted equally and universally. 
Diffusion of innovations theory suggests that a bell-curve distribution of users of a new 
medication may exist, whereby the innovators/early adopters, using the newer therapies first, 
may differ innately from those adopting later.
184,185
  Moreover, new users of newly-approved 
products may also not be treatment naïve to other alternative therapies. These users may be those 
that previously failed these therapies and thus may be different than the ultimate users of 
medications.
122,186
  
Lastly, the apparent comparative effectiveness has also been thought to be influenced by 
whether a pharmaceutical is newly-approved or not. Some patients with greater need for the new 
therapy may be treated preferentially upon release of a new pharmaceutical.
21,22
  Said another 
way, sicker patients may be more likely to initiate therapy than healthier patients. Thus, 
observational studies of factors associated with uptake of dabigatran versus warfarin are needed. 
Examining the factors associated with the use of new therapies and how these change over time 
can help to inform future research in this area. This study seeks to advance knowledge in this 
area by incorporating these concerns about newly-approved products by examining outcomes 
among new users and switchers alike. 
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CHAPTER 3:  RESEARCH METHODS 
 
3.1. OVERVIEW OF RESEARCH DESIGN AND AIMS 
The goal of this research is to investigate the factors associated with use and switching 
between anticoagulants, the comparative effectiveness and safety of initiating different 
anticoagulants, and the real-world clinical effects of switching anticoagulants in the setting of 
new market entry of dabigatran in practice. This chapter provides an overview of the analytic 
approaches that was used in this dissertation and a rationale for their uses. Details are provided 
for the conceptual and analytic frameworks used for the study, data sources, study design, 
measurements of variables, and statistical analyses to support the dissertation aims. 
Analytically, Aim 1 consists of two sub-aims (hereafter labeled as Aim 1a and Aim 1b to 
distinguish the study designs). Aim 1a examined factors associated with new users of either 
warfarin or dabigatran post-dabigatran market entry (10/19/2010), and Aim 1b examined factors 
associated with use of dabigatran among new and previous users of warfarin after dabigatran 
entered the market. Aim 2 examined comparative clinical and safety outcomes among new users 
of warfarin and dabigatran post-dabigatran market entry. Aim 3 examined effectiveness and 
safety outcomes of switching therapy classes. 
The proposed study employed a retrospective cohort design using health insurance 
claims. While randomized-controlled trials (RCTs) are considered to provide the highest-level of 
evidence, robust to many biases, employing an observational approach allows for the study of 
real-world use patterns and clinical effects. Due to costs associated with RCTs, sample sizes in 
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RCTs are often smaller. RCTs are typically more selective with a more homogenous patient 
population that may not well represent the patient population in clinical practice. Observational 
studies generally allow for the inclusion of more clinical comorbidities and diverse patient 
characteristics than RCTs.  
 
3.2. RESEARCH FRAMEWORK 
3.2.1. Conceptual Framework 
A theoretical framework can be used to explain factors associated with patient outcomes 
in anticoagulation use for stroke prevention in atrial fibrillation. The Andersen’s Behavioral 
Model of Health Services Use was used as the basis for the conceptual framework.
166
 The 
Andersen’s Behavioral Model identifies a 3-stage model where predisposing, enabling, and need 
characteristics underlie a patient’s predisposition and use of health services, including 
medications.
165,166
 The Andersen’s Model has been frequently applied in the study of medication 
use and outcomes in other settings.
167,187,188
 Applying the Andersen’s Model in this setting helps 
to identify potential factors associated with anticoagulant use for atrial fibrillation. An 
application of the Andersen’s model can be found in Figure 2. In this figure, factors were 
identified and classified into whether they are predisposing, enabling, or need characteristics 
affecting the type of medication used and their effects on outcomes. The factors and outcomes 
pictured in Figure 1 are available within the data source for the study. 
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Figure 2. Conceptual Framework 
 
 
3.2.2. Analytic Diagram 
 Beyond the conceptual framework, an analytic diagram was used to categorize the factors 
from the conceptual framework into how they was analyzed as variables in the specific aims. The 
literature review from Chapter 2 was used to identify these covariates for the analytic diagram. 
The analytic diagram in Figure 3 classifies factors identified in the literature review into those 
associated with: 1) the exposure (anticoagulation therapy), 2) the outcomes (e.g., ischemic 
stroke), and 3) both the exposure and outcomes (confounders). Some of these factors are 
measurable using the data source; other factors cannot be measured.  
The purpose of the analytic diagram is to help distinguish true confounders from other 
factors. Confounders by definition are associated with both the exposure and the outcome and 
are not mediators between exposure and outcome but can lead to biased estimates when not 
controlled for. The X1 variables are possible instrumental variables, which could be a potential 
method to address confounding in the study, but may not be able to be measured within the 
data
189-191
. In this situation, the X3 variable would not be adjusted for in regression analyses, as 
adjustment for these could lead to bias but may influence precision of the estimates, but are not 
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available within the given data source of the Truven Health MarketScan Research Databases® 
anyway.
192
 The X2 variables are considered confounders and would be adjusted for in regression 
analyses.  
 
  
 57 
 
Figure 3. Analytic Diagram 
 
 
 
 
 
 
 
 
 
 
3.3. DATA SOURCE 
The study used the TruvenHealth MarketScan® Commercial Claims and Encounters 
(CCAE) and Medicare Supplemental Databases from January 1, 2009 through December 31, 
2012. These databases include annual information on approximately 30 million commercially-
insured individuals and Medicare beneficiaries (with supplement coverage) in the US from over 
100 nationwide insurers. These databases are considered to be nationally representative of 
commercially-insured patients in the United States.
193,194
 Those Medicare Supplement enrollees 
in the database are those who receive employer-sponsored health insurance benefits and may be 
less generalizable to Medicare Part D beneficiaries on stand-alone plans. These data are also not 
generalizable to Medicaid patients, as those patients generally differ from those in commercially 
insured plans. 
This proposed dissertation research used inpatient services files, outpatient services files, 
prescription claims files, laboratory files, and annual enrollment summary files. All files are 
linked by a unique but encrypted identifier for individual enrollees. The database also includes 
X1: Exposure Only 
- Treatment preference 
- Calendar Time (diffusion 
of technology) 
X3: Outcome Only 
- Genetic factors 
Exposure: Anticoagulant 
- Warfarin 
- Dabigatran 
Outcomes 
- Clinical effectiveness 
- Risk of harm 
- Acute myocardial infarction 
X2: Exposure and Outcome 
- Age 
- Gender 
- Clinical comorbidities 
- Concomitant medications 
- Ischemic stroke and 
bleeding risk scores 
- Geographic residence (small 
area variation in treatment 
preference) 
- Type of health insurance 
- Prescription benefits 
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the REDBOOK
TM
 supplement, which provides drug name, therapeutic classification, pricing and 
product strength and dosage forms to identify drugs in the outpatient pharmaceutical claims files 
by national drug code (NDC). Inpatient services files include dates of admission and discharge, 
diagnoses and procedures, admission source, length of stay, and discharge destination for each 
individual. Outpatient services files include dates of service, procedures and diagnoses, and cost 
information for each individual patient encounter. Pharmaceutical claims files include each 
prescription filled by the patient, including dates of fill, type of medication, strength, dose, 
dosage form, quantity copay and coinsurance, and cost to the third-party payer. As with similar 
databases, no inpatient pharmaceutical claims history is available. Laboratory files are available 
on approximately 10% of patients in the MarketScan® datafiles. These tests are from the 
outpatient setting from one large national testing laboratory including dates of the tests, 
diagnosis, test result, and reference values. 
All analyses and cohort selection were performed using SAS 9.3. 
 
3.4. COHORT SELECTION 
 To address the aims of this project, two cohorts of samples were assembled: a new-user 
cohort since dabigatran market entry (10/19/2010) and a prevalent user cohort that also includes 
enrollees using warfarin prior to dabigatran market entry, with some additional restrictions. 
Published studies
11,30,151,173,195,196
 and STrengthening the Reporting of Observational studies in 
Epidemiology (STROBE) guideline recommendations from an international collaborative of 
epidemiologists, statisticians, and researchers were used to guide the study design. 
197,198
  More 
information on the inclusion and exclusion criteria is provided in the next section.  
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3.4.1. Aims 1a and 2: Cohort design and identification 
 This section describes the specifications for the new user cohort that was used for Aims 
1a, 2, and 3. By definition, new user designs for medication studies identify patients in the study 
population who are newly initiating therapy.
199
 Generally, a wash-out period in retrospective 
studies is used to ensure that patients are in fact first beginning therapy after a specific date. 
Studying new users helps to control for other disease risk factors that may be altered by previous 
use of the study drugs and fully capture any adverse events that would occur early in therapy 
use.
199
 
 
3.4.1.1 Inclusion criteria 
For all the aims of the project, we selected a cohort of patients meeting the following 
inclusion criteria: 1) filling ≥ 1 prescription for warfarin or dabigatran after 10/19/2010 
(dabigatran FDA approval date), hereafter referred to as the “index prescription” with the date of 
fill as the index prescription fill date; 2) ≥ 18 years of age at index prescription fill date; 3) 
receiving at least 1 inpatient or 2 outpatient International Classification of Diseases, 9
th
 edition 
(ICD-9) codes for atrial fibrillation (AF) (ICD-9: 427.31) occurring on separate days in the 12 
months on or prior to the index prescription fill date; and 4) maintained continuous enrollment 
for at least 12 months prior to the index prescription fill date. Of note, 1 outpatient ICD-9 AF 
code could occur after the index prescription fill date. We also required that the 2 ICD-9 codes 
occur on separate days to eliminate the possibility of using the code as a rule-out condition.  
For Aims 1a, 2 and 3, a new user cohort of patients with AF was assembled. By 
definition of a new user cohort, participants were not included if they have had a warfarin or 
dabigatran fill in the previous 12 months prior to their index prescription fill date. Patients were 
also identified as “newly-diagnosed” new users if their first ICD-9 AF code occurred within 30 
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days prior to the index prescription fill date. For Aim 1b, a prevalent user cohort of AF patients 
was assembled from this larger cohort meeting the above inclusion criteria, but who are also 
previous users of warfarin. For Aim 1b, an additional restriction of continuous eligibility was 
also applied for this prevalent user cohort and for the new user cohort to examine switching the 
12-month period following initiation. In addition, Aim 3 utilized the cohort from Aim 1a. 
For both cohorts, patients were also required to be enrolled continuously in their 
insurance plan for at least 12 months prior to their index diagnosis date and up until the index 
prescription fill date in order to adequately capture baseline clinical characteristics and 
medication use history. As context, commercial insurance databases have an approximately 25-
30% annual turnover in enrollees, with an average enrollment time of approximately 2 years.
200
 
We have found this statistic to be similar with Truven MarketScan® database.
201
 Requiring 12 
months of continuous enrollment, while common in these types of studies, may limit the patient 
sample.
200
 However, the internal validity of the study is increased when using an adequate run-in 
period – both to ascertain that patients are new users and to better capture baseline 
characteristics.
200
 New user study designs and similar inclusion criteria have been used 
previously when evaluating prescription claims data.
199,202
  
 
3.4.1.2 Exclusion criteria 
For the new user cohort used in Aims 1a, 2, and 3, patients were excluded from the study 
if they received any prior prescription for warfarin or dabigatran within the 12-month baseline 
period prior to the index date. Excluding these individuals by requiring a 12-month “clean” 
period of treatment-naïve individuals lowers the potential for including prevalent users.
199
 
Including a prevalent user population could lead to a potential induction of survivor bias, 
especially as the likelihood of switching between medications and adverse effects from switching 
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may vary over time.
199
 However, events that occur before the 12-month inclusion period may be 
missing, because the 12-month look back period is not all-inclusive. For instance, patients with a 
warfarin prescription fill more than 12 months prior to the index diagnosis date would still be 
included in the inception cohort. This limitation, however, is common to other observational 
studies using a new user design. 
Because dabigatran is only indicated in non-valvular AF, patients with ICD-9 codes 
corresponding to valvular and transient AF in the 12-month baseline period were excluded from 
the analysis to ensure that appropriate comparator groups were maintained.
13,203
 These exclusions 
are similar to those applied in the RE-LY trial and have been applied previously.
13,201
 These 
codes include ICD-9 codes for mitral valve replacement (35, 37, 35.1, 35.2, 35.9, 35.12, 35.23, 
35.24, 35.9, 35.96, 35.97, 37.4, 37.35, 37.4, 37.41), heart valve replacement (V42.2, V43.3), 
mitral valve stenosis (394.0, 394.2, 396.0, 396.1, 396.8), atrial flutter (427.32), hyperthyroidism 
(242, 242.0, 242.1, 242.2, 242.3, 242.9), hepatic-related diagnosis (571.1, 571.3, 571.5, 571.8, 
571.9, 572.8, 573.3, 573.9), vitamin K deficiency (269.0) and coagulation or antiphospholipid 
deficiencies (286.0-286.8, 286.52, 286.53, 286.59).  
 
3.4.2. Aim 1b: Cohort design and identification 
 To examine the factors associated with switching between anticoagulants and clinical 
effects following switching, Aim 1b examined the 12-month period following the index 
prescription date (or the first prescription post-10/19/2010). As previously discussed, it is 
possible that the reasons for new users to initiate one therapy versus another may differ from 
those who have been previously using warfarin therapy, so first, a cohort of newly-initiating 
patients who were continuously enrolled for 12-months after the index prescription fill date was 
constructed for Aim 1b. Secondly, a prevalent user cohort was also created, whereby patients 
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were prevalent users of warfarin, having received at least prescription in the 12-month baseline 
period. Using this prevalent user design additionally allowed the inclusion of individuals who 
have previously used warfarin and examine whether certain characteristics over the 12-month 
baseline are more associated with switching to dabigatran.   
 Thus, for Aim 1b, with one exception, the same inclusion and exclusion criteria from the 
new user cohort for Aim 1a applied, including age ≥ 18 years, ≥1 inpatient or 2 outpatient AF 
diagnoses within the previous 12 months, no reversible AF condition, no warfarin prescription 
fill, and ≥12 months of continuous eligibility and prescription drug benefits in the previous 12 
months. For the new user cohort for Aim 1b, patients were additionally excluded if they did not 
have continuous eligibility and prescription drug benefits through 12 months after the index 
anticoagulation date. For the prevalent user cohort, all of the aforementioned inclusion criteria 
applied, but patients were not excluded if they had a warfarin prescription fill in the 12-month 
baseline but they were excluded if they were not continuously enrolled through 12 months after 
their first anticoagulation date after 10/19/10. 
 
3.4.3. Aim 3: Cohort design and identification 
 For Aim 3, two subcohorts were constructed from non-valvular AF patients using 
anticoagulation after 10/19/2010. The first primary cohort was constructed from newly-initiating 
patients who switched anticoagulation following the index prescription fill date using a time-
varying method of anticoagulant switching to avoid immortal time bias.
204-206
 In this main 
cohort, patients were selected if they met the Aim 1a cohort criteria (≥18 years of age, newly-
initiating anticoagulation after 10/19/2010, having continuous eligibility and ≥1 inpatient or ≥2 
outpatient diagnoses within the previous 12 months, at least one of which occurring before the 
index prescription fill date) and were followed to see if they switched anticoagulation. 
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In this time-varying analysis, all patients were considered non-switchers from the time of 
study entry until they lost continuous eligibility, experienced the study outcomes of interest (e.g., 
clinical effectiveness outcome, as described later), switched anticoagulants, or were censored 
administratively on 12/31/2012. This time was captured as “non-switcher” time; notably, if 
patients switched after they experienced a study outcome, they were censored and not included 
as “switchers”. Patients who switched anticoagulants were measured for follow-up time as 
“switchers” then from the time of the switched until loss of continuous eligibility, administrative 
censoring, or experiencing the study outcome of interest. This time-varying exposure method 
(compared with time-fixed methodology) is designed to limit both confounding by indication and 
immortal time bias by adequately categorizing follow-up time from treatment initiation. As 
described later, patients who experienced a clinical effectiveness outcome were not censored in 
the analyses for either the harm outcome composite or acute myocardial infarction outcome, 
either before or after an anticoagulant switch. 
 
3.4.4. Study Schematic 
Figure 4 below illustrates the proposed study schematic for the cohorts.  Aims 1a and 1b 
utilized a retrospective cohort study design to determine factors associated with the 
anticoagulants’ use. Aims 2 and 3 examined comparative clinical and safety outcomes among 
users of warfarin and dabigatran post-dabigatran market entry using the cohorts assembled for 
Aim 1a and 1b with the few differences in cohort construction noted above. For Aims 2, patients 
were followed from the index medication date until either: 1) outcome; 2) loss of continuous 
eligibility; or 3) end of the administrative period. Aim 3 examined effectiveness and safety 
outcomes of switching anticoagulants compared with non-switchers using two different methods. 
For the primary analysis, patients were followed from the index prescription fill date until either: 
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1) switch; 2) outcome of interest; 3) loss of continuous eligibility; or 4) end of the administrative 
period. Patients who switched were then followed until one of the following: 1) outcome of 
interest; 2) loss of continuous eligibility; or 3) end of the administrative period.   
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Figure 4. Study Schematic: New User Cohort 
a. Aim 1a and 1b: New User and Switcher Cohorts 
 
 
 
b.  
 
 
 
 
 
 
 
 
 
 
 
Note: New User and Newly-diagnosed New User Cohorts did not require 12-months of 
continuous eligibility after index prescription date
12/31/2012 10/19/2009 10/19/2010 
Index prescription 
(anytime after 
10/19/2010) 
Measurement of baseline factors (12 months) 
 
- ≥ 18 years of age 
- ≥ 1 inpatient or 2 unique outpatient 
diagnoses on separate days (1 can be 
after index fill) 
- No reversible AF condition 
- ≥ 12 months continuous eligibility 
and prescription benefits 
 
- ≥ First AF diagnosis within 30 days 
- No anticoagulation fill in previous 
12 months 
Cohort Definitions 
Study Period 
Aim 1a: New user 
cohort 
Aim 1a: Newly-
diagnosed new user 
cohort 
Aim 1b: New user 
cohort 
- ≥ 12 months continuous eligibility 
and prescription benefits 
Aim 1b: Prevalent 
user cohort 
- ≥ 12 months continuous eligibility 
and prescription benefits 
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b. Aim 1b. Switching definition for prevalent user cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
12/31/2012 10/19/2009 10/19/2010 
Index prescription 
(anytime after 10/19/2010) 
Study Period 
If prescription 
is warfarin 
≥1 dabigatran or rivaroxaban 
fill in 12-month follow-up 
Warfarin 
Switcher 
If prescription 
is dabigatran 
Prevalent user definition 
≥1 warfarin prescription in 12 
months 
No dabigatran or rivaroxaban 
fill in 12-month follow-up 
Non-
switcher 
If prescription 
is rivaroxaban 
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c. Aim 2: New User Cohort: CER 
 
 
 
 
 
 
 
 
 
 
 
 
d. Aim 3: Anticoagulant switchers versus non-switchers (primary analysis) 
  
Case 4 
Case 3 
12/31/2012 10/19/2009 10/19/2010 
Index prescription 
(anytime after 
10/19/2010) 
Measurement of baseline factors (12 months) 
 
- ≥ 18 years of age 
- ≥ 1 inpatient or 2 unique outpatient 
diagnoses on separate days (1 can be 
after index fill) 
- No reversible AF condition 
- ≥ 12 months continuous eligibility 
and prescription benefits 
 - No warfarin fill in previous 12 
months 
Study Period 
Patients followed until either: 1) 
outcome; 2) loss of continuous 
eligibility; or 3) administrative 
censoring  
Cohort entry as 
“non-switcher” 
Cohort entry as 
“switcher” 
Follow from initial entry until anticoagulant switching, outcome of 
interest, loss of continuous eligibility, or 12/31/2012 
Note: Patients were not censored for the clinical effectiveness 
outcome if experiencing one of the harm outcomes, etc. 
12/31/2012 
 “Non-switcher” until different 
anticoagulant Rx; then “switcher” 
until outcome (X) 
 “Non-switcher” until 
administrative censoring 
Case 1 
Case 2  
“Non-switcher” until outcome (X) 
“Non-switcher” until outcome (X) 
= Anticoagulant 2 Rx 
= Outcome 
= Anticoagulant 1 Rx 
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3.4.4. Sample size 
The TruvenHealth MarketScan® research database provides information on more than 30 
million individuals.
193,194
 Sample size calculations were based on the narrowly-defined new user 
cohort used for Aim 1a and Aim 2. Based on preliminary sample size selection in the 1% sample, 
the database was anticipated to provide sufficient power for studying the aims. We anticipated 
the ability to reach this level based on the dataset. From Oct 2010 until Dec 2012, 64,935 new 
users of warfarin and dabigatran meeting the inclusion criteria were identified in the 100% 
sample.  Given parameters (80% power, 2-tail 0.05 significance level) and event rates from 
published RCTs, the relationship between the effect size and sample size was estimated using 
Proc Power in SAS and displayed in Table 6.  
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Table 6. Sample size calculations 
 
  Abbreviation: TIA: transient ischemic attack; VTE, venuous thromboembolism; AMI, Acute Myocardial Infarction 
 
The possible hazard ratios comparing warfarin versus dabigatran are displayed in Table 6 
with corresponding sample sizes required to note a statistically significant difference. These 
power calculations also assume approximately equal sample sizes in each of the new user 
groups. As the table illustrates, this total sample size should have had the power to detect at least 
a 10% relative risk difference for the clinical effectiveness and harm outcomes composites and 
the acute myocardial infarction endpoints between warfarin and dabigatran. This relative risk 
difference is generally considered to be clinically significant. 
 
3.5. MEASUREMENTS 
3.5.1. Treatments 
Treatment was determined using National Drug Codes (NDC) codes from the outpatient 
pharmaceutical files. Patients were classified by the type of medication used initially following 
  Power = 80% and alpha = 0.05 (two-tailed)    
Outcomes Reference 
12-month 
event-free 
rate 
 Hazard Ratio    
Total N 
needed 
1.40 1.35 1.30 1.25 1.20 1.15 1.10 1.05 
Stroke (TIA or 
ischemic) 
0.95
7
 N 4,516 5,774 7,688 10,822 16,526 28,694 63,022 245,934 
VTE 0.93
6
 N 3,234 4,132 5,502 7,744 11,822 20,520 45,060 175,792 
Effectiveness 
Composite 
0.88
6
 N 1,898 2,424  3,226  4,536  6,922  12,008  26,350  102,732  
Intracranial 
hemorrhage 
0.99
207
 N 22,480 28,748 38,292 53,936 82,392 143,130 314,516 1,227,960 
Gastrointestinal 
hemorrhage 
0.95
131
 N 4,516 5,774 7,688 10,822 16,526 28,694 63,022 245,934 
Other bleeding 
events 
0.96
208
 N 5,640 7,210 9,600 13,518 20,642 35,846 78,740 307,310 
Harm Composite 0.78
131
 N 1,048 1,338  1,778  2,498  3,806  6,594  14,450  56,254 
AMI 0.86
72
 N 1,600 2,082 2,770 3,896 5,942 10,306 22,610 88,122 
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the diagnosis date, with either warfarin or Coumadin® use classified as ‘warfarin’ and fills for 
dabigatran being classified as dabigatran users. Prescription refill records are often considered 
the ‘gold-standard’ for measuring medication use and have demonstrated similar sensitivity and 
specificity as other observational adherence methods, including pill counts, self-report and 
electronic records.
209,210
 Prescription fill information was also measured, including anticoagulant 
strength/dose, quantity and days’ supply information. Other medications were measured as 
indicated in the Covariates section, including copay costs.  
 
3.5.2. Outcomes 
3.5.2.1 Medication Switching 
For Aim 1b, as indicated in Figure 4, a medication switch was defined as the first 
prescription claim for a different anticoagulant (e.g., warfarin, dabigatran or rivaroxaban) in the 
outpatient pharmaceutical claims file within the 12 months following the index prescription fill 
date. This date was referred to as the medication switch date. The anticoagulant that the index 
medication was switched to was also reported. Prescription claims for warfarin and Coumadin® 
were classified as the same pharmaceutical product for this research. Individuals without a 
medication switch throughout the entire follow-up period were classified as non-switchers.  
For Aim 3, as indicated in Figure 4, a medication switch was defined as the first 
prescription claim for a different anticoagulant (e.g., warfarin or dabigatran) in the outpatient 
pharmaceutical claims files. If patients were not previously administratively censored, lost 
continuous eligibility, or experienced a study outcome and then received a prescription for a 
different anticoagulant, this date is heretofore referred to as the medication switch date. Patients 
switching from warfarin or dabigatran to rivaroxaban were not included in the main analysis.  
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3.5.2.2 Clinical Effectiveness 
Clinical effectiveness was defined as a composite of the occurrence of ischemic stroke, 
TIA, and other thromboembolic events in the follow-up period. The presence of either a primary 
or secondary diagnosis using ICD-9 coding in the inpatient or outpatient medical claims was 
used. Validated ICD-9 coding algorithms were used to measure the outcome events for clinical 
effectiveness, which are based on published studies found in the literature.
104,211-214
 Table 7 
displays the ICD-9 coding schema used to identify clinical effectiveness outcomes; these 
algorithms are discussed further in the following sections. Patients with previous ischemic stroke 
were not excluded from the analysis; of note, previous stroke history was adjusted for in the 
regression analyses. 
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Table 7. International Classification of Disease, 9th Edition (ICD-9) codes  
for clinical effectiveness outcome definitions in inpatient and outpatient service claims files 
 
Outcome ICD-9 Codes Diagnosis position* 
Stroke 
  Ischemic stroke 
  Transient ischemic attack 
 
433.01, 433.11, 433.21, 433.31, 
433.81, 433.91, 434 (excluding 
434.x0), 436 
435 
 
Primary or Secondary 
Primary* 
Other thromboembolic event (deep 
vein thrombosis, pulmonary 
embolism) 
415, 451, 453 Primary or Secondary 
  * Inpatient service claims files only 
 
3.5.2.3 Risk of Harm 
The risk of harm is defined as a composite of the occurrence of severe adverse side 
effects from the use of anticoagulant therapies. The severe adverse side effects was the presence 
of a primary or secondary diagnosis of intracranial hemorrhage/hemorrhagic stroke, 
gastrointestinal hemorrhage, other bleeding events, and inpatient hospitalization in the inpatient 
or outpatient medical files in the follow-up period. Validated ICD-9 coding algorithms from the 
published literature were used to measure these outcomes. Table 8 displays the ICD-9 codes 
used for the risk of harm outcomes; these algorithms are discussed further in the following 
sections.  
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Table 8. International Classification of Disease, 9th Edition (ICD-9) codes 
 for risk of harm outcome definitions in outpatient or inpatient service claims files 
 
Outcome ICD-9 Codes Diagnosis field position 
Intracranial hemorrhage or 
hemorrhagic stroke 
430, 431, 432 Primary or Secondary 
Gastrointestinal hemorrhage 455.2, 455.5, 455.8, 456.0, 
456.20, 459.0, 578 
Any 
Other bleeding events 423.0 (hemopericardium), 
593.81 (vascular disorders of 
kidney), 599.7 (hematuria), 
719.11 (hemarthrosis), 784.7 
(epistaxis), 784.8 (hemorrhage 
from throat), 786.3 
(hemoptysis) 
Any 
Hospitalization in the follow-up - Any encounter in inpatient 
services files 
Measured separately for Aims 2 and 3  
Myocardial infarction
§
 410.x1 Primary or Secondary* 
  * Inpatient service claims files only 
   § 
Not included in risk of harm composite outcome 
 
3.5.2.4. Myocardial Infarction 
Notably, AMI was measured as an outcome for the study. However, because of how the 
RE-LY trial collated its outcomes, was not included in either the individual risk of effectiveness 
or risk of harm composites, but is listed in Table 8. AMI has been thought to be both a “harm” 
outcome, in that the RE-LY trial showed a slight increase in the risk of AMI compared with 
warfarin (with an unknown pathophysiology); however, ischemic stroke and AMI frequently co-
occur in patients, and warfarin has been used to anticoagulant in patients with AMI.  
 
3.5.2.5. Algorithms to identify outcomes 
 Tables 7 and 8 illustrate the ICD-9 codes used for the clinical effectiveness outcome and 
harm outcome definitions in Aims 2 and 3. Each of these clinical effectiveness outcomes was 
identified using ICD-9 codes in the inpatient or outpatient service claims files unless otherwise 
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specified; specific diagnosis field position requirements are listed in the table. Outcomes were 
assessed based on the presence of medical or inpatient claims with either a primary or secondary 
diagnosis. For Aim 1b, these outcomes were measured as independent variables to be tested for 
an association with a medication switch. For Aims 2 and 3, these outcomes were considered 
dependent variables in the comparative effectiveness and safety analyses among new users.  
All these ICD-9 codes have been validated and/or used frequently in the published 
literature (when validation studies not available). Each of these outcomes was identified in 
inpatient or outpatient service claims files; specific diagnosis field position requirements are 
listed in Tables 7 and 8. 
 While a variety of algorithms have been studied to identify these outcomes using ICD-9 
codes, some have better reported correlation with clinical records. Usually ICD-9 diagnostic 
measures are compared using positive predictive value (PPV), which is the proportion of positive 
tests that are true positives; the higher the PPV, the higher the probability that a positive test 
indicates the underlying disease condition. Validated algorithms identifying ischemic stroke have 
generally performed well, resulting in positive predictive values of 85% of higher.
211,215-218
 Some 
algorithms in a recent systematic review recommended also including transient ischemic attack 
(TIAs) as part of the composite endpoint, shorter ischemic strokes of less severe nature, as long 
as they were identified in the inpatient file only in the principal position.
211,219
 TIA tended to 
have lower PPV than ischemic stroke algorithms.
211
 Studies comparing algorithms using the 
primary diagnosis code versus the secondary code found slightly higher PPV for algorithms 
using primary versus secondary, but others have recommended both positions.
211,216
 In studying 
thromboembolic events, the highest PPV has been reported for the combined use of ICD-9 codes 
415 (pulmonary embolism), 451, and 453 (deep vein thrombosis) for identifying a VTE event, 
with a PPV of 65 to 95% in either the primary or secondary diagnostic field.
64,214
 Studies have 
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also recommended studying VTE events in tandem in ICD-9 algorithms compared with either 
DVT or PE alone.
64,214
  
Compared with the clinical effectiveness outcomes, comparably fewer validation studies 
have been conducted on risk of harm outcomes.
211,215,220
 Validation studies examining the 
identification of intracranial hemorrhage (including intracerebral hemorrhage and subarachnoid 
hemorrhage) through ICD-9 codes have reported PPVs of 77% or higher compared with 
abstraction of medical charts, in both the inpatient and outpatient setting.
211,215
 The reported 
PPVs ranged from 80% to 94% for patients with a primary or secondary discharge diagnosis; one 
study examining codes in any position of the inpatient file still reported a high PPV for 
intracranial bleeds.
211,215,221
 Other bleeding events validation studies are even less frequently 
studied in the literature.
211
 Because these conditions are less likely to present as the primary or 
secondary diagnoses (and more likely to be less severe), these conditions were identified by 
diagnosis codes used from previous studies using any diagnosis field position in either the 
outpatient or inpatient service claims files. In addition, because of limitations with how the 
coding schemes for intracranial hemorrhage and hemorrhagic stroke overlap in clinical practice, 
these outcomes were combined together.  
Acute myocardial infarction, by comparison, is generally considered to be a relatively 
well-validated outcome. Previously-validated algorithms for identifying AMI have yielded PPV 
of 89% to 97% when using 410.x1 in the primary or secondary discharge field.
220,222
 
Sensitivity analyses were also conducted on this outcome definition, specifically 
restricting to only outcomes that occurred in the inpatient setting, which would help examine the 
comparative effectiveness of the agents on clinically-significant events. 
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3.5.3. Covariates 
 Several covariates have been identified from the predisposing characteristics, enabling 
resources, and need characteristics from the previously-described analytic model. The Truven 
Health MarketScan® database dictionary and user guide were used to identify the variables 
which were available. The covariates used in the analysis are frequently used in the published 
literature in this field of research.
11,13,174,202,223,224
 These covariates thought to be predictive of the 
outcomes in this study were included in the analytic models, described in later sections. These 
covariates were measured in the 12-month baseline period prior to the medication fill under 
study for that aim using published algorithms. For Aims 1a, 1b, 2, and the primary analysis for 
Aim 3, these covariates were measured in the 12 months prior to the index prescription fill date. 
These definitions are summarized in Table 9 below. 
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Table 9. Covariate descriptions and coding strategies for patient  
characteristics in 12-month baseline period 
 
Patient Characteristics Covariate Coding Covariate Definition 
Predisposing Characteristics   
Age at Diagnosis 
Continuous; Categorical (<55 
years, 55-64 years, 65-74 years, 
>74 years) 
Age in years at time of prescription 
fill 
Sex 1=Male, 2=Female Sex from enrollment file 
Geographic Region 
Northeast, North central, West, 
South 
Region from enrollment file 
Enabling Resources   
Insurance Type 
Comprehensive, HMO, POS, PPO, 
CDHP 
Type of insurance from enrollment 
file 
Prescription benefits generosity None, Poor, Fair, Good 
Ratio of patient cost-sharing for 
prescription payments relative to 
total payments for prescriptions 
Index prescription generosity 
(measured descriptively not as 
covariate) 
None, Poor, Fair, Good 
Ratio of patient cost-sharing for 
index anticoagulation 
prescription(s), relative to total 
payments 
Need Characteristics   
     Comorbidities   
Previous ischemic stroke 0=Absent, 1=Present Ischemic stroke diagnosis 
Renal Impairment 0=Absent, 1=Present 
Chronic kidney disease or End 
Stage Renal Disease diagnosis 
Congestive Heart Failure 0=Absent, 1=Present Congestive heart failure diagnosis 
Previous venous thromboembolism 
(VTE) 
0=Absent, 1=Present VTE diagnosis 
Hyperlipidemia 0=Absent, 1=Present Hyperlipidemia diagnosis 
Hypertension 0=Absent, 1=Present Hypertension diagnosis 
Diabetes Mellitus 0=Absent, 1=Present Diabetes Mellitus diagnosis 
Previous myocardial infarction 0=Absent, 1=Present Myocardial infarction diagnosis 
Coronary artery disease 0=Absent, 1=Present Coronary artery disease diagnosis 
Previous major bleeding 0=Absent, 1=Present 
Diagnosis of hemorrhagic or 
gastrointestinal bleeding 
Anemia 0=Absent, 1=Present Diagnosis of anemia 
Peptic Ulcer disease 0=Absent, 1=Present Diagnosis of peptic ulcer disease 
Peripheral vascular disease 0=Absent, 1=Present 
Diagnosis of peripheral vascular 
disease 
Sleep apnea 0=Absent, 1=Present Diagnosis of sleep apnea 
Cognitive impairment 0=Absent, 1=Present 
Diagnosis of dementia, 
Alzheimer’s 
     Patient Disease Severity   
Charlson Comorbidity Index (CCI) 
Continuous, Categorical (0, 1-2, 3-
5, 6-8, ≥9) 
Patient disease severity 
CHADS2 Continuous, Categorical (0, 1, ≥2) Ischemic Stroke Risk score 
CHA2DS2-VASc Continuous, Categorical (0, 1, ≥2) Ischemic Stroke Risk score 
ATRIA 
Continuous, Categorical (0-3, 4, 
≥5) 
Bleeding Risk score 
HAS-BLED Continuous, Categorical (0-2, ≥3) Bleeding Risk score 
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Number of hospitalizations Continuous, Categorical (0, ≥1) 
Number of hospitalizations in 
baseline 
Concomitant treatments and 
therapies 
  
Antiplatelet therapy 0=Non-use, 1=Use 
Prescription fill for clopidogrel, 
Aggrenox or aspirin 
Gastroprotective agents 0=Non-use, 1=Use 
Prescription fill for PPIs, H2RAs, 
GI protectants (e.g., sucralfate) 
Antiarrhythmics 0=Non-use, 1=Use 
Prescription fill for flecainide, 
amiodarone, dronedarone, sotalol, 
propafenone and dofetilide 
Rate control therapy 0=Non-use, 1=Use 
Prescription fill for beta-blockers, 
digoxin, or calcium channel 
blocker 
Catheter ablation 0=No CA, 1=CA Procedure for catheter ablation 
Hormone use 0=Non-use, 1=Use 
Prescription fill for oral 
contraceptive or hormone 
replacement therapy 
ACEI/ARB therapy 0=Non-use, 1=Use Prescription fill for ACEI/ARB 
Statin therapy 0=Non-use, 1=Use 
Prescription fill for HMG Co-A-
reductase (statin) 
  Abbreviations: HMO, Health Maintenance Organization, POS, Point-of-service; PPO, Preferred provider organization; CDHP,   
consumer-driven health plan , PPI, proton pump inhibitor; H2RA, H2 receptor antagonist; GI, gastrointestinal; CA, catheter 
ablation; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker 
 
 
3.5.3.1   Patient characteristics 
Clinical and demographic characteristics and their coding strategies can be found in 
Table 9 based on whether they can be classified as predisposing, enabling or need characteristics. 
Based on the literature, all of these clinical and demographic characteristics were considered to 
be X2 covariate variables (identified by the analytic framework) and are displayed by type of 
characteristic from the conceptual model.  
 
3.5.3.1.1 Predisposing characteristics 
Available predisposing characteristics, such as age, gender, type of health plan, and 
geographic location was included as covariates in the 12-month baseline period prior to the index 
prescription fill date. Sex was coded as “male” or “female”. Geographic region was coded from 
the “Region” variable in the database, which is based on the employee residence at the time of 
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the index prescription fill. Previous research in a variety of disease has indicated that patient 
geographic residence is associated with varying quality of health care received. Controlling for 
broad geographic regions can help adjust for these variations in care received prior to AF 
diagnosis to help identify true clinical differences between anticoagulants. Northeast was used as 
the reference category. Per the TruvenHealth MarketScan® user guide, as of 2011, the 3-digit zip 
code field throughout the enrollment, inpatient and outpatient files, and pharmaceutical files is 
no longer supported and has been removed due to data quality issues. Thus, the most granular 
geographic variable available is the variable indicating the patient’s state. 
 
3.5.3.1.2 Enabling characteristics 
Enabling factors were measured based on information available in the databases. Type of 
insurance was classified based on the “Plan Indicator” variable in the database, as follows: 
comprehensive, health maintenance organization (HMO), non-capitated point-of-service (POS), 
preferred provider organization (PPO), and other (basic/major medical, exclusive provider 
organization, capitated or partially-capitated point-of-service and consumer-driven health plans). 
Prescription benefits generosity was calculated from the method described by Artz et al
225
, which 
sums the enrollee’s cost-sharing contributions for all prescription drugs divided by the total net 
prescription drug payments (including brand and generic products), because the overall 
copayment burden may influence medication preferences and a patient’s predisposition towards 
a certain therapy. This prescription benefits generosity measure would not include the study 
anticoagulant. If a patient has no record of any prescription fill prior to the anticoagulation in the 
12-month baseline period, they were coded with a ‘missing’ value. The ratio was initially 
categorized into four levels: None (ratio > 0.99), Poor (ratio > 0.80 and ≤ 0.99), Fair (ratio > 0.20 
and ≤ 0.80) and Good (ratio ≥ 0 and ≤ 0.20).  
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 The patient’s index anticoagulation copay cost and relative cost-sharing proportion 
compared with the amount paid by the insurer was also measured and categorized using the 
method by Artz et al described above.
225
 Multiple anticoagulation fills may have occurred on the 
same day (e.g., multiple strengths of warfarin), and these were summed together. These two 
covariates were examined descriptively and not included in regression analyses. 
 
3.5.3.1.3 Need characteristics 
Need characteristics included patient baseline comorbidities, patient disease severity, risk 
of ischemic stroke and bleeding from disease severity measures, and concomitant medications 
thought to be associated with prognosis in atrial fibrillation. These factors were previously 
described in Chapter 2. Patient disease severity coding schemes have been published previously, 
along with diagnosis field code positions.
103,105,111,202
  
The Charlson Comorbidity Index (CCI) is a commonly-used composite measure of 
disease burden which serves as a proxy for patient health status; the higher the score, the greater 
the comorbidity burden.
226,227
 The CCI algorithm using ICD-9 codes has been previously 
published in a variety of settings and was employed to garner patient baseline disease 
burden.
28,226,227
 The CCI was measured from the 12-month baseline period. In addition, all 
factors related to adverse outcomes from the medication use were also measured following the 
index prescription fill date until the medication switch date. These were classified as covariates 
for Aims 1b and 3 for adjustment in the switcher analysis as previously discussed. 
Risk of ischemic stroke was measured using both the CHADS2 and CHA2DS2-VASc risk 
scores while risk of bleeding was measured using the ATRIA and HAS-BLED risk scores. As 
previously discussed in Chapter 2, ATRIA risk factors are currently considered to be more 
reliably measured in medical claims compared with other severity indices. As of March 2014, 
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CHA2DS2-VASc score has been recommended for use in the United States over the CHADS2 
score.
5
 In addition, the HAS-BLED risk score was measured as a sensitivity analysis as it 
includes additional risk factors beyond the ATRIA and has been more commonly used in 
observational studies using secondary claims. All of these risk scores were also assessed 
descriptively. 
 
3.6. ANALYSES 
This is a retrospective observational cohort study studying factors associated with use, 
clinical effectiveness and safety following anticoagulation with either warfarin or dabigatran. For 
these analyses for all aims, commercially-insured patients were also analyzed separately from the 
Medicare Supplement patients as a sensitivity analysis, because these patients could have 
different clinical and demographic backgrounds.
37,193
 The following sections detailed the 
analyses plan for each specific aim. 
 
3.6.2. Aim 1 
Specific Aim #1: Assess and investigate patient factors associated with new use of either 
warfarin or dabigatran and switching between anticoagulants in patients with atrial fibrillation. 
Hypothesis 1: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will 
not differ between new users of warfarin compared with dabigatran.  
Hypothesis 2: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will 
not differ between new users who switch anticoagulants within 12 months compared with 
those who do not switch. 
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Analytic model: 
 
 
 
 
3.6.2.2 Statistical analysis and model diagnostics 
As previously described, Aim 1 was analytically structured into two sub-aims: Aim 1a 
and Aim 1b. Aim 1a assessed factors associated with new use of either warfarin or dabigatran; 
Aim 1b assessed factors associated with switching from the index anticoagulant following 
dabigatran market entry. Both sub-aims used the ischemic stroke and bleeding risk scores as 
primary independent variables for the analysis. Even though these sub-aims involved the 
separation of cohorts (new user and prevalent user), the statistical analysis of the factors 
associated with the anticoagulant use is the same. 
The number and proportion of patients initiating each medication was described.  
Descriptive statistics of initiation by medication (Aim 1a) and switches (Aim 1b), including 
direction (Aim 1b) were presented for each major demographic and clinical characteristic across 
the entire study period, including the absolute standardized differences between the proportions. 
The time between the index medication and the medication switch date was measured and 
reported descriptively  
For Aim 1a, the anticoagulation doses and patient cost-sharing (e.g., copayments) at the 
time of the index prescription were also presented for the doses used in clinical practice and 
assessed descriptively. Time trends in initiation of the index anticoagulation medication were 
also examined. 
Equation 1 
Anticoagulant treatment = α + β1(X1) + βx(Xl) + ε 
α = Intercept 
βx = Regression coefficient for X1 
Xl = Independent variable (a risk score) 
βx = Vector of all measured variable coefficients for the X 
Xl = Vector of all other measured baseline covariates 
ε = Error term 
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Each covariate was tested separately to determine the bivariate relationship between the 
predictor and the outcome, without controlling for the other covariates. Multivariable modified 
Poisson regression models were also applied to investigate the initiation and switch of warfarin 
and dabigatran for new AF patients with each variable added to the model simultaneously to 
examine the independent effects of each covariate.  
While binary outcomes (e.g., warfarin vs. dabigatran) are often analyzed using logistic 
regression models to obtain odds ratios for characteristics between two treatment groups, 
estimating relative risks (RRs) can be more preferable.
228
 RRs tend to be more interpretable than 
odds ratios, especially in commonly-occurring events (such as the anticoagulants each being 
used frequently in new users, which is suggested by the 100% sample).
229
 Relative risk 
estimation via a modified Poisson approach (using robust error variances) was used to compare 
characteristics of the comparator groups (using Proc Genmod and a repeated statement in SAS), 
which lead to direct RRs.
230
 By contrast, log-binomial models assume that the probability of an 
outcome increases linearly on the log scale, while logistic regression models assume that the 
probability of an outcome increases linearly on the logit scale, which can lead to differences in 
the predicted probabilities between the two models, especially when the outcome is common.
228
 
Even compared with the log-binomial model (also yields relative risks using a log scale), the 
modified Poisson approach avoids the possibility of too narrow confidence intervals and 
convergence issues and may be a better fit for these data for this aim.   
For Aim 1a, the association between new use of each medication and the baseline 
characteristics was tested using bivariate and multivariate regression to estimate the likelihood of 
receipt of warfarin versus dabigatran, studying ischemic stroke and bleeding risk clinical 
prediction scores as the main independent variables. For Aim 1b, the association between 
switching from the index anticoagulant compared with not switching was assessed using 
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bivariate and multivariate regression to estimate the likelihood of switching using the clinical 
prediction scores as the main independent variables. The multivariable regression models 
included each of the predictors previously described, except for those already included in the risk 
scores. The general form of the model for Aims 1a and 1b is provided in Equation 1 above. For 
Aim 1a, sensitivity analyses were conducted on each of the ischemic stroke and bleeding risk 
clinical prediction scores (e.g., ATRIA versus HAS-BLED). 
 For Aim 1a, the Quasilikelihood under the Independence model Criterion (QIC) was also 
used for model comparisons and model selection. Interaction terms were also examined for 
potential inclusion in the multivariate model to determine any variation in a priori determined 
possible relationships, including age and sex. Upon examining for this effect measure 
modification, if the interactions are not significant, then they are deemed unnecessary as they 
would add no additional explanatory power to the model. These tests were conducted to help 
choose the overall model. 
 
3.6.3. Aim 2 
Specific Aim #2: Investigate the comparative clinical outcomes (risk of harm and clinical 
effectiveness) following new use of either warfarin or dabigatran, adjusting for baseline patient 
factors. 
3.6.3.1 Hypothesis 
Hypothesis 3: There are no significant differences in the risk of clinical effectiveness 
outcomes or harm outcomes in new users of warfarin compared with users of dabigatran. 
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Statistical model:  
 
 
 
 
3.6.3.2 Statistical analysis and model diagnostics 
 As previously summarized, Aim 2 tests the comparative effectiveness and safety of 
warfarin versus dabigatran in AF patients initiating anticoagulation in an intention-to-treat 
analysis. Aim 2 used the same cohort specified in Aim 1a and followed individuals until either 
one of the composite outcomes was observed or loss of continuous eligibility or the end of the 
administrative period at 12/31/2012 occurred, using an intention to treat (ITT) perspective.
231
 In 
ITT analysis, every individual beginning warfarin or dabigatran therapy is assigned to that 
therapy for the analysis, regardless of potential non-adherence, withdrawal or anything else that 
occurs following the first prescription fill.
231
 
Descriptive statistics were generated including the outcome rates per 1,000 person years 
in each anticoagulant group, the time to the composite outcome events, and the proportion of 
patients censored. Cox proportional hazard models were also used to estimate the relationship 
between anticoagulant use and being event-free after controlling for confounders.
232
 Cox 
proportional hazards methods use a semi-parametric model that accounts for multiple predictor 
variables and provide partial likelihood estimation of experiencing an event by factoring out the 
baseline hazard of experiencing an event from the covariates. The general form of the model is 
provided in Equation 2 above. In this equation, β represents the effect of the exposure on the 
hazard of experiencing the outcome.
232,233
   
Equation 2 
hl(tlxl) = h0(t)*exp(βTTl+βxXi), 
t = survival time (in days) from the index date to event or censoring 
Ti = Treatment (1=dabigatran; 0=warfarin) 
Xi = Vector of all measured baseline covariate confounders 
βT= Coefficient of X1, the change in survival time 
βx = Vector of  coefficients of Xi 
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Cox models assume that covariates are independent of time and that hazards are 
proportional across strata of the variable and constant over time, in the event of time-varying 
covariates. Nested and non-nested models were tested for the AIC to select covariates for the 
final models. Deviance residuals were used to plot model fit and assess functional form. Ties 
were assessed using Efron’s method, where ties are those instances where two or more patients 
have the same study time. Additionally, the proportional hazard assumption (in that covariates 
are multiplicatively related to the baseline hazard and that time does not change this relationship) 
was assessed using Schoenfeld residuals, supremum tests, Kaplan-Meier plots, and interaction 
terms with time. Outcomes of anticoagulation were first regressed in the Cox models as the only 
independent variable (unadjusted model) to examine the effect of the additionally measured 
covariates added to the multivariable models. 
These Cox methods all assume that the patients are independently grouped and that the 
data do not derive from the same unit or cluster (e.g., are not grouped hierarchically under 
providers). Other studies using these databases have assumed independence of observations and 
given the vastness of the database and high prevalence of the condition, we assume that 
clustering is not common and negligible. 
Separate multivariable Cox proportional hazards models were also constructed for a 
composite of measures of risk (e.g., hemorrhagic bleeding, major bleeding, etc.) and a composite 
of measures of effectiveness (e.g., ischemic stroke, etc.).
233,234
 Cause-specific Cox proportional 
hazards models were also conducted on each of the clinical effectiveness and risk of harm 
outcomes, whereby patients were censored at the time one of the other events occurred. 
Typically, composite measures are used as primary analysis to avoid issues of competing risk.
235
 
However, as a secondary analysis, cause-specific models were used. As with Aims 1a and 1b, 
interaction terms were evaluated for inclusion in the final regression models.  
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3.6.3.3. Propensity Score Risk Adjustment  
Risk adjustment methods through multivariate regression, while useful, may not be 
sufficient when the potential for unmeasured confounding or confounding by indication exists.
236
 
Because individuals are not randomly selected to receive a specific treatment in this study, 
endogeneity (selection bias) between treatment and outcomes may exist. In addition, risk 
adjustment methods assume that all confounders are either measured or that unmeasured 
confounders are “ignorable” if other measured confounders are controlled. 
Propensity score (PS) methods attempt to control for lack of randomization in 
observational studies by balancing covariate distributions between treatment groups.
237,238
 
Estimates of the average treatment effect in the treated group can be obtained by PS matching 
between two comparable groups, such that pairs are formed and these matched individuals have 
similar values of the PS. Other options involving propensity scores are including the PS as a 
covariate in multivariable regression models, stratification, or using weighting through inverse-
probability treatment weighting (IPTW) or standardized mortality ratios (SMR) weighting from 
an estimated propensity score in a regression model. 
In particular, the PS method proposed in this research employed IPTW as a primary 
analysis. Specifically, IPTW uses propensity score weights to create a study sample whereby the 
distribution of measured baseline characteristics does not depend on treatment. In IPTW, each 
subject’s weight is equal to the inverse of the probability of receiving that particular treatment. 
Regression models can be weighted by the inverse probability of treatment to estimate the 
average treatment effect of receiving the treatment. Because weights may be unstable for 
individuals with very low probabilities of receiving treatment, stabilizing weights and ‘trimming’ 
subjects are methods often used and were examined here.  
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For Aim 2, propensity score-adjusted hazard ratios were presented for the Cox 
proportional hazard models. For this study, IPTW was used as the primary analysis rather than 
matching on subjects, so as to preserve sample size. These propensity scores were fit by a 
logistic regression model to predict treatment with the use of the measured covariates. These 
propensity score models included confounder variables.
237,238
 Stabilizing weights and trimming 
of subjects were used depending on the need when the weights are created.
239
 SMR weighting 
was also used as a secondary analysis, which provides estimates of the treatment effect in the 
treated group. 
These propensity scores were first used to investigate the balance in the treatment groups 
of patients initiating treatment since market entry. Propensity scores were constructed comparing 
the baseline characteristics of the new anticoagulant initiators. These propensity scores were 
used to examine overlap in the distribution of baseline and clinical covariates of users initiating 
warfarin and dabigatran occurs. The absolute standardized difference was also used to compare 
the baseline characteristics between warfarin and dabigatran users, whereby significant 
imbalance of baseline characteristics between groups is usually characterized by an absolute 
standardized difference > 10.
240
 Secondly, the models used IPTW from the propensity scores as a 
weight in the Cox proportional hazards models to estimate the comparative effect of warfarin 
versus dabigatran, adjusting for any covariate imbalances. The IPTW propensity score deciles 
were examined for any underlying heterogeneity of treatment effect in a sensitivity analysis. 
 
3.6.4. Aim 3 
Specific Aim #3: Explore the comparative clinical outcomes (risk of harm and clinical 
effectiveness) of switching from warfarin to dabigatran or dabigatran to warfarin compared with 
non-switchers, adjusting for patient clinical and demographic factors. 
 89 
 
3.6.4.1 Hypotheses 
Hypothesis 4: Switching from warfarin to dabigatran will not be associated with increased risk of 
harm or clinical effectiveness outcomes compared with those who switch remain on warfarin. 
Hypothesis 5: Switching from dabigatran to warfarin will not be associated with an increased 
risk of harm or clinical effectiveness outcomes compared with those who remain on dabigatran. 
3.6.4.2 Statistical analysis and model 
Statistical model:  
 
 
 
 
Equation 3 illustrates the statistical model for this aim. For the primary analysis, 
warfarin switchers were compared with non-switchers, and dabigatran switchers were compared 
with non-switchers. Descriptive statistics were generated including the outcome rates per 1,000 
patient years, the proportion of patients censored, and the time to each event. For both analyses, 
Cox proportional hazards regression was used to assess the association with treatment and 
outcomes. Equation 3 and Aim 2 describe the general model and the diagnostic approach for 
assessing Cox proportional hazards models. These models were adjusted using the covariates 
identified in Table 9 using the previously-described diagnostic steps. The dependent variable for 
each model was time to outcome event. In the primary analysis, patient days of follow-up were 
classified as “non-switcher” time until the anticoagulant switch date occurred (or until 
experiencing the outcome of interest or censoring due to loss-to-follow-up or administratively on 
12/31/2012). This time-varying exposure approach has been previously described in settings 
examining users versus non-users of medications.
206
 
Equation 3 
hl(tlxl) = h0(t)*exp(βTTl+βxXi), 
t = survival time (in days) from the switch date to event or censoring 
Ti = Treatment (1=switcher; 0=non-switcher) 
Xi = Vector of all measured baseline covariate confounders 
βT= Coefficient of X1, the change in survival time 
βx = Vector of  coefficients of Xi 
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3.7. SENSITIVITY AND EXPLORATORY ANALYSES 
 Certain sensitivity analyses and exploratory analyses were conducted throughout the 
study. These additional analyses were classified as sensitivity analyses when the analyses were 
primarily intended to examine the robustness of the study conclusion, such as the lack of 
mortality data. Other descriptive exploratory analyses were also conducted because of known 
limitations in the data (such as limited laboratory data), but because of the primary intention-to-
treat approach of this dissertation, were descriptive in nature. These approaches included 
assessments of warfarin patients’ monitoring values and medication adherence in the follow-up 
period. 
 
3.7.1. Mortality 
 Because the TruvenHealth MarketScan® databases do not measure mortality, 
censoring/dropout could be attributable to unmeasured death. To test the robustness of the results 
for Aim 2 and Aim 3, we tested whether significantly more ‘censoring’ occurs in one 
anticoagulant group versus another. In addition, the robustness of the results was tested again in 
the Cox proportional hazards models, whereby all those dropping out were assumed to have 
experienced the outcome in the anticoagulant group. For patients with a hospitalization in the 
follow-up period, the discharge variable was examined descriptively to see whether in-hospital 
mortality had occurred.  
 
3.7.2. Outcomes: Transient Ischemic Attack and Hemorrhagic Stroke 
 While some algorithms recommended also including transient ischemic attack (TIAs) as 
part of the composite endpoint, TIAs tend to have lower PPVs than ischemic stroke algorithms 
and the other clinical effectiveness endpoints.
211,219
 To test the robustness of the results for Aim 
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2, we tested whether removing TIA as part of the composite clinical effectiveness endpoint 
affects the results. Because TIAs are difficult to identify diagnostically, including TIAs as part of 
the endpoint could possibly adversely influence the results.  
 In addition, the parent RE-LY trial measured hemorrhagic stroke both as a clinical 
effectiveness and a harm outcome, effectively double-counting the outcomes. In this study, the 
number of hemorrhagic events in the warfarin group far outweighed the number in the dabigatran 
group, which was a primary driver of the efficacy endpoint in the study. Because the primary 
results of this study included hemorrhagic stroke as a risk of harm outcome solely (but still 
included it in the full composite), a sensitivity analysis for Aim 2 was also conducted including 
the hemorrhagic stroke/intracranial hemorrhagic endpoint in the clinical effectiveness outcomes.  
  
3.7.3. Stratification by dabigatran strengths 
 Because the RE-LY trial showed different efficacy in prevention of stroke and systemic 
embolism during separate analyses of dabigatran strengths (110mg and 150mg in the trial), this 
present study also stratified initiators of dabigatran 75mg and dabigatran 150mg in Aim 2. For 
this study, the comparative effectiveness and safety of the two dabigatran strengths were also 
studied in stratified analyses using all doses warfarin as the referent group (as was done in the 
RE-LY trial). Multivariable and propensity-score adjustment was used for these separate survival 
analyses and Cox proportional hazards regression in the methods discussed above. 
 
3.7.4. Clinical and demographic subgroups  
 To explore any underlying heterogeneity in treatment effects, clinical and demographic 
subgroups were also examined in Aim 2. We stratified patients with certain characteristics that 
were identified as contributing to non-overlap of the propensity scores and among characteristics 
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known to affect treatment effects, such as age and clinical prediction risk scores. For these 
analyses, the composite outcomes of the clinical effectiveness and safety were examined using 
Cox proportional hazards regression and the application of stratum-specific inverse probability 
treatment weighted propensity scores. 
 
3.7.5. International Normalized Ratio (INR) laboratory values  
 As previously described, the TruvenHealth MarketScan® databases contain some 
laboratory values on approximately 10% of enrollees. INRs, used to measure the effectiveness of 
warfarin, can be captured through laboratory tests but may also be point of care measurements, 
done without extensive laboratory examination.
10,135,164
 Because the TTR for users of warfarin 
has been thought to affect clinical outcomes, INRs were captured for those users of warfarin with 
available laboratory data.
118
 These INRs were averaged during the follow-up period descriptively 
for Aim 2, because the TTR has been seen to drastically affect apparent efficacy in the RCTs 
examining the new OACs. 
 
3.7.6. Medication adherence 
For Aim 2, patient medication adherence in the follow-up period was also measured 
descriptively comparing between warfarin and dabigatran. We used the proportion of days 
covered by the prescription supply calculated from the prescription refill records in the outpatient 
pharmaceutical claims in the follow-up period. Conforming to current literature, a patient was 
defined as adherent if the patient had ≥80% of days covered with prescription supply. Patient 
medication refill rates were also measured descriptively, defined as the proportion of patients 
filling the index medication again in the follow-up period. These analyses were performed 
descriptively because of the intention-to-treat approach of this dissertation. 
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3.8. LIMITATIONS 
As with other studies using observational data, unmeasured confounding may affect the 
overall study conclusions. However, the proposed approaches have been shown to limit the 
effects of unmeasured confounding and heterogeneity in treatment effects. As with other 
observational designs, causality is often difficult to ascertain, but these approaches may limit this 
concern. Other limitations due to various study design configurations and assumptions have been 
previously described in these chapters or are outlined in Chapter 5. 
 
3.9. SUMMARY 
 The approaches described in Chapter 3 assess the factors associated with new use of 
anticoagulants, switching between anticoagulants, comparative effectiveness of new use of 
anticoagulants, and effects following switching between anticoagulants using Poisson and 
logistic regression, survival analysis, and the application of propensity scores.  
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CHAPTER 4:  RESULTS 
AIM 1: ANTICOAGULANT USE AND SWITCHING 
 
4.1. AIM 1A. RISK SCORES AND ANTICOAGULANT USE 
4.1.1. Descriptive statistics 
4.1.1.1. Cohort identification 
Over 400,000 unique patients were identified as receiving at least one prescription for 
warfarin or dabigatran after 10/19/2010 until 12/31/2012. Of these, there were 64,935 treatment-
naïve AF patients included in the final cohort (Figure 5). In total, 33,843 (52.1%) patients were 
newly-diagnosed with AF, having received their first ICD-9 code for AF within the 30 days prior 
to the index anticoagulation prescription fill. Of these, 43,865 (67.6%) used warfarin and 21,070 
(32.5%) used dabigatran. There were 93,335 patients who were classified as prevalent users of 
warfarin – i.e., having received warfarin within 12 months prior to the index prescription fill date 
or the first prescription fill after 10/19/2010.  
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Figure 5. New User Cohort Flow Diagram 
 Inclusion  Exclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.1.2. Baseline demographic characteristics 
Patient sociodemographic characteristics among new users of warfarin and dabigatran are 
shown in Table 10, including the absolute standardized differences for each characteristic 
category between the two anticoagulants. As previously described in Chapter 3, absolute 
standardized differences are indexes which measure the effect size between two groups to assess 
imbalance between groups, with differences greater than 10% in absolute value generally 
indicating imbalance. New users of dabigatran were more likely to be younger, male, from the 
South region, use high-deductible health or preferred provider organization insurance health 
plans, and have good prescription benefits coverage (ratio ≥ 0 and ≤ 0.20) for all of their 
 Include: Newly-diagnosed with AF within 30 
days prior to index prescription fill date 
- Exclude: Reversible AF conditions (such as 
hyperthyroidism) or valvular AF at time of index 
diagnosis or in previous 12 months 
– Exclude: Warfarin prescription fill in 12 months 
prior to index prescription fill date 
 Include: Maintained ≥ 12 months of continuous 
eligibility and prescription benefits prior to index 
prescription fill date 
 Include: ≥ 1 prescription fill for warfarin or 
dabigatran following 10/19/2010 
 Include: ≥18 years of age at index prescription 
fill date 
 
N=401,913 
 Include: ≥ 1 inpatient or 2 unique outpatient 
diagnoses on separate days (ICD-9: 427.31) in 12 
months prior to index prescription fill date 
N=401,834 N=79 
N=292,663 N=109,171 
N=223,013 N=69,650 
N=158,270 N=64,743 
N=64,935 
New User 
Cohort 
N=93,335 
 
N=33,843 
Newly-diagnosed 
New User Cohort 
N=31,092 
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medications filled within the previous 12 months. The proportion of newly-diagnosed AF 
patients with these sociodemographic characteristics was similar across all these baseline 
demographic categories.  
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Table 10. Demographic characteristics of new users and newly-diagnosed 
 new users of warfarin and dabigatran 
 
 New users Newly-diagnosed new users 
Baseline Characteristic 
Warfarin,  
N (%) 
Dabigatran, 
N (%) 
Absolute 
SD 
Warfarin, 
N (%) 
Dabigatran,  
N (%) 
Absolute 
SD 
Age 
  < 55 years 
 
3,886 (8.9) 
 
2,963 (14.1) 
 
20.2 2,107 (9.5) 1,727 (14.7) 23.5 
  55-64 years 10,146 (23.1) 6,443 (30.6) 20.5 5,317 (24.1) 3,626 (30.8) 19.6 
  65-74 years 9,792 (22.3) 4,838 (23.0) 2.1 5,063 (22.9) 2,672 (22.7) 0.6 
  ≥ 75 years 20,041 (45.7) 6,826 (32.4) 34.3 9,591 (43.4) 3,740 (31.8) 28.1 
Male Gender 25,562 (58.3) 13,363 (63.4) 11.6 12,867 (58.3) 7,481 (63.6) 12.2 
Region 
  Northeast 
 
7,589 (17.3) 
 
3,513 (16.7) 
 
2.1 3,777 (17.1) 1,999 (17.0) 0.3 
  North Central 15,408 (35.1) 6,107 (29.0) 15.7 7,767 (35.2) 3,458 (29.4) 14.9 
  South 12,181 (27.8) 7,864 (37.3) 26.1 6,131 (27.8) 4,477 (38.1) 28.2 
  West 7,732 (17.6) 3,259 (15.5) 7.2 4,189 (19.0) 1,659 (14.1) 16.5 
Insurance plan 
  Comprehensive 15,701 (35.8) 6,812 (32.3) 
 
8.9 7,760 (35.1) 3,893 (33.1) 5.1 
  HMO 6,368 (14.5) 1,723 (8.2) 24.3 3,475 (15.7) 907 (7.7) 29.9 
  POS 1,973 (4.5) 1,226 (5.8) 8.6 1,037 (4.7) 693 (5.9) 7.8 
  PPO 16,889 (38.5) 9,766 (46.4) 19.4 8,510 (38.5) 5,411 (46.0) 18.4 
  CDHP 707 (1.6) 464 (2.2) 6.7 385 (1.7) 276 (2.4) 7.6 
Prescription generosity 
  No coverage (> 0.99) 716 (1.6) 35 (0.2) 
 
15.8 296 (1.3) 22 (0.2) 13.7 
  Poor coverage(> 0.80 
and ≤ 0.99) 909 (2.1) 26 (0.1) 
9.8 
468 (2.1) 18 (0.2) 18.7 
  Fair coverage (> 0.20 
and ≤ 0.80) 21,410 (48.8) 9,769 (46.4) 
5.6 
10,762 (48.7) 5,458 (46.4) 5.3 
  Good coverage (≥ 0 and 
≤ 0.20) 20,830 (47.5) 11,240 (53.3) 
13.5 
10,552 (47.8) 6,267 (53.3) 12.8 
  Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred  
provider organization; CDHP, consumer-driven health plan 
 
4.1.1.3. Baseline clinical characteristics 
Clinical characteristics of the new users of warfarin and dabigatran are shown in Table 
11. Patients using warfarin for the first time were more likely to have experienced relevant 
comorbidities, particularly ischemic stroke, congestive heart failure, and venous 
thromboembolism.  Across both new users and newly-diagnosed new users, the proportion of 
patients receiving warfarin was more likely to have comorbidities, and higher ischemic stroke 
risk and bleeding risk scores. The absolute standardized differences were somewhat lower 
among patients who were newly-diagnosed with the exception of hyperlipidemia, peptic ulcer 
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disease, and cognitive deficiency, although the underlying proportion of patients with those 
comorbidities altogether influenced these differences. For example, at most, 1.0% of patients 
were diagnosed with cognitive deficiency, which led to small cell sizes for both new users and 
newly-diagnosed new users. Patients were also more likely to have had a previous hospitalization 
if they received warfarin. However, AF patients were more likely to receive dabigatran if they 
had a catheter ablation in the previous 12 months. Examining the ischemic stroke clinical 
prediction risk scores, as predicted, the CHADS2 score classified more individuals as low or 
intermediate risk of ischemic stroke compared with the CHA2DS2VASc score.  
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Table 11. Clinical characteristics of new users and newly-diagnosed  
new users of warfarin and dabigatran  
 
 New users Newly-diagnosed new users 
Baseline Characteristic 
Warfarin, N 
(%) 
Dabigatran, 
N (%) 
Absolute 
SD 
Warfarin, 
N (%) 
Dabigatran,  
N (%) 
Absolute 
SD 
Ischemic Stroke 4,710 (10.7) 1,495 (7.1) 18.9 1,984 (9.0) 709 (6.0) 14.4 
Congestive Heart Failure 12,414 (28.3) 3,851 (18.3) 32.7 5,793 (26.2) 2,022 (17.2) 26.5 
VTE 5,385 (12.3) 538 (2.6) 81.8 2,025 (9.2) 232 (2.0) 34.9 
Hyperlipidemia 21,710 (49.5) 10,456 (49.6) 0.2 10,730 (48.6) 5,777 (49.1) 1.2 
Hypertension 32,043 (73.0) 14,578 (69.2) 9.1 15,900 (72.0) 8,068 (68.6) 8.1 
Myocardial infarction 2,001 (4.6) 500 (2.4) 19.9 1,106 (5.0) 312 (2.7) 14.7 
Coronary artery disease 15,000 (34.2) 5,942 (28.2) 16.5 6,951 (31.5) 3,076 (26.1) 14.5 
Peripheral vascular disease 3,892 (8.9) 1,150 (5.5) 20.2 1,628 (7.4) 571 (4.9) 13.2 
Renal impairment 5,517 (12.6) 1,210 (5.7) 39.8 2,481 (11.2) 618 (5.3) 25.7 
Diabetes  13,957 (31.8) 5,610 (26.6) 14.6 6,824 (30.9) 3,264 (27.7) 8.6 
Major bleeding 5,975 (13.6) 1,983 (9.4) 19.1 2,385 (10.8) 916 (7.8) 13.1 
Anemia 8,736 (19.9) 2,241 (10.6) 39.4 3,853 (17.5) 1,102 (9.4) 28.7 
Peptic Ulcer disease 320 (0.7) 93 (0.4) 6.7 136 (0.6) 44 (0.4) 45.6 
Sleep Apnea 4,546 (10.4) 2,526 (12.0) 6.6 1937 (8.8) 1,187 (10.1) 6.2 
Cognitive deficiency 438 (1.0) 126 (0.6) 7.3 157 (0.7) 45 (0.4) 69.0 
CCI 
  0 10,051 (22.9) 7,091 (33.7) 
 
28.7 5,350 (24.2) 4,008 (34.1) 28.7 
  1-2 17,657 (40.3) 9,058 (43.0) 6.5 9,345 (42.3) 5,215 (44.3) 4.8 
  3-5 11,871 (27.1) 4,001 (19.0) 26.2 5,608 (25.4) 2,104 (17.9) 22.3 
  6-8 3,165 (7.2) 686 (3.3) 29.9 1,322 (6.0) 323 (2.8) 18.8 
  ≥ 9 1,121 (2.6) 234 (1.1) 20.1 453 (2.1) 115 (1.0) 10.8 
CHADS2 
  0 
 
4,432 (10.1) 
 
3,342 (15.9) 
 
21.3 2,381 (10.8) 1,874 (15.9) 21.7 
  1 11,319 (25.8) 7,044 (33.4) 20.1 5,937 (26.9) 3,932 (33.4) 18.2 
  ≥2 28,114 (64.1) 10,684 (50.7) 31.3 13,760 (62.3) 5,959 (50.7) 26.2 
CHA2DS2-VASc 
  0 2,935 (6.7) 
 
2,444 (11.6) 
 
20.9 1,531 (6.9) 1,366 (11.6) 24.9 
  1 6,339 (14.5) 4,665 (22.1) 24.1 3,387 (15.3) 2,626 (22.3) 25.1 
  ≥2 34,591 (78.9) 13,961 (66.3) 30.8 17,160 (77.7) 7,773 (66.1) 27.8 
ATRIA 
  0-3 30,667 (69.9) 17,602 (83.5) 
 
65.8 16,124 (73.0) 10,018 (85.2) 32.1 
  4 4,158 (9.5) 1,501 (7.1) 12.6 2,047 (9.3) 808 (6.9) 11.3 
  ≥5 9,040 (20.6) 1,967 (9.3) 50.6 3,907 (17.7) 939 (8.0) 34.4 
HAS-BLED       
  0-2 38,249 (87.2) 19,608 (93.1) 20.3 19,764 (89.5) 11,128 (94.6) 19.3 
  ≥3 5,616 (12.8) 1,462 (6.9) 31.1 2,314 (10.5) 637 (5.4) 22.9 
Hospitalizations       
  ≥1 25,231 (57.5) 9,431 (44.8) 30.1 13,809 (62.5) 5,726 (48.7) 31.2 
Catheter ablation 391 (0.9) 459 (2.2) 12.5 55 (0.3) 44 (0.4) 2.6 
Abbreviations: SD, Standardized difference; CCI, Charlson comorbidity index 
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4.1.1.4. Baseline medication use characteristics 
The distributions of patients receiving relevant concomitant medications within the 12 
months prior to or including the index prescription fill date are shown in Table 12. The absolute 
standardized differences indicate that the medication use characteristics are relatively balanced 
between both groups of anticoagulant users. However, patients receiving warfarin were 
somewhat more likely to receive antiplatelet therapy, a gastroprotective agent (e.g., PPI), rate 
control therapy with digoxin, beta-blockers or calcium channel blockers, and ACEI/ARBs. 
Newly diagnosed new user patients were more likely to receive an antiarrhythmic while overall 
new user warfarin patients were less likely to receive one. 
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Table 12. Medication use characteristics of new users and newly-diagnosed  
new users of warfarin and dabigatran  
 
  New users  Newly-diagnosed new users 
Baseline Characteristic 
Warfarin, 
 N (%) 
Dabigatran, 
N (%) 
Absolute 
SD 
Warfarin, 
N (%) 
Dabigatran,  
N (%) 
Absolute 
SD 
Antiplatelet therapy 5,726 (13.1) 2,684 (12.7) 1.6 2,962 (13.4) 1,360 (11.6) 7.1 
Gastroprotective agent 5,558 (12.7) 2,267 (10.8) 8.2 2,740 (12.4) 1,186 (10.1) 9.4 
Antiarrhythmic 9,991 (22.8) 5,344 (25.4) 7.6 4,329 (19.6) 2,217 (18.8) 2.6 
Digoxin 7,435 (16.9) 2,973 (14.1) 10.5 3,365 (15.2) 1,479 (12.6) 9.6 
Beta-blocker 29,513 (67.3) 14,132 (67.1) 0.5 15,753 (71.4) 8,089 (68.8) 6.1 
Calcium channel blocker 18,501 (42.2) 8,602 (40.8) 3.4 10,013 (45.4) 4,939 (42.0) 8.0 
ACEI/ARB 25,001 (57.0) 11,891 (56.4) 1.4 13,478 (61.0) 6,977 (59.3) 3.9 
Statin 23,964 (54.6) 11,205 (53.2) 3.2 12,488 (56.6) 6,308 (53.6) 6.8 
Hormone 1,626 (3.7) 959 (4.6) 6.0 894 (4.1) 536 (4.6) 3.5 
Abbreviations: SD, Standardized difference; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker 
 
4.1.1.5. Baseline characteristics: Means and standard deviations 
The means and standard deviations for the sociodemographic and clinical characteristics 
which were also measured continuously are displayed in Table 13. The mean age, CCI, stroke 
risk and bleeding risk prediction scores, and the average number of hospitalizations were all 
higher in those AF patients filling warfarin as their first anticoagulation prescription. The patient 
ages in the cohort ranged from 18 to 103 years of age.  
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Table 13. Means of baseline characteristics of new users and newly-diagnosed 
 new users of warfarin and dabigatran  
 
 New users Newly-diagnosed new users 
Baseline Characteristic 
Warfarin, 
Mean (SD) 
Dabigatran, 
Mean (SD) 
Warfarin, 
Mean (SD) 
Dabigatran,  
Mean (SD) 
Age 71.4 (12.2) 67.5 (12.4) 70.7 (12.0) 67.2 (12.4) 
CCI 2.3 (2.3) 1.6 (1.9) 2.1 (2.2) 1.5 (1.8) 
CHADS2 2.1 (1.3) 1.7 (1.2) 2.0 (1.2) 1.6 (1.2) 
CHA2DS2-VASc 2.9 (1.7) 2.3 (1.6) 2.8 (1.6) 2.3 (1.5) 
ATRIA 2.9 (2.4) 2.0 (1.9) 2.7 (2.3) 1.9 (1.8) 
HAS-BLED 1.4 (1.0) 1.3 (0.9) 1.3 (1.0) 1.1 (0.8) 
Number of hospitalizations 0.8 (0.9) 0.5 (0.7) 0.8 (0.8) 0.6 (0.7) 
  Abbreviations: SD, standard deviation; CCI, Charlson comorbidity index 
 
4.1.1.6. Index anticoagulant prescription characteristics 
For the anticoagulation prescriptions filled on each patient’s index prescription date, the 
index prescription benefits generosity and distribution of dosage strengths are shown in Table 
14. Approximately 90% of dabigatran users received the 150mg dose. Of the 1,448 patients 
receiving the 75mg dose indicated for patients with renal insufficiency, only 21.7% had 
diagnosed renal insufficiency. By contrast, 9.7% of patients receiving the 150mg had diagnosed 
chronic kidney disease, for whom the 150mg dose is neither FDA-approved nor recommended in 
clinical guidelines. More than half of warfarin patients received 5mg as their index prescription 
strength, which is generally the guideline-recommended warfarin starting dose. Lastly, of the 
43,865 patients newly using warfarin, 1,817 (4.1%) patients filled more than one dosage strength 
on the same day.   
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Table 14. Characteristics of the initial warfarin and dabigatran prescriptions 
 New users Newly-diagnosed new users 
Baseline Characteristic 
Warfarin, 
N (%) 
Dabigatran, 
N (%) 
Warfarin, 
N (%) 
Dabigatran,  
N (%) 
Prescription generosity 
  No coverage 17,321 (39.5) 63 (0.3) 8,732 (39.6) 30 (0.3) 
  Poor coverage 3,938 (8.98) 20 (0.1) 2,141 (9.7) 9 (0.1) 
  Fair coverage 10,339 (23.6) 4,760 (22.6) 5,310 (24.1) 2,550 (21.7) 
  Good coverage 12,267 (28.0) 16,227 (77.0) 5,895 (26.7) 9,176 (78.0) 
Dosage strength     
  1mg 2,858 (6.5) N/A 1,149 (5.2) N/A 
  2mg 4,953 (11.3) N/A 2,287 (10.4) N/A 
  2.5mg 5,279 (12.0) N/A 2,555 (11.6) N/A 
  3mg 2,977 (6.8) N/A 1,258 (5.7) N/A 
  4mg 2,754 (6.3) N/A 1,142 (5.2) N/A 
  5mg 24,452 (55.7) N/A 13,315 (60.3) N/A 
  6mg 725 (1.7) N/A 236 (1.1) N/A 
  7.5mg 1,108 (2.5) N/A 542 (2.5) N/A 
  10mg 676 (1.5) N/A 263 (1.2) N/A 
  75mg N/A 1846 (8.8) N/A 950 (8.1) 
  150mg N/A 19,234 (91.3) N/A 10,818 (92.0) 
 
In addition, the mean warfarin copay ($5.95, 6.54 SD) was lower than the mean 
dabigatran copay ($37.34, 33.11 SD), as was the proportion of the index prescription paid by the 
patient relative to insurance benefits. The highest warfarin copay was $233.57 (for brand) while 
the lowest warfarin copay was $0, with 25
th
, 50
th
, and 75
th
 percentiles at $1.54, $5.00, and $8.84, 
respectively. The highest dabigatran copay was $784.51 while the lowest dabigatran copay was 
$0, with 25
th
, 50
th
, and 75
th
 percentiles at $20.00, $30.00, and $75.00, respectively.  
Table 14 also indicates that patients with dabigatran had a lower cost-sharing burden than 
patients receiving warfarin. Less than 1% of dabigatran patients paid more than 80% of the 
overall index prescription cost, while more than 75% of dabigatran patients paid less than 20% of 
the overall index prescription cost. By comparison, almost 50% of warfarin patients paid more 
than 80% of the overall index prescription cost. 
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4.1.1.7. Trends in initiation of anticoagulation 
Trends in the index date of anticoagulant for each patient initiating therapy were also 
examined via calendar months and calendar quarters. These calendar months and quarters are 
displayed in Figure 6 and were determined in the time interval whereby each new user AF 
patient’s index prescription was filled. New prescriptions for warfarin spiked in January 2011 
(and somewhat in January 2012), but generally decreased over time. New prescriptions for 
newly-diagnosed AF patients receiving warfarin were fairly stable over time but dipped 
somewhat within the 2011 calendar year and then again in the 2012 calendar year. By contrast, 
new prescriptions for dabigatran increased from the 4
th
 quarter of 2010 through the 2
nd
 quarter of 
2011 but then appeared to decrease beginning in the 1
st
 quarter of 2012 – in line with the FDA-
approval of rivaroxaban, another NOAC. Notably, this introduction of rivaroxaban may explain 
why the proportion of new users initiating anticoagulation in each month appears to decrease 
overall in 2012. 
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Figure 6. Trends in initiation of warfarin and dabigatran, 2010-2012 
Figure 6a. Initiation of anticoagulation for each patient with atrial fibrillation by calendar 
month  
  
Figure 6b. Initiation of anticoagulation for each patient with atrial fibrillation by calendar 
quarter  
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4.1.2. Bivariate analyses of anticoagulant selection 
The bivariate association between each clinical and sociodemographic covariate level and 
anticoagulation use was also assessed, by definition without controlling for the other covariates. 
These associations were assessed using relative risk estimation by modified Poisson regression 
with robust error variance. These associations are presented in Table 15 with warfarin as the 
referent group. Categories of covariates with fewer than 2% of patients (or n=500, whichever 
was smaller) with that characteristic were combined with another relevant level (e.g., “No” and 
“Poor” prescription benefits generosity), when possible. The other identified small cell 
categories included peptic ulcer disease, cognitive deficiency, and catheter ablation. These 
associations were conducted on both new users and newly-diagnosed new user cohorts. 
In these bivariate associations, because of the large sample size, almost all of the baseline 
sociodemographic and clinical characteristics were statistically significantly associated with 
anticoagulant selection, as seen in Table 15. The sole exceptions included: hyperlipidemia, 
antiplatelet therapy (new user only), antiarrhythmic therapy (newly-diagnosed new user only), 
beta-blocker therapy (new user only), and ACEI/ARB therapy (new user only). These suggested 
that the new users and newly-diagnosed new users of dabigatran and warfarin are significantly 
different from each other at baseline. 
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Table 15. Bivariate association between warfarin and dabigatran use and baseline 
sociodemographic and clinical characteristics in the 12-month baseline period 
 
 New Users Newly-diagnosed new users 
Baseline Characteristic RR 95% CI RR 95% CI 
Demographic     
Age (ref: <55 years)     
  55-64 years 0.90 0.87-0.93** 0.90 0.86-0.94** 
  65-74 years 0.76 0.74-0.79** 0.77 0.73-0.80** 
  ≥ 75 years 0.59 0.57-0.61** 0.62 0.60-0.65** 
Gender (ref: Female) 1.16 1.13-1.19** 1.16 1.12-1.19** 
Region (ref: Northeast)     
  North Central 0.92 0.89-0.95** 0.87 0.84-0.91** 
  South 1.27 1.23-1.31** 1.20 1.15-1.25** 
  West 0.96 0.92-0.99* 0.81 0.76-0.85** 
Insurance plan (ref: 
Comprehensive)     
  HMO 0.70 0.67-0.73** 0.61 0.57-0.65** 
  POS 1.25 1.20-1.32** 1.18 1.11-1.25** 
  PPO 1.20 1.17-1.23** 1.14 1.11-1.18** 
  CDHP 1.30 1.21-1.39** 1.23 1.12-1.35** 
Prescription generosity 
(ref: None/Poor)     
  Fair coverage 8.66 6.77-11.09** 6.76 4.99-9.16** 
  Good coverage 9.69 7.57-12.40** 7.49 5.53-10.14** 
Clinical (ref: 0/None 
unless specified)     
Ischemic Stroke 0.72 0.69-0.76** 0.74 0.70-0.80** 
Congestive Heart Failure 0.67 0.65-0.69** 0.69 0.65-0.69** 
VTE 0.26 0.24-0.28** 0.28 0.25-0.32** 
Hyperlipidemia 1.00 0.98-1.03 1.01 0.98-1.04 
Hypertension 0.88 0.86-0.90** 0.90 0.87-0.93** 
Myocardial infarction 0.61 0.56-0.66** 0.62 0.56-0.69** 
Coronary artery disease 0.83 0.80-0.85** 0.84 0.81-0.87** 
Peripheral vascular 
disease 0.69 0.58-0.83** 0.73 0.68-0.79** 
Renal impairment 0.53 0.50-0.56** 0.55 0.52-0.59** 
Diabetes  0.84 0.82-0.86** 0.90 0.87-0.93** 
Major bleeding 0.74 0.71-0.77** 0.78 0.74-0.83** 
Anemia 0.59 0.56-0.61** 0.60 0.57-0.64** 
Peptic Ulcer disease 0.69 0.58-0.83** 0.70 0.54-0.91* 
Sleep Apnea 1.11 1.08-1.15** 1.10 1.05-1.16** 
Cognitive deficiency 0.69 0.59-0.80** 0.64 0.49-0.83** 
CCI (ref: 0)     
  1-2 0.82 0.80-0.84** 0.84 0.81-0.86** 
  3-5 0.61 0.59-0.63** 0.64 0.61-0.67** 
  6-8 0.43 0.40-0.46** 0.46 0.41-0.51** 
  ≥ 9 0.42 0.37-0.47** 0.47 0.40-0.56** 
CHADS2 (ref: 0)     
  1 0.89 0.86-0.92** 0.90 0.87-0.94** 
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  ≥2 0.64 0.62-0.66** 0.69 0.66-0.71** 
CHA2DS2-VASc (ref: 0)     
  1 0.93 0.90-0.97** 0.93 0.88-0.97** 
  ≥2 0.63 0.61-0.65** 0.66 0.64-0.69** 
ATRIA (ref: 0-3)     
  4 0.73 0.70-0.76** 0.74 0.70-0.78** 
  ≥5 0.49 0.47-0.51** 0.51 0.48-0.54** 
HAS-BLED (ref: 0-2)     
  ≥3 0.61 0.58-0.64** 0.60 0.56-0.64** 
Hospitalizations     
  ≥1 0.71 0.69-0.72** 0.69 0.67-0.71** 
Catheter ablation 1.68 1.58-1.79** 1.28 1.03-1.60* 
Medication use     
Antiplatelet therapy 0.98 0.95-1.01 0.89 0.85-0.94** 
Gastroprotective agent 0.88 0.85-0.91** 0.85 0.81-0.90** 
Antiarrhythmic 1.10 1.07-1.13** 0.97 0.93-1.01 
Digoxin 0.86 0.83-0.89** 0.86 0.82-0.90** 
Beta-blocker 0.99 0.97-1.02 0.92 0.89-0.95** 
Calcium channel blocker 0.96 0.94-0.99* 0.91 0.89-0.94** 
ACEI/ARB 0.98 0.96-1.01 0.95 0.93-0.98* 
Statin 0.96 0.94-0.98** 0.93 0.90-0.95** 
Hormone 1.15 1.09-1.21** 1.08 1.01-1.16* 
  *p<0.05 
  **p<0.001 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS, 
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism; 
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker 
 
Other bivariate analyses were also conducted among characteristics not included in the 
multivariate analyses (discussed in the next section). Among all new users, AF patients who 
were newly-diagnosed were 15% more likely to receive dabigatran versus warfarin compared 
with those who were not newly-diagnosed (RR: 1.15, 95% CI: 1.12-1.18). New user AF patients 
were much more likely to receive dabigatran if they had also received dronedarone, a newer 
antiarrhythmic, specifically in the previous 12 months (RR: 1.61, 95% CI: 1.56-1.67). There was 
a similar likelihood among newly-diagnosed new users with regard to dronedarone receipt (RR: 
1.66, 95% CI: 1.66-1.58). 
The scores for the ischemic stroke, bleeding risk and overall clinical severity were also 
compared using those variables as continuous in bivariate analyses for both new users and 
newly-diagnosed new users as sensitivity analyses. These analyses are shown in the Appendix in 
 109 
 
Appendix table 1. For example, for each additional year of age, new users were 1% less likely 
to receive dabigatran versus warfarin (RR: 0.99, 95% CI: 0.98-0.99). Overall, these bivariate 
associations were very similar as those assessed categorically in Table 15 for both new users and 
newly-diagnosed new users.  
 
4.1.3. Multivariate analyses of anticoagulant selection 
4.1.3.1 Main analyses 
 The associations between ischemic stroke and bleeding risk scores and anticoagulant 
selection were also assessed using multivariable relative risk estimation by modified Poisson 
regression with robust error variance (Table 16). In this model, the independent variables were 
CHA2DS2-VASc and ATRIA risk scores, with the dependent variable being selection for a 
particular anticoagulant. Warfarin was used as the referent group for all analyses. These models 
adjusted for all other baseline clinical characteristics which were not already included in the risk 
scores to avoid collinearity issues to ensure appropriate interpretation of the association of 
ischemic stroke and bleeding risk scores with anticoagulant selection. The associations with the 
other baseline characteristics are shown in Appendix table 2. 
 We found that high ischemic stroke risk was significantly associated with anticoagulant 
selection. Compared with warfarin, new users of dabigatran were significantly less likely to have 
CHA2DS2-VASc ≥ 2 or ATRIA score ≥4, even after adjusting for other clinical and demographic 
characteristics. These results indicate that AF patients using dabigatran were less likely to be at 
high ischemic stroke or bleeding risk when newly initiating therapy. However, intermediate 
ischemic stroke risk was not associated with any differential anticoagulant selection. AF patients 
newly initiating anticoagulation were also less likely to have other clinical comorbidities. These 
results were also seen consistently in the sensitivity analysis of newly-diagnosed new users.  
 110 
 
Table 16.  Multivariable association between ischemic stroke and bleeding  
risk prediction scores and warfarin and dabigatran selection 
 
 
  *p<0.05 
  **p<0.001 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval 
  NOTE: Adjusted for all other measured baseline covariates, except for those already included in risk scores, as shown in 
Appendix table 2 
 
4.1.3.2. Model fit diagnostics 
The Quasilikelihood under the Independence model Criterion (QIC) was used to compare 
the insertion of CHADS2 and the HAS-BLED score as possible predictors instead of the 
CHA2DS2-VASc and ATRIA risk scores. The QIC is analogous to the Akaike’s Information 
Criterion (AIC) but is instead used for models fitting generalized estimating equation, such as the 
regression model used in this case. The QIC can be used for model selection, whereby the 
optimal model would have the lowest possible QIC. The model possibilities and resultant QICs 
are shown in Appendix table 3 and indicate that indeed the CHA2DS2-VASc and ATRIA risk 
scores lead to a better model fit for both new users and newly-diagnosed new users, as that 
model possibility has the lowest QIC.  
Notably, hyperlipidemia and the other medication use characteristics in the bivariate 
analyses not shown to be significantly significant were still included in the multivariable model 
as they were specified a priori, have been thought to be confounders in other research settings, 
and may still modify the relationship between predictor and anticoagulant use. The relative risks 
and 95% confidence intervals for the baseline covariates included in the model are shown in the 
 New Users Newly-diagnosed new users 
Baseline Characteristic RR 95% CI RR 95% CI 
Demographic     
CHA2DS2-VASc (ref: 0)     
  1 0.97 0.94-1.01 0.97 0.92-1.02 
  ≥2 0.91 0.87-0.95** 0.92 0.87-0.98* 
ATRIA (ref: 0-3)     
  4 0.86 0.82-0.89** 0.85 0.80-0.91** 
  ≥5 0.72 0.69-0.76** 0.71 0.67-0.76** 
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Appendix (Appendix table 2). Key interactions (e.g., age and gender) were also examined. As 
discussed in the previous section, age was examined via restriction to the commercially-insured 
and Medicare supplement patients, and some slight differences were noted. In addition, gender 
was also examined as an interaction term, and it was not found to have a significant interaction 
with either the ATRIA score or the CHA2DS2-VASc score. 
 
4.1.3.3. Sensitivity analyses 
The cohorts were also stratified based on the data sources into commercially-insured and 
Medicare supplemental claims (Appendix table 4). In these analyses, we observed similar 
associations between bleeding prediction risk scores and anticoagulant selection in the 12-month 
follow-up period similar to the original results presented in Table 16. The sole difference from 
the full combined cohort was that neither intermediate nor high ischemic stroke risk was 
associated with anticoagulation selection among the sub-cohort of Medicare Supplement 
beneficiaries. 
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4.2. AIM 1B: RISK SCORES AND ANTICOAGULANT SWITCHING 
4.2.1. Descriptive statistics 
4.2.1.1. Cohort identification 
In total, 64,935 AF patients were treatment-naïve. Of these, 33,712 patients were 
continuously enrolled for at least 12 months after the index anticoagulant fill date. Figure 7 
shows the switcher cohort selection, as an extension from the new user cohort flow diagram in 
Figure 5. Of note, these are individuals who are eligible for switching anticoagulants, not that 
they did within the 12-months post anticoagulation fill. The new users were examined as the 
primary analysis, with the prevalent users as a secondary analysis. Of the new users, 21,989 
(65.2%) and 11,723 (34.8%) filled warfarin and dabigatran as their index prescriptions, 
respectively. Of note, a similar proportion filled each anticoagulation of the newly-diagnosed 
new users, with 10,776 (63.0%) and 6,343 (37.1%) filling warfarin and dabigatran, respectively. 
By contrast, 78,937 (98.1%) of the prevalent users of warfarin had warfarin as their first 
prescription fill post 10/19/2010. The remaining 1.9% of patients were, in fact, previous users of 
warfarin who used dabigatran as their first prescription post 10/19/2010. 
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Figure 7. Switcher Flow Diagram 
 Inclusion  Exclusion 
 
 
 
 
 
  
 
 
 
4.2.1.2. New users: Anticoagulant switching characteristics 
In total, 4,216 new user patients switched therapy within 12 months of treatment 
initiation (12.5%). Of the total new users, 2,800 (12.7%) of warfarin patients and 1,416 (12.1%) 
of dabigatran patients switched. The demographic, clinical, and medication use characteristics of 
the AF patients switching from warfarin and dabigatran are provided in Table 17. Examining the 
absolute standardized differences, switchers of warfarin compared with non-switchers were less 
likely to be aged ≥ 75 years, have an HMO health plan, have CHF, renal impairment, VTE, or 
anemia, or have high ischemic stroke risk or bleeding risk scores. Switchers from warfarin were, 
however, more likely to have a PPO health plan and previous hormone use. Switchers of 
dabigatran compared with non-switchers were more likely to be ≥75 years of age, have higher 
ischemic stroke risk, and use beta-blockers. However, switchers of dabigatran were less likely to 
be younger, male, have previously experienced an ischemic stroke, and have a previous catheter 
ablation. Overall, the characteristics descriptively appear more balanced between dabigatran 
 Include: ≥1 prescription fill for warfarin or dabigatran 
after 10/19/2010, ≥18 years of age, ≥1 inpatient or ≥2 
outpatient AF diagnoses, no reversible AF condition, 
≥12 months continuous eligibility prior to index fill 
– Exclude: Warfarin prescription fill in 12 months 
prior to index prescription fill date 
 Include: Maintained ≥ 12 months of continuous 
eligibility and prescription benefits after the index 
prescription fill date 
N=158,270 N=64,743 
N=114,201 N=44,069 
N=33,712 
New users 
N=80,489 
Prevalent users 
 
N=21,989 
Warfarin new users 
N=11,723 
Dabigatran new users 
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switchers and non-switchers compared with warfarin users. Upon further analysis, of the 
warfarin switchers, 11.7% switched to dabigatran while 1.3% switched to rivaroxaban. By 
contrast, of the dabigatran switchers, 8.9% switched to warfarin while 3.6% switched to 
rivaroxaban.  
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Table 17. Characteristics of switchers and non-switchers of new users  
of warfarin and dabigatran within 12-months following treatment 
 
 Warfarin New Users (N=21,989) Dabigatran New Users (N=11,723) 
Baseline Characteristic 
Switcher,  
N (%) 
Non-
Switcher, 
N (%) 
Absolute 
SD 
Switcher, N 
(%) 
Non-Switcher, 
N (%) 
Absolute 
SD 
Switching, N (%) 2,800 (12.7) 19,189 (87.3)  1,416 (12.1) 10,307 (87.9)  
Demographic       
Age 
  < 55 years 246 (8.8) 
 
1,695 (8.8) 0.0 142 (10.0) 1,452 (14.1) 18.1 
  55-64 years 771 (27.5) 4,195 (21.9) 16.0 361 (25.5) 2,934 (28.5) 8.6 
  65-74 years 705 (25.2) 4,421 (23.0) 6.4 333 (23.5) 2,428 (23.6) 0.3 
  ≥ 75 years 1,078 (38.5) 8,878 (46.3) 19.1 580 (41.0) 3,493 (33.9) 17.4 
Male Gender 1,654 (59.1) 11,232 (58.5) 1.4 826 (58.3) 6,548 (63.5) 12.0 
Region 
  Northeast 398 (14.2) 3,279 (17.1) 10.9 219 (15.5) 1,685 (16.3) 2.9 
  North Central 876 (31.3) 6,618 (34.5) 8.5 369 (26.1) 2,872 (27.9) 5.1 
  South 938 (33.5) 5,379 (28.0) 14.4 571 (40.3) 4,016 (39.0) 3.2 
  West 493 (17.6) 3,395 (17.7) 0.3 239 (16.9) 1,579 (15.3) 5.6 
Insurance plan 
  Comprehensive 1,082 (38.6) 7,504 (39.1) 1.2 552 (39.0) 3,669 (35.6) 8.4 
  HMO 212 (7.6) 2,760 (14.4) 34.1 100 (7.1) 744 (7.2) 0.5 
  POS 165 (5.9) 911 (4.8) 6.4 72 (5.1) 646 (6.3) 7.5 
  PPO 1,161 (41.5) 6,729 (35.1) 15.6 611 (43.1) 4,610 (44.7) 3.8 
  CDHP 54 (1.9) 299 (1.6) 3.1 27 (1.9) 215 (2.1) 2.1 
Benefits generosity 
  No coverage 40 (1.4) 291 (1.5) 1.2 2 (0.1) 15 (0.2) 4.5 
  Poor coverage 42 (1.5) 361 (1.9) 4.6 0 (0.0) 11 (0.1) N/A 
  Fair coverage 1,267 (45.3) 9,419 (49.1) 8.9 671 (47.4) 4,762 (46.2) 2.8 
  Good coverage 1,451 (51.8) 9,118 (47.5) 9.9 743 (52.5) 5,519 (53.5) 2.3 
Clinical       
Ischemic Stroke 260 (9.3) 1,801 (9.4) 0.5 75 (5.3) 741 (7.2) 11.6 
Congestive Heart Failure 611 (21.8) 4,993 (26.0) 12.9 242 (17.1) 1,765 (17.1) 0.0 
VTE 159 (5.7) 2,189 (11.4) 33.0 42 (3.0) 267 (2.6) 3.3 
Hyperlipidemia 1,253 (44.8) 8,809 (45.9) 2.6 694 (49.0) 4,880 (47.3) 3.9 
Hypertension 1,971 (70.4) 13,526 (70.5) 0.2 988 (69.8) 6,943 (67.4) 5.6 
Myocardial infarction 86 (3.1) 747 (3.9) 6.4 30 (2.1) 240 (2.3) 2.0 
Coronary artery disease 865 (30.9) 6,319 (32.9) 5.3 440 (31.1) 2,905 (28.2) 7.8 
Peripheral vascular 
disease 193 (6.9) 1,510 (7.9) 5.4 91 (6.4) 569 (5.5) 5.1 
Renal impairment 184 (6.6) 2,092 (10.9) 23.3 83 (5.9) 527 (5.1) 4.7 
Diabetes  845 (30.2) 5,915 (30.8) 1.6 375 (26.5) 2,650 (25.7) 2.3 
Major bleeding 318 (11.4) 2,465 (12.8) 5.9 137 (9.7) 997 (9.7) 0.0 
Anemia 338 (12.1) 3,424 (17.8) 22.9 151 (10.7) 990 (9.6) 4.8 
Peptic Ulcer disease 12 (0.4) 130 (0.7) 6.7 3 (0.2) 44 (0.4) 6.3 
Sleep Apnea 343 (12.3) 1,914 (10.0) 9.4 176 (12.4) 1,175 (11.4) 4.1 
Cognitive deficiency 15 (0.5) 137 (0.7) 4.0 8 (0.6) 55 (0.5) 1.8 
CCI 
  0 
 
760 (27.1) 4,810 (25.1) 5.7 
 
447 (31.6) 3,573 (34.7) 8.2 
  1-2 1,278 (45.6) 7,923 (41.3) 10.2 630 (44.5) 4,488 (43.5) 2.4 
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  3-5 624 (22.3) 4,978 (25.9) 11.0 286 (20.2) 1,856 (18.0) 7.1 
  6-8 105 (3.8) 1,151 (6.0) 15.8 43 (3.0) 297 (2.9) 0.8 
  ≥ 9 33 (1.2) 327 (1.7) 6.4 10 (0.7) 93 (0.9) 3.4 
CHADS2 
  0 352 (12.6) 2,075 (10.8) 7.3 190 (13.4) 1,663 (16.1) 10.4 
  1 820 (29.3) 5,197 (27.1) 6.0 446 (31.5) 3,512 (34.1) 6.9 
  ≥2 1,628 (58.1) 11,917 (62.1) 9.2 780 (55.1) 5,132 (49.8) 12.1 
CHA2DS2-VASc 
  0 224 (8.0) 1,340 (7.0) 5.0 125 (8.8) 1,189 (11.5) 12.8 
  1 505 (18.0) 2,808 (14.6) 11.7 253 (17.9) 2,239 (21.7) 12.8 
  ≥2 2,071 (74.0) 15,041 (78.4) 11.0 1,038 (73.3) 6,879 (66.7) 15.6 
ATRIA 
  0-3 2,249 (80.3) 13,963 (72.8) 18.8 1,181 (83.4) 8,734 (84.7) 3.7 
  4 238 (8.5) 1,683 (8.8) 1.5 91 (6.4) 714 (6.9) 2.8 
  ≥5 313 (11.2) 3,543 (18.5) 30.3 144 (10.2) 859 (8.3) 8.5 
HAS-BLED       
  0-2 2,122 (75.8) 13,717 (71.5) 10.5 1,117 (78.9) 8,202 (79.6) 1.8 
  ≥3 678 (24.2) 5,472 (28.5) 12.6 299 (21.1) 2,105 (20.4) 2.2 
Hospitalizations       
  ≥1 1,456 (52.0) 10,588 (55.2) 7.4 580 (41.0) 4,512 (43.8) 6.8 
Catheter ablation 26 (0.9) 188 (1.0) 1.5 7 (0.5) 230 (2.2) 33.7 
Medication Use       
Antiplatelet therapy 363 (13.0) 2,365 (12.3) 2.8 186 (13.1) 1,388 (13.5) 1.6 
Gastroprotective agent 330 (11.8) 2,293 (11.9) 0.4 155 (10.9) 1,083 (10.5) 1.7 
Antiarrhythmic 707 (25.3) 4,214 (22.0) 9.7 361 (25.5) 2,567 (24.9) 1.7 
Digoxin 482 (17.2) 3,282 (17.1) 0.3 205 (14.5) 1,497 (14.5) 0.0 
Beta-blocker 1,868 (66.7) 12,714 (66.3) 0.9 1,010 (71.3) 6,853 (66.5) 11.3 
Calcium channel blocker 1,201 (42.9) 7,923 (41.3) 3.8 598 (42.2) 4,197 (40.7) 3.6 
ACEI/ARB 1,671 (59.7) 10,842 (56.5) 7.3 803 (56.7) 5,835 (56.6) 0.2 
Statin 1,551 (55.4) 10,308 (53.7) 3.9 766 (54.1) 5,622 (54.5) 0.9 
Hormone 150 (5.4) 704 (3.7) 10.4 75 (5.3) 499 (4.8) 3.1 
Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred 
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin receptor blocker 
  
4.2.1.2. Prevalent users of warfarin: Anticoagulant switching characteristics 
Of the 80,489 prevalent users of warfarin, 10,561 (13.1%) switched therapies within 12-
months. The demographic, clinical and medication use characteristics of these prevalent users are 
provided in Table 18. Prevalent users were less likely to switch (more likely to be classified as 
“Non-Switchers”) if they were >75 years of age, resided in the North Central Region, had HMO 
health insurance, had poor or fair benefits generosity, VTE, renal impairment, high ischemic 
stroke risk (CHA2DS2-VASc or CHADS2 ≥ 2), or high bleeding risk (ATRIA ≥ 5). Prevalent 
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users were more likely to switch (more likely to be classified as “Switchers”) if they were 55-64 
or 65-74 years of age, resided in the South Region, had PPO health insurance, had good benefits 
generosity, sleep apnea, catheter ablation, intermediate ischemic stroke risk (CHA2DS2-VASc = 
1), low bleeding risk (ATRIA < 4) or anti-arrhythmic therapies.  
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Table 18. Characteristics of switchers and non-switchers of prevalent  
users of warfarin within 12-months following treatment 
 
 Prevalent Users (N=80,489) 
Baseline Characteristic 
Switcher,  
N (%) 
Non-Switcher,  
N (%) 
Absolute 
SD 
Switching, N (%) 10,561 (13.1) 69,928 (86.9)  
Demographic    
Age 
  < 55 years 588 (5.6) 3,378 (4.8) 4.8 
  55-64 years 2,169 (20.5) 10,828 (15.5) 16.2 
  65-74 years 2,847 (27.0) 15,360 (22.0) 14.3 
  ≥ 75 years 4,957 (46.9) 40,362 (57.7) 25.3 
Male Gender 6,392 (60.5) 40,640 (58.1) 5.5 
Region 
  Northeast 1,885 (17.8) 13,468 (19.3) 5.1 
  North Central 2,579 (24.4) 22,973 (32.9) 24.6 
  South 4,171 (39.5) 20,856 (29.8) 24.2 
  West 1,908 (18.1) 12,537 (17.9) 0.7 
Insurance plan 
  Comprehensive 4,851 (45.9) 32,049 (45.8) 0.2 
  HMO 626 (5.9) 11,352 (16.2) 57.8 
  POS 627 (5.9) 3130 (4.5) 8.2 
  PPO 4,054 (38.4) 20,921 (29.9) 21.3 
  CDHP 135 (1.3) 782 (1.1) 2.5 
Benefits generosity 
  No coverage 38 (0.4) 362 (0.5) 2.2 
  Poor coverage 75 (0.7) 1,040 (1.5) 13.5 
  Fair coverage 5,016 (47.5) 37,587 (53.8) 14.7 
  Good coverage 5,432 (51.4) 30,939 (44.2) 16.6 
Clinical    
Ischemic Stroke 698 (6.6) 4,644 (6.6) 0.0 
Congestive Heart Failure 2,265 (21.4) 16,856 (24.1) 8.4 
VTE 473 (4.5) 5352 (7.7) 21.1 
Hyperlipidemia 4,691 (44.4) 29,040 (41.5) 6.9 
Hypertension 6,984 (66.1) 45,529 (65.1) 2.3 
Myocardial infarction 120 (1.1) 879 (1.3) 2.7 
Coronary artery disease 3,501 (33.2) 22,296 (31.9) 3.4 
Peripheral vascular 
disease 726 (6.9) 5295 (7.6) 3.8 
Renal impairment 714 (6.8) 6302 (9.0) 11.8 
Diabetes  3,022 (28.6) 20,511 (29.3) 1.9 
Major bleeding 1,544 (14.6) 9,953 (14.2) 1.5 
Anemia 1,284 (12.2) 9,937 (14.2) 8.1 
Peptic Ulcer disease 51 (0.5) 331 (0.5) 0.0 
Sleep Apnea 1,433 (13.6) 6,887 (9.9) 14.5 
Cognitive deficiency 69 (0.7) 492 (0.7) 0.0 
CCI 
  0 3,098 (29.3) 19,416 (27.8) 4.1 
  1-2 4,692 (44.4) 30,041 (43.0) 3.3 
  3-5 2,308 (21.9) 16,579 (23.7) 5.5 
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  6-8 373 (3.5) 3,159 (4.5) 7.5 
  ≥ 9 90 (0.9) 733 (1.1) 3.0 
CHADS2 
  0 1,203 (11.4) 6,804 (9.7) 7.2 
  1 3,258 (30.8) 19,218 (27.5) 8.9 
  ≥2 6,100 (57.8) 43,906 (62.8) 11.5 
CHA2DS2-VASc 
  0 595 (5.6) 3,593 (5.1) 3.0 
  1 1,660 (15.7) 8,226 (11.8) 14.3 
  ≥2 8,306 (78.6) 58,109 (83.1) 12.1 
ATRIA 
  0-3 8,459 (80.1) 53,274 (76.2) 10.0 
  4 799 (7.6) 5,300 (7.6) 0.0 
  ≥5 1,303 (12.3) 11,354 (16.2) 15.6 
HAS-BLED    
  0-2 8,208 (77.7) 53,504 (76.5) 3.0 
  ≥3 2,353 (22.3) 16,424 (23.5) 3.7 
Hospitalizations    
  ≥1 3,173 (30.0) 20,538 (29.4) 1.6 
Catheter ablation 216 (2.1) 721 (1.0) 10.8 
Medication Use    
Antiplatelet therapy 810 (7.7) 4,420 (6.3) 7.2 
Gastroprotective agent 1,247 (11.8) 7,752 (11.1) 2.9 
Antiarrhythmic 2,845 (26.9) 14,578 (20.8) 17.6 
Digoxin 2,878 (27.3) 19,566 (28.0) 2.0 
Beta-blocker 7,278 (68.9) 47,226 (67.5) 3.3 
Calcium channel blocker 4,614 (43.7) 28,109 (40.2) 8.4 
ACEI/ARB 6,676 (63.2) 42,125 (60.2) 6.8 
Statin 6,792 (64.3) 42,677 (61.0) 7.5 
Hormone 458 (4.3) 2513 (3.6) 4.8 
  Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred 
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin receptor blocker 
 
4.2.1.3. Anticoagulant switching time periods 
The time to switching anticoagulants were also descriptively assessed for both the new 
user and prevalent user cohorts. Of the 4,216 AF patients newly-initiating an anticoagulant and 
switching within 12-months, the mean time from initiation until discontinuation was 136.6 days 
(106.4 SD). Among patients who switched, the switch from warfarin was shorter than the switch 
to dabigatran. Specifically, the mean switch time from warfarin was 127.4 days (102.1 SD) while 
the mean switch time from dabigatran was 155.0 days (112.3 SD). Of the prevalent users, the 
mean switch time was 168.4 days (97.3 SD). Of the patients newly-initiating warfarin and 
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switching within 12 months, 568 (20.3%) and 1,002 (35.8%) switched therapies within 30 and 60 
days since initiation, respectively. These proportions represent 1.7% and 3.0% of the total 
warfarin new-initiators. The proportion of patients newly-initiating dabigatran and switching 
within 30 and 60 days was somewhat lower (30 days: 16.7%, N=236; 60 days: 29.0%, N=411). 
As many as 151 (5.4%) and 51 patients (3.6%) of the warfarin and dabigatran patients who 
switched to another anticoagulant did so within 7 days of newly-initiating the respective 
therapies.  
 
4.2.1.4. Anticoagulant switching prescription copayments 
The distributions of the proportion of the index prescription copayments paid by the new 
user and prevalent user AF patients are shown in Appendix table 5. 
 
4.2.2. Bivariate analyses 
The bivariate association between each clinical and sociodemographic covariate level and 
anticoagulation switching for each type of anticoagulant was also assessed, by definition without 
controlling for the other covariates. These associations were assessed using relative risk 
estimation by modified Poisson regression with robust error variance. These associations are 
presented in Table 19 with “non-switching” as the referent group for each anticoagulant 
comparison. These associations were conducted on both the new user and prevalent user cohorts 
using the same methodology as Aim 1a. 
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Table 19. Bivariate association between anticoagulant switching and baseline 
sociodemographic and clinical characteristics in the 12-month baseline period 
 
 Warfarin New Users Dabigatran New Users Prevalent Users 
Baseline Characteristic RR 95% CI RR 95% CI RR 95% CI 
Demographic       
Age (ref: <55 years)       
  55-64 years 1.23 1.07-1.40* 1.23 1.02-1.48* 1.13 1.04-1.22* 
  65-74 years 1.09 0.95-1.24 1.35 1.12-1.63* 1.05 0.97-1.14 
  ≥ 75 years 0.85 0.75-0.97* 1.60 1.34-1.90** 0.74 0.68-0.80** 
Gender (ref: Female) 1.02 0.95-1.09 0.83 0.75-0.91** 1.09 1.05-1.13** 
Region (ref: Northeast)       
  North Central 1.02 0.92-1.13 1.00 0.86-1.16 0.82 0.78-0.87** 
  South 1.29 1.17-1.43** 1.09 0.95-1.26 1.35 1.29-1.42** 
  West 1.10 0.98-1.24 1.15 0.97-1.36 1.07 1.01-1.14* 
Insurance plan (ref: 
Comprehensive)   
  
  
  HMO 0.57 0.50-0.67** 0.92 0.75-1.12 0.40 0.37-0.43** 
  POS 1.23 1.06-1.43* 0.78 0.62-0.98* 1.27 1.17-1.37** 
  PPO 1.18 1.10-1.27** 0.91 0.82-1.01 1.23 1.19-1.28** 
  CDHP 1.23 0.96-1.58 0.86 0.60-1.24 1.12 0.95-1.31 
Prescription generosity (ref: 
None/Poor)   
  
  
  Fair coverage 1.06 0.86-1.31 1.73 0.45-6.59 1.58 1.32-1.89** 
  Good coverage 1.23 1.00-1.52 1.66 0.44-6.33 2.00 1.67-2.40** 
Clinical (ref: 0/None unless 
specified)   
  
  
Ischemic Stroke 0.99 0.88-1.12 0.75 0.60-0.93* 1.00 0.93-1.07 
Congestive Heart Failure 0.82 0.75-0.89** 1.00 0.88-1.13 0.88 0.84-0.92** 
VTE 0.50 0.43-0.59** 1.13 0.85-1.50 0.60 0.55-0.66** 
Hyperlipidemia 0.96 0.90-1.03 1.06 0.96-1.17 1.11 1.07-1.15** 
Hypertension 1.00 0.92-1.07 1.10 0.99-1.23 1.04 1.00-1.08* 
Myocardial infarction 0.80 0.66-0.99* 0.92 0.65-1.29 0.91 0.77-1.08 
Coronary artery disease 0.92 0.85-0.99* 1.13 1.02-1.25* 1.05 1.01-1.09* 
Peripheral vascular disease 0.88 0.77-1.02 1.15 0.95-1.40 0.91 0.85-0.98* 
Renal impairment 0.61 0.52-0.70** 1.13 0.92-1.39 0.76 0.71-0.82** 
Diabetes  0.97 0.90-1.05 1.04 0.93-1.16 0.97 0.93-1.01 
Major bleeding 0.88 0.79-0.99* 1.00 0.85-1.18 1.03 0.98-1.09 
Anemia 0.67 0.60-0.74** 1.11 0.95-1.30 0.85 0.81-0.90** 
Peptic Ulcer disease 0.66 0.38-1.14 0.53 0.18-1.58 1.02 0.79-1.31 
Sleep Apnea 1.22 1.10-1.35** 1.09 0.94-1.26 1.36 1.29-1.43** 
Cognitive deficiency 0.77 0.48-1.25 1.05 0.55-2.01 0.94 0.75-1.17 
CCI (ref: 0)       
  1-2 1.02 0.94-1.11 1.11 0.99-1.24 0.98 0.94-1.02 
  3-5 0.82 0.74-0.90** 1.20 1.05-1.38* 0.89 0.85-0.93** 
  6-8 0.61 0.50-0.74** 1.14 0.85-1.52 0.77 0.69-0.85** 
  ≥ 9 0.67 0.48-0.94* 0.87 0.48-1.58 0.79 0.65-0.97* 
CHADS2 (ref: 0)       
  1 0.94 0.84-1.05 1.10 0.94-1.29 0.96 0.91-1.03 
  ≥2 0.83 0.74-0.92** 1.29 1.11-1.49* 0.81 0.77-0.86** 
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CHA2DS2-VASc (ref: 0)       
  1 1.06 0.92-1.23 1.07 0.87-1.31 1.19 1.08-1.29** 
  ≥2 0.85 0.74-0.96* 1.38 1.16-1.64** 0.88 0.82-0.95* 
ATRIA (ref: 0-3)       
  4 0.89 0.79-1.01 0.95 0.78-1.16 0.96 0.89-1.02 
  ≥5 0.59 0.52-0.66** 1.21 1.03-1.42* 0.75 0.71-0.79** 
HAS-BLED (ref: 0-2)       
  ≥3 0.83 0.76-0.89** 1.04 0.92-1.17 0.94 0.90-0.98* 
Hospitalizations       
  ≥1 0.89 0.83-0.96* 0.90 0.82-1.00* 1.03 0.99-1.07 
Catheter ablation 0.95 0.66-1.34 0.24 0.12-0.50** 1.77 1.57-2.00** 
Medication use       
Antiplatelet therapy 1.05 0.95-1.17 0.98 0.84-1.13 1.02 0.94-1.11 
Gastroprotective agent 0.99 0.89-1.10 1.04 0.89-1.22 1.06 1.01-1.12* 
Antiarrhythmic 1.17 1.08-1.26** 1.03 0.92-1.15 1.33 1.28-1.39** 
Digoxin 1.01 0.92-1.10 1.00 0.87-1.15 0.97 0.93-1.09 
Beta-blocker 1.02 0.95-1.10 1.22 1.10-1.36** 1.06 1.02-1.10* 
Calcium channel blocker 1.06 0.99-1.14 1.06 0.96-1.17 1.13 1.09-1.17** 
ACEI/ARB 1.12 1.04-1.20* 1.00 0.91-1.11 1.12 1.08-1.16** 
Statin 1.06 0.99-1.14 0.98 0.89-1.09 1.13 1.09-1.17** 
Hormone 1.40 1.21-1.63** 1.09 0.87-1.35 1.18 1.09-1.29** 
  *p<0.05 
  **p<0.001 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS, 
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism; 
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blockers 
 
In these bivariate associations, many of the baseline sociodemographic and clinical 
characteristics were statistically significantly associated with anticoagulant selection, as seen in 
Table 19. These suggested that the switchers and non-switchers for each type of anticoagulant 
may significantly differ from each other in the 12-month baseline period. When examining the 
warfarin new user cohort, being from the South region and being 55-64 years of age, having a 
PPO plan, sleep apnea and using antiarrhythmics, ACEI/ARB or hormone therapies were 
significantly associated with switching from warfarin in the 12-month follow-up period. Patients 
were less likely to switch if they were ≥ 75 years of age, had an HMO plan, had CHF, VTE, 
anemia or renal impairment, had higher comorbidity burden, higher risk of ischemic stroke or 
bleeding, and had a previous hospitalization.  
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When examining the patients initiating dabigatran, patients greater than 55 years of age, 
with coronary artery disease, moderate comorbidity burden, higher ischemic stroke risk or 
bleeding risk and using beta-blocker therapies were more likely to switch from dabigatran. 
Patients were less likely to switch from dabigatran if they were male, had a POS plan, had 
previous ischemic stroke, were previously hospitalized or had a catheter ablation procedure. By 
comparison, patients with bleeding risk or ischemic stroke risk or congestive heart failure, VTE, 
renal impairment, anemia or PVD were less likely to switch if they were prevalent users. 
However, prevalent user patients with hypertension, hyperlipidemia and sleep apnea were more 
likely to switch. There was a significant amount of geographic variation between the regions, 
particularly among the prevalent users. 
Lastly, among new users, newly-diagnosed AF was significantly associated with 
switching for warfarin in the 12-month follow-up period (warfarin RR: 1.32, 95% CI: 1.24-1.42; 
dabigatran RR: 1.03, 95% CI: 0.94-1.14), and a new diagnosis of AF was also adjusted for in the 
multivariate analyses discussed in the next section. 
 
4.2.3. Multivariate analyses 
4.2.3.1. Main analyses 
 The associations between ischemic stroke and bleeding risk scores and anticoagulant 
switching were also assessed using multivariable relative risk estimation by modified Poisson 
regression with robust error variance (Table 20). In this model, the independent variables were 
CHA2DS2-VASc and ATRIA risk scores, with the dependent variable being selection for a 
particular anticoagulant. Non-switchers were used as the referent group for all analyses using 
both the new user and the prevalent user cohorts and the methods described in Aim 1a. The 
associations with the other baseline characteristics are shown in Appendix table 6. 
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 Compared with non-switchers, patients initiating warfarin were significantly less likely to 
switch therapies with high bleeding risk (RR: 0.69, 95% CI: 0.61-0.79). By comparison, patients 
initiating dabigatran were significantly more likely to switch with high ischemic stroke risk (RR: 
1.35, 95% CI: 1.09-1.66) compared with non-switchers. Comparatively, patients who are newly-
initiating dabigatran are more likely to switch with high baseline ischemic stroke risk, which 
appears to be driven by advanced age. 
By contrast, in the prevalent users of warfarin, having a high ischemic stroke risk was 
associated with an 8% reduction in the likelihood of switching anticoagulants, while intermediate 
ischemic stroke risk was paradoxically associated with a 12% increase in switching. Similar to 
the new users of warfarin, however, high bleeding risk in the 12-month baseline was associated 
with a lower risk of switching (RR: 0.82, 95% CI: 0.77-0.87).  
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Table 20.  Multivariable association between ischemic stroke and bleeding  
risk prediction scores and anticoagulant switching 
 
 *p<0.05 
 **p<0.001 
 Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval 
 NOTE: Adjusted for all other measured baseline covariates, except for those already included in risk scores, as shown in 
Appendix table 2 
 
4.2.3.2. Model fit diagnostics 
Just as in Aim 1a, the Quasilikelihood under the Independence model Criterion (QIC) 
was used to compare the insertion of CHADS2 and the HAS-BLED score as possible predictors 
instead of the CHA2DS2-VASc and ATRIA risk scores. The model possibilities and resultant 
QICs are shown in Appendix table 8 and again indicate that indeed the inclusion of the ATRIA 
risk score leads to a better model fit across both the warfarin and prevalent user models, as that 
model possibility had lower QICs than HAS-BLED. However, the models incorporating 
CHADS2 and ATRIA (instead of CHA2DS2-VASc) had slightly lower QICs. The QICs were, 
indeed, marginally higher for the model including CHA2DS2-VASc and ATRIA, but the 
directionality and significance of the findings were similar. Moreover, intermediate ischemic 
stroke risk was associated with a reduction in the likelihood of switching – not just high ischemic 
stroke risk, but this difference was seen more strongly in the CHADS2 models compared with the 
CHA2DS2-VASc models. These slight differences are likely due to differentiation differences in 
patients at intermediate risk between the two scores. Despite this slight difference, CHA2DS2-
VASc  and ATRIA were determined appropriate to be used in further analyses, because current 
 All Warfarin New Users All Dabigatran New Users Prevalent Users 
Risk Score RR 95% CI RR 95% CI RR 95% CI 
Demographic      
CHA2DS2-VASc (ref: 0)      
  1 1.01 0.87-1.17 1.06 0.86-1.31 1.12 1.03-1.22* 
  ≥2 0.88 0.76-1.02 1.35 1.09-1.66* 0.91 0.84-0.99* 
ATRIA (ref: 0-3)      
  4 0.95 0.83-1.08 0.91 0.74-1.12 0.96 0.90-1.03 
  ≥5 0.69 0.61-0.79** 1.12 0.94-1.33 0.82 0.77-0.87** 
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clinical guidelines are emphasizing the use of the CHA2DS2-VASc  score instead of the CHADS2 
and the ATRIA score is better measured in this data source.  
The relative risks and 95% confidence intervals for the baseline covariates included in the 
model are shown in the Appendix (Appendix table 6). Key interactions (e.g., age and gender) 
were also examined. As discussed in the previous section, age was examined via restriction to 
the commercially-insured and Medicare supplement patients, and some slight differences were 
noted. As with Aim 1a, gender was also investigated as an interaction term, and the term was not 
found to significantly interact with either score. 
 
4.2.3.3. Sensitivity analyses 
Just as in Aim 1a, the cohorts were also stratified based on the data sources into 
commercially-insured and Medicare supplemental claims (Appendix table 7). In the analysis of 
the new user cohort, the directions and significance of the associations between bleeding 
prediction risk scores and anticoagulant switching were largely similar to the original results for 
both warfarin and dabigatran. However, the strength of the associations did differ somewhat 
between the groups, with a stronger association between bleeding risk and switching seen in the 
CCAE group. Some differences with regard to ischemic stroke risk were also seen between the 
CCAE and Medicare supplement, however. Specifically, for warfarin initiators, no difference 
was seen between ischemic stroke risk and switching in the CCAE population, but higher 
ischemic stroke risk was associated with a slightly lower likelihood of switching in the Medicare 
Supplement group. These differences could possibly be due to age influencing switching. There 
were no differences in ischemic stroke risk and switching in the dabigatran initiators, however.  
When examining the prevalent user cohort, there was one difference from the primary 
results when stratifying on insurance status. Intermediate and high ischemic stroke risk was, in 
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fact, associated with a reduction in the risk of switching within the 12-month follow-up period 
among Medicare beneficiaries, but not in the commercially-insured patients. However, there 
were few major differences in bleeding risk associations with switching between both the CCAE 
and Medicare supplement population – bleeding risk just had a slightly stronger association with 
not switching in the CCAE arm. Overall, the direction of the estimates was similar even when 
examining the two groups separately. 
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AIM 2: COMPARATIVE EFFECTIVENESS 
 
4.3. AIM 2: COMPARATIVE EFFECTIVENESS OF ANTICOAGULANTS 
4.3.1. Descriptive statistics  
4.3.1.1. Cohort identification 
A total of 64,935 patients were included in the new user cohort, which was the primary 
analysis. Newly-diagnosed new users were also examined as a secondary analysis. The clinical 
and demographic characteristics of the cohort were previously shown in Aim 1a.  In Aim 2, 
patients were followed from anticoagulant initiation until they experienced an outcome of 
interest, lost continuous eligibility, or were censored administratively on 12/31/2012 (the end of 
available data). The mean patient follow-up time from initiation was 323 days with an 
interquartile range of 113 days to 513 days. For the warfarin new users, the mean follow-up time 
was 311 days; for dabigatran new users, the mean follow-up time was 349 days.  
 
4.3.1.2. Crude outcome rates 
The unadjusted rates of outcomes in the new user cohort were also examined. The 
identification of clinical effectiveness and harm outcomes were previously discussed in Chapter 
3 (Methods). Table 21 shows the observed rate of the clinical effectiveness and harm outcomes 
by the type of anticoagulant initiated, standardized by 1,000 person-years of anticoagulant 
exposure. The overall incidence of ischemic stroke, TIA, and VTE was 177.36 per 1,000 person-
years (PYs). As shown below in Table 21, the overall unadjusted outcome rates were higher 
among warfarin users compared with dabigatran users across both the new users and newly-
diagnosed new users. For the effectiveness outcome endpoints, 54,667 (84.3%) of the patients 
were censored either administratively on 12/31/2012 at the end of the data collection period or 
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because of loss of continuous eligibility. For the harm outcome composites, 42,473 of the 
patients were censored (65.4%) for these same reasons (administratively on 12/31/2012 or loss of 
continuous eligibility). 
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Table 21. Outcome rates per 1,000 person-years by anticoagulant initiated 
 
 New Users Newly-diagnosed new users 
Outcome Type Warfarin Dabigatran Warfarin Dabigatran 
Clinical Effectiveness     
  Ischemic stroke 108.6 66.0 95.8 60.5 
  TIA 12.9 9.7 11.6 7.7 
  VTE 131.0 30.7 111.8 30.7 
  Composite 222.7 93.3 195.3 88.2 
Harm     
  Hemorrhagic stroke/ 
intracranial hemorrhage 16.3 7.1 14.4 6.2 
  Gastrointestinal 
hemorrhage 90.8 70.8 84.9 69.7 
  Other bleeding event 121.5 90.0 119.0 87.1 
  Hospitalization 391.7 310.8 375.3 309.6 
  Composite 419.1 338.6 401.6 337.4 
Myocardial infarction 21.8 13.1 22.9 13.4 
  Abbreviations: TIA, Transient Ischemic Attack; VTE, Venous thromboembolism 
 
4.3.2. Preliminary assessment of model specifications 
As described in Chapter 3, the association between anticoagulant and the hazard of 
experiencing an outcome was examined using Cox proportional hazards regression via bivariate 
models, multivariable models, and propensity-score adjusted models. First, the baseline 
characteristics and their associations with anticoagulant exposure and outcomes were assessed 
for whether they are confounders and should be included (or not included) in the models. This 
process was previously shown in the Analytic Diagram (Chapter 3, Figure 3) and the Cox 
proportional hazards model (Chapter 3, Equation 2).  
These baseline characteristics and their associations with exposure and the composite 
outcomes are shown in Appendix table 9. These tests were done in order to determine which 
covariates should be considered confounder variables (X3) for the analysis and thus included in 
statistical adjustments. Overall, these tests indicated that there was only one variable (i.e., 
hormone use) that statistically should be considered an X1 variable, a variable statistically 
associated solely with exposure that should not be included in propensity score analysis.
238
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Accordingly, this variable was not included in the propensity score analyses. Other variables 
were still included in the propensity score analysis as they were specified a priori based on 
associations seen in the literature and were seen to be confounders.
189
  
In addition to multivariable adjustment, inverse-probability treatment weighting (IPTW) 
(with stabilized weights) was used as the primary propensity score adjustment method to control 
for measured confounding to estimates of the average effect of treatment in the study population. 
The kernel densities for the propensity score plots are shown in Appendix figure 1. After 
examining individual covariates included in the propensity score model, the ones most 
contributing to the non-overlap seen in the warfarin group (solid line) were the baseline 
prescription benefits’ generosity and venous thromboembolism covariates. Applying stabilized 
weights, the mean probabilities of receiving anticoagulation with dabigatran and warfarin 
(referent) were 1.01 (SD: 1.25) and 1.00 (SD: 0.23), respectively. For the newly-diagnosed new 
users, after applying stabilized weights, the groups’ mean probabilities were 1.00 (SD: 0.78) for 
dabigatran and 1.00 (SD: 0.24) for warfarin, respectively. The balance of the covariates for the 
new user groups following the IPTW is shown in Appendix table 10. Based on absolute 
standardized differences (whereby >10 indicates imbalance), there was no imbalance in 
covariates after weighting in the IPTW propensity score, which indicates good balance. The c-
statistic for the propensity score for the new user group was 0.69, indicating good fit. 
Standardized mortality ratio (SMR) propensity score weighting was also conducted as 
another adjustment method to estimate the comparative effectiveness of anticoagulants. As 
previously described in Chapter 3, in SMR weighting, weights are applied standardized to the 
treated group, estimating the average treatment effects among treated patients (e.g., in this 
setting, dabigatran patients). The mean SMR weight for the warfarin new user group was 0.48 
(SD: 0.34) (as by definition, the dabigatran group’s mean was 1 with SD equal to 0).  
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4.3.3. Main Results 
4.3.3.1. Composite outcomes 
 These comparative effectiveness and safety of dabigatran and warfarin among new 
anticoagulant initiators is shown in Table 22 for unadjusted, multivariable-adjusted, and 
propensity score-adjusted models. The estimated treatment effects comparing new users of 
dabigatran to warfarin on risk of outcomes among only outcomes that occurred in the inpatient 
setting are shown in Appendix table 11. 
For the primary analyses, applying propensity scores using IPTW yielded a point 
estimate closer to the null, yielding a 30% reduction in the hazard of experiencing one of the 
clinical effectiveness outcomes (adjusted HR: 0.70, 95% CI: 0.67-0.73). By contrast, dabigatran 
users were no less likely to experience one of the harm outcomes included in the composite 
endpoint (adjusted HR: 1.02, 95% CI: 0.99-1.05) compared with warfarin, after multivariable 
adjustment.   
For the multivariate analysis, compared with warfarin, dabigatran showed a 38% 
reduction in the hazard of experiencing one of the clinical effectiveness composite outcomes 
(adjusted [Hazard Ratio] HR: 0.62, 95% CI: 0.59-0.66). Multivariable models included 
adjustment for the covariates that were described in Appendix table 10. The full model results 
are shown in Appendix table 12 for the multivariable analyses among new users. Applying 
SMR weighting moved the effect estimates slightly closer to the null, but the estimates of the 
risk of harm were still similar as multivariable-adjusted and IPTW-weighted analyses. The 
testing of assumptions, functional forms and model diagnostics are shown in Section 4.3.3.3. 
In addition, applying trimming (5%) to the propensity scores did not appreciably change 
the effect estimates. Applying trimming to the IPTW propensity scores resulted in an adjusted 
HR of 0.68 (95% CL: 0.65-0.71) for the clinical effectiveness composite and an adjusted HR of 
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1.01 (95% CL: 0.98-1.04) for the harm outcome composite in the survival analysis regresssion. 
These findings are very similar to the original stabilized IPTW estimates shown in Table 22 
below.   
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Table 22. Multivariable Cox models comparing dabigatran and warfarin use 
 and outcomes in atrial fibrillation 
 
Outcome Type 
Unadjusted 
HR (95% CI) 
MV Adjusted 
HR (95% CI) 
PS-IPTW 
HR (95% CI) 
PS-SMR 
HR (95% CI) 
Clinical 
Effectiveness 
  
  
  Ischemic stroke 0.66 (0.62-0.70)** 0.85 (0.80-0.91)** 0.92 (0.87-0.98)* 0.90 (0.83-0.96)* 
  TIA 0.83 (0.70-0.97)* 0.97 (0.82-1.16) 1.07 (0.92-1.25) 1.00 (0.82-1.22) 
  VTE 0.25 (0.23-0.27)** 0.41 (0.38-0.45)** 0.51 (0.47-0.54)** 0.52 (0.47-0.56)** 
  Composite 0.43 (0.41-0.45)** 0.62 (0.59-0.66)** 0.70 (0.67-0.74)** 0.74 (0.69-0.78)** 
Harm     
  Hemorrhagic 
stroke/intracranial 
hemorrhage 
 
 
0.47 (0.40-0.57)** 
 
 
0.62 (0.51-0.74)** 
 
 
0.64 (0.54-0.75)** 
 
 
0.65 (0.53-0.80)** 
  GI hemorrhage 0.85 (0.80-0.90)** 1.08 (1.01-1.15)* 1.19 (1.12-1.26)** 1.08 (1.00-1.15) 
  Other bleeding 0.80 (0.76-0.84)** 0.91 (0.86-0.96)** 0.91 (0.86-0.96)** 0.91 (0.86-0.97)* 
  Hospitalization 0.84 (0.81-0.86)** 0.97 (0.94-1.01) 1.00 (0.97-1.02) 0.98 (0.95-1.01) 
  Composite 0.85 (0.83-0.88)** 1.00 (0.97-1.03) 1.02 (0.99-1.05) 1.00 (0.97-1.03) 
AMI 0.66 (0.57-0.76)** 0.86 (0.74-0.99)* 0.88 (0.77-1.00) 0.87 (0.74-1.02) 
 *p<0.05; **p<0.001 
 Abbreviations: HR, Hazard Ratio; CI, Confidence interval; MV, multivariable model; PS, Propensity score; IPTW, 
Inverse probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, Transient ischemic attack; VTE, 
venous thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction 
 
4.3.3.2. Cause-specific outcomes 
The cause-specific survival analyses yielded similar results. In these analyses, patients 
were followed from anticoagulant initiation until any outcome was experienced, they lost 
continuous eligibility or they were censored administratively at 12/31/2012. In these primary 
analyses using IPTW, initiating dabigatran resulted in a statistically significant reduction in the 
hazard of VTE (adjusted HR: 0.51, 95% CI: 0.47-0.54), ischemic stroke (adjusted HR: 0.92, 95% 
CI: 0.87-0.98), hemorrhagic stroke (adjusted HR: 0.64, 95% CI: 0.54-0.76), other bleeding 
(adjusted HR: 0.91, 95% CI: 0.86-0.96), and myocardial infarction (adjusted HR: 0.88, 95% CI: 
0.77-1.00) compared with warfarin initiation. However, dabigatran was also associated with an 
increased hazard of GI hemorrhage (adjusted HR: 1.19, 95% CI: 1.12-1.26). Hospitalizations and 
TIAs did not differ between the anticoagulant groups. 
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4.3.3.3. Model diagnostics 
The deviance residuals showed appropriate distribution for the main covariates assessed. 
Proportional hazards assumptions were also tested for both the composite of effectiveness and 
composite of harm outcomes. These tests did not reveal any violations of the assumption for the 
models. These tests are shown here in the Kaplan Meier plots (Appendix figure 2) for the 
association of anticoagulation with the clinical effectiveness and harm composites among new 
users. In addition, examining the Schoenfeld residuals also did not yield any violations of the 
proportional hazards assumptions. Including an interaction term for time in the models also did 
not indicate a violation of the proportional hazards assumption. In addition, supremum tests for 
heterogeneity of treatment effect were non-significant. The AICs were lower for the full 
multivariable model compared with other models.  
 
4.3.4. Sensitivity analyses 
4.3.4.1. Subgroup analyses 
4.3.4.1.1. Newly-diagnosed new users 
 The effect estimates for the comparative effectiveness and safety of anticoagulation 
among newly-diagnosed new users as a sensitivity analysis are shown in Table 23. Similar to 
new users, the subgroup of newly-diagnosed new users also showed a significant reduction in the 
hazard of experiencing a clinical effectiveness outcome when initiating dabigatran compared 
with warfarin. The overall associations are very similar; in fact, a stronger reduction in clinical 
outcomes was observed when examining the newly-diagnosed new users (e.g., the HR is further 
away from the null). Thus, if there was unmeasured confounding, it would be likely to bias the 
estimates down and away from the null (as the warfarin group would likely have higher rates of 
frailty compared with dabigatran as seen in Aim 1). This suggests that perhaps unmeasured 
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confounding may be more present among the newly-diagnosed new users than the overall new 
user sample (or that dabigatran is more beneficial in newly-diagnosed patients). When examining 
the comparative safety of the agents via the safety composite, dabigatran and warfarin appeared 
to be no different in reducing the hazard of experiencing an adverse outcome. These results were 
also similar to the overall new user subgroup. 
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Table 23. Multivariable Cox models comparing the use of dabigatran  
with warfarin and outcomes in newly-diagnosed AF patients 
 
Outcome Type 
Unadjusted 
HR (95% CI) 
MV Adjusted 
HR (95% CI) 
PS-IPTW 
HR (95% CI) 
PS-SMR 
HR (95% CI) 
Clinical 
Effectiveness  
 
  
  Ischemic stroke 0.68 (0.62-0.74)** 0.86 (0.78-0.94)** 0.89 (0.82-0.97)* 0.90 (0.81-1.00) 
  TIA 0.73 (0.57-0.93)* 0.84 (0.65-1.09) 0.86 (0.68-1.10) 0.83 (0.63-1.11) 
  VTE 0.29 (0.26-0.32)** 0.45 (0.40-0.51)** 0.45 (0.40-0.50)** 0.55 (0.49-0.63)** 
  Composite 0.46 (0.43-0.50)** 0.65 (0.60-0.70)** 0.67 (0.62-0.71)** 0.75 (0.69-0.82)** 
Harm     
  Hemorrhagic 
stroke/intracranial 
hemorrhage 0.46 (0.35-0.60)** 0.58 (0.44-0.76)** 
 
 
0.58 (0.45-0.75)** 
 
 
0.62 (0.46-0.83)* 
  GI hemorrhage 0.88 (0.81-0.96)* 1.08 (0.99-1.19) 1.10 (1.01-1.19)** 1.09 (0.98-1.21) 
  Other bleeding 0.78 (0.72-0.84)** 0.86 (0.79-0.93)** 0.86 (0.80-0.93)** 0.85 (0.78-0.93)** 
  Hospitalization 0.86 (0.83-0.90)** 0.98 (0.94-1.02) 0.98 (0.94-1.02) 0.98 (0.93-1.03) 
  Composite 0.88 (0.84-0.91)** 1.00 (0.96-1.04) 1.00 (0.96-1.04) 1.00 (0.95-1.05) 
AMI 0.63 (0.52-0.76)** 0.80 (0.66-0.98)* 0.85 (0.71-1.01) 0.82 (0.66-1.02) 
  Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse 
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous 
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction 
 
4.3.4.1.2. Stratification by commercial insurance and Medicare patients 
 The analyses were also conducted separately among commercially-insured beneficiaries 
and Medicare supplement beneficiaries (Appendix table 13) for both new users and newly-
diagnosed new users. No statistically significant differences in the harm composite were seen 
between the users of dabigatran compared with warfarin for any subgroup. However, dabigatran 
was seen to be even more protective in terms of the clinical effectiveness endpoint compared 
with warfarin within commercially-insured beneficiaries (adjusted HR: 0.46, 95% CI: 0.42-0.51 
for new users). While still statistically significant, the effect of dabigatran in reducing the hazard 
of experiencing a clinical effectiveness outcome was less pronounced among only the Medicare 
supplement beneficiaries (adjusted HR: 0.77, 95% CI: 0.73-0.81). All in all, the associations 
were similar across the groups, only the strength of the associations slightly differed for the 
clinical effectiveness endpoint. 
 138 
 
4.3.4.1.3. Stratification by dabigatran strengths 
 The comparative effectiveness and safety of the two dabigatran strengths (75mg and 
150mg) were also studied in separate survival analyses using warfarin as the referent group. 
These results are shown in Appendix table 14. Using both multivariable and PS-adjustment, 
dabigatran 150mg showed a statistically significant reduction in the hazard of experiencing one 
of the composite outcomes compared with warfarin. However, the comparative safety of 
dabigatran 150mg did not differ compared to warfarin. By contrast, there was no statistical 
difference in clinical effectiveness seen between dabigatran 75mg and warfarin; however, 
dabigatran 75mg showed an increased hazard of experiencing one of the harm outcomes, which 
could possibly be due to some unmeasured confounding. 
 
4.3.4.2. Sensitivity analyses  
4.3.4.2.1. Influence of mortality 
 A known limitation of the Truven Health MarketScan
®
 is that when patients lose 
continuous eligibility, it is unknown whether they are changing plans or whether they have 
actually died. Death occurrences, outside of the hospital setting, within these data are unknown. 
First, to attempt to explore this limitation, the discharge location of the patients who experienced 
a hospital admission as their censoring outcome for the harm outcome composite was examined. 
Of the 14,219 warfarin patients who were hospitalized in the follow-up period after initiation, 
381 (2.7%) patients were coded as “Died” or “Other died status” upon discharge from their 
hospitalization outcome. By contrast, of the 5,932 dabigatran patients who were hospitalized, 95 
(1.6%) were coded with “Died” or “Other died status” for their discharge dispensation location. 
Crude test statistics on this difference in the proportion of hospitalizations associated with 
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mortality yielded a chi-square of 22.44 (p<0.001), suggesting that there was a significant 
difference in the proportion of hospitalizations in the follow-up period that resulted in death. 
Secondly, the proportion of patients who were lost to follow-up (and not censored 
administratively on 12/31/2012) was also examined. In sum, 5,543 (12.6%) of warfarin patients 
and 2,314 (11.0%) of dabigatran patients were lost to follow-up (chi-square 35.97, p<0.001), 
suggestive of possible significant differences in the proportion of patients who were lost to 
follow-up. These patients, by definition, did not experience any one of the composite outcomes. 
Finally, this limitation was explored by again conducting the multivariable survival 
analysis between anticoagulant initiation and the hazard of experiencing one of the composite 
outcomes – this time applying a statistical assumption that every patient who lost continuous 
eligibility actually died. In other words, those who were lost to follow-up were included in the 
composite endpoints as another outcome, censored at the date they were lost to follow up. These 
findings, along with the other sensitivity analyses in this section are shown in Table 24. The 
sensitivity analyses on mortality suggest that dabigatran only slightly reduced the hazard of 
experiencing both a clinical effectiveness and harm outcomes when assuming that all patients 
who lost continuous eligibility actually died. These results were in contrast to the primary 
findings particularly when considering magnitude, whereby in the original results, no significant 
difference in the reduction of the harm outcomes was found.  
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Table 24. Sensitivity analyses comparing the use of dabigatran with warfarin and  
outcomes in AF patients initiating anticoagulation 
 
Outcome Type 
Effectiveness composite 
HR (95% CI) 
Harm composite 
HR (95% CI) 
Original results   
  MV-adjusted 0.62 (0.59-0.66)** 1.00 (0.97-1.03) 
  PS-IPTW 0.70 (0.67-0.74)** 1.02 (0.99-1.05) 
Sensitivity analysis 1   
  MV-adjusted 0.96 (0.93-0.99)* 0.92 (0.89-0.96)* 
  PS-IPTW 0.92 (0.89-0.96)** 0.97 (0.94-0.99)* 
Sensitivity analysis 2   
  MV-adjusted 0.63 (0.60-0.66)** N/A 
  PS-IPTW 0.71 (0.68-0.74)** N/A 
Sensitivity analysis 3   
  MV-adjusted 0.63 (0.60-0.66)** N/A 
  PS-IPTW 0.71 (0.68-0.74)** N/A 
*p<0.05; **p<0.001  
 Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse 
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous 
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction 
 NOTE: Sensitivity analysis 1: Influence of mortality by including patients lost-to-follow-up; Sensitivity analysis 2: 
Inclusion of transient ischemic attack; Sensitivity analysis 3: Inclusion of hemorrhagic stroke 
 
Overall, these explorations suggest that there could be some differential effects of 
dabigatran on the risk of mortality compared with warfarin, in that dabigatran may lead to 
slightly lower mortality risk. Specifically, there were fewer dabigatran patients who experienced 
morality upon hospitalization, and fewer dabigatran patients were lost to follow-up – outside of 
being censored administratively on 12/31/2012. However, none of these explorations were direct 
measures, and the re-analyses of the Cox proportional hazards regression relied on the very 
unlikely assumption that everyone who was lost to follow-up actually died. Thus, it could be 
reasonably assumed that not being able to have mortality as part of the composite outcomes may 
not have significantly affected the results, but it is still a possible limitation of the Truven Health 
MarketScan® database. 
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4.3.4.2.2. Inclusion of transient ischemic attacks (TIAs) 
While some algorithms have recommended including transient ischemic attacks as part of 
the composite endpoint for the effectiveness of anticoagulants, the specificity of identifying them 
in claims data has been called into question. To test the robustness of results, TIA was removed 
as part of the composite clinical effectiveness endpoint, which reduced the overall number of 
events by 186 in the composite endpoint. Because the overall event rate was almost the exact 
same, the multivariate-adjusted survival analysis yielded the exact same hazard ratios, which 
were the same as the initial results without including TIA (Table 24). Among the newly-
diagnosed new users, the results were similar: adjusted HR: 0.65, 95% CL: 0.61-0.70) and PS-
IPTW HR: 0.67 (95% CL: 0.63-0.71). These findings suggest that the overall results were robust 
to the removal of TIA in the clinical effectiveness composite. 
 
4.3.4.2.3. Inclusion of hemorrhagic stroke 
 To perhaps provide a closer analog to the RE-LY trial that was used for FDA-approval of 
dabigatran, an outcome of hemorrhagic stroke was also included in the primary clinical 
effectiveness endpoint. Specifically, the RE-LY trial included hemorrhagic stroke in the primary 
stroke or systemic embolism in their primary endpoint. In our study’s sensitivity analysis, 
patients were then followed from anticoagulation initiation until they experienced either 
ischemic stroke, VTE, TIA, or hemorrhagic stroke/intracranial hemorrhage or were censored due 
to loss of continuous eligibility or administratively on 12/31/2012. In total, an additional 283 
events were identified in our study and included in the composite clinical effectiveness endpoint. 
The multivariable survival analysis and analysis using IPTW were very similar to the primary 
results (Table 24). Among newly-diagnosed new users, the adjusted HR was 0.65 (95% CI: 0.61-
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0.70). These findings suggest that the overall results were robust to the inclusion of hemorrhagic 
stroke in the clinical composite of effectiveness. 
 
4.3.4.2.4. Heterogeneity of treatment effects 
When examining the IPTW propensity score deciles, a little underlying heterogeneity for 
the estimated treatment effects was seen, particularly for the composite of the risk of harm 
outcomes (Appendix figure 3). However, there does appear to be some treatment effect 
heterogeneity in the lower IPTW propensity score deciles, indicating that dabigatran treatment 
was more beneficial in patients less likely to be treated with dabigatran. Said another way, 
anticoagulation with warfarin was less beneficial in patients who were more likely to be treated 
with warfarin. These finding suggest there could still be some imbalance in covariates, although 
covariate distributions post-propensity score weighting were similar (Appendix table 10). There 
were, however, few individuals treated with dabigatran contrary to prediction, as can be seen in 
the kernel density plots.  
As previously described, subgroup analyses stratifying by baseline characteristics were 
also conducted to examine any treatment effect heterogeneity. Specifically, strata of patients with 
ischemic stroke, VTE, CHF, AMI and levels of prescription benefits’ generosity, ATRIA, 
CHA2DS2-VASc, and ages were examined using stratum-specific propensity scores and Cox 
proportional hazards regression (Appendix table 15). Some treatment effect heterogeneity was 
noted in the hazard of experiencing the clinical effectiveness composite of dabigatran compared 
with warfarin, particularly among patients with previous VTE (HR: 0.50, 95% CI: 0.35-0.72), 
ATRIA ≥ 5 (HR: 0.73, 95% CI: 0.60-0.90), CHA2DS2-VASc ≥ 2 (HR: 0.84, 95% CI: 0.77-0.92), 
and age ≥ 75 years (HR: 0.89, 95% CI: 0.79-1.01). Dabigatran patients with higher ATRIA (≥ 5), 
CHA2DS2-VASc ≥ 2 and age ≥ 75 years were also noted to have a slightly lower hazard of 
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experiencing the harm composite compared with patients on warfarin with the same 
characteristics. 
 
4.3.4.3. Exploratory analyses  
4.3.4.3.1. Assessment of International Normalized Ratios (INRs) 
 The International Normalized Ratio laboratory results were collected from the laboratory 
data files in the Truven Health MarketScan® database for the AF patients included in the cohort. 
The Laboratory Observation Identifiers Names and Codes (LOINC) identifier for the INR test 
was “5902-2”, describing a coagulation assay that included an INR test. CPT procedure codes 
known to be associated with INR test were assessed, and the code “85610” was found to be the 
only one in the laboratory files. Of these, the only LOINC identifier associated with INRs was 
the 5902-2. Of the available INRs in the database, INRs were captured when they occurred on or 
after the index prescription fill date, before one of the outcomes included in the composite, and 
before loss of continuous eligibility or administrative censoring on 12/31/2012.  
In total, 463 warfarin initiators had any INR laboratory values available within the 
follow-up period for a total of 1,816 INRs measured. The mean INR laboratory value was 2.24 
(SD: 0.91). Each patient’s available measured INRs were summed, averaged, and calculated for 
the proportion of INRs which were in therapeutic range (2.0-3.0). Two-hundred and three 
warfarin initiators had only 1 INR measured in the eligible follow-up period; the mean number 
of INRs measured for each patient was 3.92 (SD: 5.03). For these 463 warfarin patients, the 
average mean INR value over the follow-up period was 2.10 (SD: 0.87). Of the 260 warfarin 
patients with at least 2 INRs measured in the data, more than 56.2% had <60% of their measured 
INRs within the therapeutic range of 2.0-3.0 for anticoagulation in atrial fibrillation.  
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4.3.4.3.2. Medication adherence  
 Medication adherence and refill patterns were also examined descriptively. The 
proportion of patients refilling their anticoagulation therapy at least once was also calculated 
post-initiation. Of the 43,865 patients initiating warfarin, 81.8% refilled their warfarin 
prescription at least once. Of the 21,070 patients initiating dabigatran, 77.7% refilled their 
prescription at least once. Comparing the two anticoagulants using multivariate logistic 
regression, adjusting for the measured baseline characteristics, demonstrated that the dabigatran 
patients were indeed significantly less likely to refill their prescription. Specifically, initiating 
dabigatran was associated with a 20% lower odds of refilling dabigatran (OR: 0.80, 95% CI: 
0.76-0.83). The bivariate OR comparing dabigatran refill likelihood to warfarin refill likelihood 
was also very similar before adjusting for the baseline characteristics (OR: 0.78, 95% CI: 0.74-
0.81).  
Adherence to each anticoagulant was calculated as the proportion of days covered (PDC) 
by the prescription supply calculated from refill records in the claims in the 12-months post-
anticoagulation initiation. Conforming to current literature, if the patient had ≥80% of days 
covered with prescription supply, a patient was defined as adherent. In total, 33,711 patients 
were continuously enrolled for at least 12 months post-anticoagulation initiation and had their 
medication adherence patterns assessed. Among these patients, the mean PDC was 0.62 (SD: 
0.33) and 0.64 (SD: 0.35) for warfarin and dabigatran initiators, respectively. In total, 41.3% 
were adherent to warfarin, and 48.6% were adherent to dabigatran. Multivariable logistic 
regression was used to compared the odds of being adherent to dabigatran compared with 
warfarin over the 12-months post anticoagulation initiation, adjusting for the measured baseline 
characteristics. This analysis indicated that patients filling dabigatran had a higher (45%) 
likelihood of being adherent (OR: 1.45, 95% CI: 1.38-1.52). Notably, patients were more likely 
 145 
 
to be adherent with high ischemic stroke risk (OR: 1.57, 95% CI: 1.21-1.50) compared with 
those with low ischemic stroke risk. However, elevated bleeding risk was not statistically 
associated with adherence.  
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AIM 3: CLINICAL EFFECTS OF SWITCHING ANTICOAGULANTS 
 
4.4. AIM 3: CLINICAL EFFECTS ASSOCIATED WITH SWITCHING  
4.4.1. Descriptive statistics 
4.4.1.1. Cohort identification 
In total, 64,935 AF patients were treatment-naïve and met overall study criteria. Of the 
43,865 patients who initiated warfarin, 42,752 patients were included in the cohort. For this 
study, only patients switching to dabigatran or warfarin were assessed, so 1,113 patients were 
excluded as switchers because they switched from warfarin to rivaroxaban in the follow-up 
period. In total, 2,373 warfarin initiators also contributed follow-up time as “switchers”, because 
they switched to dabigatran after initiating warfarin before they experienced any of the measured 
outcomes, lost continuous eligibility or were censored administratively.  These patients are 
characterized as “warfarin switchers” throughout this aim.  Of the 20,070 patients who initiated 
dabigatran, 19,799 patients were included in the cohort; 1,271 patients were excluded because 
they switched from dabigatran to rivaroxaban in the follow-up period. In addition, 959 
dabigatran initiators also contributed follow-up time as “switchers” and are characterized as 
“dabigatran switchers” through this aim. Of the patients who switched, warfarin patients 
switched in a mean 114.5 days (SD: 125.0), and dabigatran patients switched in a mean 116.8 
days (SD: 134.6).  
 
4.4.1.2. Baseline characteristics 
 Baseline characteristics are shown in Table 25. Patients were only included once in the 
descriptive statistics. If patients contributed any follow-up time as “switchers”, they were 
classified as “switchers” and not as “non-switchers” for the numbers and percentages of the 
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baseline characteristics, because these are baseline characteristics measured in the 12-month 
period prior to the first anticoagulant initiation.  
As expected, the distribution of the baseline characteristics concur with the findings in 
Aim 1b, which examined characteristics associated with switching over the 12-month follow-up 
period in patients who retained continuous eligibility for 12 months. Here in Aim 3, patients who 
initiated warfarin and switched to dabigatran were younger, have slightly better prescription 
benefits generosity, and were less likely to have had ischemic stroke, congestive heart failure, or 
other comorbidities. Patients who switched from warfarin to dabigatran also had lower baseline 
ischemic stroke risk and bleeding risk. In addition, warfarin switchers were slightly more likely 
to be using concomitant antiarrhythmic therapies compared with non-switchers.  
Similarly to Aim 1b, patients who initiated dabigatran and then switched to warfarin were 
mostly similar to those who did not switch to warfarin – with some small exceptions. Patients 
who switched were slightly more likely to be older, female and have higher ischemic stroke risk 
compared with non-switchers. However, patients who switched were also slightly less likely to 
have ischemic stroke, congestive heart failure, acute myocardial infarction, or higher bleeding 
risk at baseline compared with non-switchers. Overall, the characteristics were more 
descriptively similar among dabigatran switchers and non-switchers compared with warfarin 
switchers and non-switchers. 
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Table 25. Baseline characteristics of warfarin and dabigatran switchers 
 and non-switchers 
 
Baseline Characteristic 
Warfarin 
switcher, N 
(%) 
Warfarin 
non-
switcher, N 
(%) 
Absolute 
SD 
Dabigatran 
switcher,  
N (%) 
Dabigatran 
non-switcher, 
N (%) 
Absolute 
SD 
Demographic       
Age 
  < 55 years 
 
224 (9.4) 
 
3,557 (8.8) 2.8 
 
100 (10.3) 
 
2,728 (14.5) 18.3 
  55-64 years 681 (28.7) 9,143 (22.6) 17.1 283 (29.2) 5,812 (30.9) 4.6 
  65-74 years 600 (25.3) 8,914 (22.1) 9.4 235 (24.3) 4,290 (22.8) 4.5 
  ≥ 75 years 868 (36.6) 18,765 (46.5) 24.6 350 (36.2) 6,001 (31.9) 10.9 
Male Gender 1,435 (60.5) 23,467 (58.1) 5.5 534 (55.2) 12,082 (64.2) 20.8 
Region 
  Northeast 
 
337 (14.2) 
 
7,090 (17.6) 12.7 
 
156 (16.1) 
 
3,177 (16.9) 2.8 
  North Central 726 (30.6) 14,373 (35.6) 13.3 282 (29.1) 5,509 (29.3) 0.5 
  South 782 (33.0) 10,982 (27.2) 15.3 357 (36.9) 6,971 (37.0) 0.3 
  West 440 (18.5) 7,099 (17.6) 3.0 162 (16.7) 2,874 (15.3) 4.9 
Insurance plan 
  Comprehensive 
 
863 (36.4) 
 
14,439 (35.8) 1.5 
 
334 (34.5) 
 
6,030 (32.0) 6.4 
  HMO 192 (8.1) 6,086 (15.1) 34.0 89 (9.2) 1,543 (8.2) 4.7 
  POS 150 (6.3) 1,762 (4.4) 10.8 60 (6.2) 1,083 (5.8) 2.3 
  PPO 1,000 (42.1) 15,398 (38.1) 9.7 423 (43.7) 8,766 (46.6) 6.9 
  CDHP 47 (2.0) 635 (1.6) 4.0 21 (2.2) 422 (2.2) 0.0 
Benefits generosity 
  No/poor coverage 
 
77 (3.2) 
 
1,508 (3.7) 3.9 
 
3 (0.3) 
 
55 (0.3) 0.0 
  Fair coverage 1,108 (46.7) 19,762 (49.0) 5.4 458 (47.3) 8,748 (46.5) 1.9 
  Good coverage 1,188 (50.1) 19,079 (47.3) 6.5 507 (52.4) 10,028 (53.3) 2.1 
Clinical       
Ischemic Stroke 141 (5.9) 4,476 (11.1) 29.7 43 (4.4) 1,366 (7.3) 19.3 
Congestive Heart Failure 488 (20.6) 11,676 (28.9) 25.9 162 (16.7) 3,480 (18.5) 6.3 
VTE 71 (3.0) 5,236 (13.0) 78.5 28 (2.9) 480 (2.6) 2.5 
Hyperlipidemia 1,094 (46.1) 20,074 (49.7) 8.4 488 (50.4) 9,344 (49.6) 1.8 
Hypertension 1,660 (70.0) 2,980 (73.3) 7.9 684 (70.7) 12,991 (69.0) 4.0 
Myocardial infarction 59 (2.5) 1,898 (4.7) 19.5 16 (1.7) 457 (2.4) 7.6 
Coronary artery disease 674 (28.4) 13,971 (34.6) 16.9 294 (30.4) 5,264 (28.0) 20.2 
Peripheral vascular 
disease 
136 (5.7) 3,680 (9.1) 
19.9 
55 (5.7) 1,011 (5.4) 
1.8 
Renal impairment 149 (6.3) 5,299 (13.1) 37.4 57 (5.9) 1,089 (5.8) 0.6 
Diabetes  702 (29.6) 12,913 (32.0) 6.5 239 (24.7) 5,016 (26.6) 5.6 
Major bleeding 236 (10.0) 5,608 (13.9) 17.3 81 (8.4) 1,760 (9.4) 4.9 
Anemia 281 (11.8) 8,301 (20.6) 35.4 96 (9.9) 2,028 (10.8) 4.1 
Peptic Ulcer disease 9 (0.4) 306 (0.8) 8.9 3 (0.3) 88 (0.5) 5.2 
Sleep Apnea 279 (11.8) 4,137 (10.3) 6.3 115 (11.9) 2,271 (12.1) 0.8 
Cognitive deficiency 8 (0.3) 420 (1.0) 18.0 3 (0.3) 111 (0.6) 7.7 
CCI 
  0 
 
715 (30.1) 
 
9,014 (22.3) 21.5 
 
329 (34.0) 
 
6,362 (33.8) 0.5 
  1-2 1,051 (44.3) 16,123 (39.9) 10.5 419 (43.3) 8.068 (42.8) 21.8 
  3-5 514 (21.7) 11,107 (27.5) 17.8 187 (19.3) 3,549 (18.9) 1.3 
  6-8 73 (3.1) 3,045 (7.5) 34.7 23 (2.4) 636 (3.4) 9.1 
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  ≥ 9 20 (0.8) 1,090 (2.7) 29.8 10 (1.0) 216 (1.2) 2.8 
CHADS2 
  0 
 
318 (13.4) 
 
3,963 (9.8) 
 
14.2 
 
141 (14.6) 
 
3,022 (16.1) 
 
5.6 
  1 743 (31.3) 10,275 (25.5) 15.7 330 (34.1) 6,331 (33.6) 1.3 
  ≥2 1,312 (55.3) 26,141 (64.7) 21.8 497 (51.3) 9,478 (50.3) 2.3 
CHA2DS2-VASc 
  0 
 
209 (8.8) 
 
2,629 (6.5) 11.1 
 
96 (9.9) 
 
2,234 (11.9) 9.0 
  1 468 (19.7) 5,684 (14.1) 18.6 209 (21.6) 4,203 (22.3) 2.2 
  ≥2 1,696 (71.5) 32,066 (79.4) 19.7 663 (68.5) 12,394 (65.8) 6.3 
ATRIA 
  0-3 
 
1,927 (81.2) 
 
27,852 (69.0) 30.2 
 
817 (84.4) 
 
15,715 (83.5) 2.6 
  4 193 (8.1) 3,882 (9.6) 7.4 68 (7.0) 1,341 (7.1) 0.5 
  ≥5 253 (10.7) 8,645 (21.4) 44.9 83 (8.6) 1,775 (9.4) 3.9 
HAS-BLED       
  0-2 2,207 (93.0) 35,020 (86.7) 21.5 914 (94.4) 17,511 (93.0) 5.9 
  ≥3 166 (7.0) 5,359 (13.3) 32.9 54 (5.6) 1,320 (7.0) 8.3 
Hospitalizations       
  ≥1 1,119 (47.2) 23,546 (58.3) 26.0 413 (42.7) 8,530 (45.3) 6.2 
Catheter ablation 17 (0.7) 364 (0.9) 3.4 11 (1.1) 431 (2.3) 16.1 
Medication Use       
Antiplatelet therapy 268 (11.3) 5,305 (13.1) 7.6 106 (11.0) 2,409 (12.8) 7.7 
Gastroprotective agent 262 (11.0) 5,162 (12.8) 7.7 109 (11.3) 2,009 (10.7) 2.5 
Antiarrhythmic 577 (24.3) 9,116 (22.6) 5.1 247 (25.5) 4,788 (25.4) 0.3 
Digoxin 406 (17.1) 6,848 (17.0) 0.3 142 (14.7) 2,650 (14.1) 2.2 
Beta-blocker 1,554 (65.5) 27,194 (67.4) 4.4 667 (68.9) 12,595 (66.9) 4.7 
Calcium channel blocker 1,047 (44.1) 17,009 (42.1) 4.8 410 (42.4) 7,634 (40.5) 19.4 
ACEI/ARB 1,413 (59.5) 22,909 (56.7) 6.4 535 (55.3) 10,628 (56.4) 2.5 
Statin 1,275 (53.7) 22,073 (54.7) 2.3 517 (53.4) 10,006 (53.1) 0.7 
Hormone 120 (5.1) 1,445 (3.6) 9.5 60 (6.2) 832 (4.4) 10.3 
  Abbreviations: HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred provider organization; CDHP, 
consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-enzyme inhibitor; ARB, 
angiotensin receptor blocker 
 
4.4.1.3. Crude outcome rates 
The outcome rates of patients who switched anticoagulation following initiation were 
also examined standardized by 1,000 person-years of exposure in the cohort. These rates are 
shown in Table 26 for the clinical effectiveness composite, harm composite, and AMI below; 
just as in Aim 2, AMI was not included in either of the aforementioned composites but was 
followed separately as an outcome. As described in Chapter 3, patients were not censored for the 
other two outcomes if they experienced the outcome of interest for each analysis. Said another 
way, patients who experienced an ischemic stroke were censored for the clinical effectiveness 
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composite but not for the harm composite or the acute myocardial infarction outcome. As seen in 
the table, the crude outcome rates were higher among patients who were non-switchers compared 
with switchers for both warfarin and dabigatran switchers. For instance,, patients who did not 
switch from warfarin to dabigatran had a crude clinical effectiveness outcome rate of 238.5 
events/1,000 person-years compared with those who switched (51.2 events/1,000 person years). 
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Table 26. Outcome rates per 1,000 person-years by warfarin and  
dabigatran switching groups 
 
 Warfarin Dabigatran 
Outcome Type Switchers
§
 Non-switchers Switchers
§
 Non-switchers 
Clinical effectiveness 
composite 
51.2 238.5 
66.8 92.7 
Harm Composite 273.0 495.7 345.5 408.2 
Acute myocardial infarction 8.8 19.5 9.4 11.9 
  §
 Warfarin switchers: patients who switched from warfarin to dabigatran; Dabigatran switchers: patients who 
switched from dabigatran to warfarin 
 
4.4.2. Main Results 
4.4.2.1. Composite outcomes 
 The associations between anticoagulant switching and outcome composites were also 
assessed using multivariable Cox proportional hazards regression (Table 27), using the 
aforementioned methods and model specifications in Chapter 3. As previously described, 
patients were censored at their first outcome, whether it was a clinical effectiveness or harm 
outcome, or acute myocardial infarction.  
Multivariable models were adjusted for the measured baseline characteristics in the 12-
months prior to anticoagulant initiation that were previously described in Chapter 3. The full 
model results are shown in Appendix table 16 for warfarin analyses and Appendix table 17 for 
dabigatran analyses. Patients who switched from warfarin to dabigatran were 32% less likely to 
experience a clinical effectiveness outcome (adjusted HR: 0.68, 95% CI: 0.66-0.71), 32% less 
likely to experience a harm composite outcome (adjusted HR: 0.68, 95% CI: 0.65-0.71), and 
32% less likely to experience an AMI (HR: 0.68, 95% CI: 0.66-0.70). Patients who switched 
from dabigatran to warfarin were no more likely to experience a clinical effectiveness outcome 
(adjusted HR: 1.02, 95% CI: 0.97-1.08), a harm outcome (adjusted HR: 1.06, 95% CI: 0.97-
1.15), or an AMI (adjusted HR: 0.99, 95% CI: 0.94-1.04).  
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Table 27. Multivariable Cox models of the association between anticoagulant switching and 
clinical effectiveness and harm outcomes 
 
Anticoagulant groups  
(referent: non-switchers) 
Clinical 
effectiveness 
composite 
HR (95% CI) 
Harm composite 
HR (95% CI) 
Acute myocardial 
infarction 
HR (95% CI) 
Warfarin to dabigatran switchers    
  Unadjusted 0.67 (0.65-0.70)** 0.67 (0.64-0.70)** 0.66 (0.64-0.68)** 
  MV-adjusted 0.68 (0.66-0.71)** 0.68 (0.65-0.71)** 0.68 (0.66-0.70)** 
Dabigatran to warfarin switchers    
  Unadjusted 1.02 (0.97-1.08) 1.05 (0.97-1.14) 0.99 (0.94-1.04) 
  MV-adjusted 1.02 (0.97-1.08) 1.06 (0.97-1.15) 0.99 (0.94-1.04) 
  *p<0.05; **p<0.001 
  Abbreviations: HR, Hazard Ratio; CI, Confidence interval; MV, multivariable model 
  REF: Non-switching 
 
4.4.2.2. Model diagnostics and specifications 
Categories of covariates with fewer than 2% of patients with that characteristic were 
combined with another relevant level (e.g., “No”, “Poor”, and “Fair” prescription benefits 
generosity) or omitted from the model adjustments (e.g., consumer-driven health plan, cognitive 
deficiency, and peptic ulcer disease), when possible. These were done to ensure that very small 
cell sizes for certain categories would not affect the model dispersion or the positivity 
assumption. The deviance residuals showed appropriate distributions. Proportional hazards 
assumptions were tested for both composite outcomes and the AMI for the models. These tests 
did not reveal any violations of the assumptions for the models, using either Schoenfeld residuals 
or including an interaction term for time.  
 
4.4.3. Sensitivity analyses 
4.4.3.1. Primary analysis: Stratification by commercial insurance and Medicare beneficiaries 
Just as in Aim 1a, the cohorts were also stratified based on the data sources into 
commercially-insured and Medicare supplemental claims, and the analyses were conducted 
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separately (Appendix table 18). The associations between switching anticoagulants were similar 
to the main results. Switching from dabigatran to warfarin trended towards an increased risk of 
the harm composite compared with non-switching when examining the Medicare supplement 
group separately. Despite the small sample sizes, dabigatran switching was seen to be slightly 
more harmful among Medicare beneficiaries compared with commercially-insured patients 
alone. The other associations were very similar when analyzing the subgroups individually. 
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CHAPTER 5:  DISCUSSION 
The goal of the dissertation was to examine the utilization, comparative effectiveness and 
safety, and clinical effects of switching anticoagulation among patients with atrial fibrillation 
(AF) in real-world US clinical practice. These three aims document the results of this research. 
In summary, in Aim 1, we sought to examine the utilization and switching of anticoagulation 
among patients initiating anticoagulation for the prevention of ischemic stroke and systemic 
embolism in atrial fibrillation, focusing in particular on how predictions of ischemic stroke and 
bleeding risk influenced anticoagulant selection. In Aim 2, we examined the comparative 
effectiveness of dabigatran and warfarin among patients with non-valvular atrial fibrillation 
newly-initiating anticoagulation. In Aim 3, we examined the clinical effects of switching 
anticoagulation and whether switching to a different anticoagulant was associated with a higher 
risk of stroke and other clinical effects. This concluding chapter synthesizes the findings from 
these three aims, discusses the findings’ implications, highlights the strengths and weaknesses of 
the study, and provides suggestions for further work in this area. 
 
5.1. SUMMARY OF FINDINGS 
5.1.1. Aim 1: Patterns of use and switching of anticoagulants 
5.1.1.1. Aim 1a: Patterns of anticoagulant utilization 
In this large study of 64,935 AF patients initiating anticoagulation, we found that 
demographic and clinical characteristics differed strongly between new users of warfarin and 
dabigatran. Patients using warfarin for the first time were more likely to be older and have 
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previous clinical comorbidities, particularly ischemic stroke, congestive heart failure and venous 
thromboembolism. Patients initiating warfarin were also more likely to have higher ischemic 
stroke risk (as assessed by the CHADS2 or CHA2DS2-VASc scores), higher bleeding risk (as 
assessed by the HAS-BLED or ATRIA scores), and lower prescription benefits’ generosity, 
which measures how much patients paid for their prescription medications relative to how much 
their insurance paid.  The lower the prescription benefits’ generosity, the higher the patient’s 
relative out-of-pocket prescription drug cost burden. 
When adjusting for patient baseline characteristics using multivariable regression, we still 
found that the strong associations with ischemic stroke risk and bleeding risk between warfarin 
initiators compared with dabigatran initiators persisted. Patients using dabigatran were 8% less 
likely to have high ischemic stroke risk and 28% less likely to have high bleeding risk compared 
with warfarin users. Other patient characteristics were also still associated with anticoagulant 
selection, including prescription benefits’ generosity which was one of the strongest predictors of 
initiation of dabigatran in this analysis. Patients with good prescription benefits’ coverage (<20% 
paid out of pocket in the previous 12 months) were 10 times more likely to initiate dabigatran 
compared with warfarin.  
 
5.1.1.2. Aim 1b: Anticoagulant switching patterns 
 In Aim 1b, among the 33,712 patients with atrial fibrillation initiating anticoagulation 
who were still enrolled in their insurance plans 12 months later, we found that approximately 
12% switched their initial anticoagulant therapy. Approximately 30% of the patients who 
switched anticoagulants did so within 60 days of initiation. Notably, dabigatran initiators and 
warfarin initiators switched anticoagulants at relatively equal rates. However, characteristics of 
switchers compared with non-switchers of the two anticoagulants differed drastically.  
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Patients who switched away from warfarin had fewer comorbidities, low ischemic stroke 
risk, and low bleeding risk. By contrast, on most other measures, dabigatran switchers did not 
appear to differ systematically from non-switchers, with the exception of age, gender, coronary 
artery disease and increased ischemic stroke risk. After controlling for baseline patient 
characteristics, dabigatran patients were 35% more likely to switch with higher baseline ischemic 
stroke risk but were no different than non-switchers with regard to baseline bleeding risk. 
Prevalent users of warfarin followed similar switching patterns to new initiators of warfarin in 
that they were more likely to switch if they had lower rates of comorbidities, lower ischemic 
stroke, and lower bleeding risk. 
These results suggest that patients initiating warfarin may be more concerned with the 
risk of harm (bleeding) of dabigatran and may be less likely to switch to dabigatran with higher 
bleeding risk. These findings are in concert with the patterns of use observed by new initiators in 
Aim 1, in which dabigatran patients were less likely to have higher bleeding risk. Of all the 
clinical and prognostic characteristics associated with dabigatran switching, the association 
between high ischemic stroke risk and not switching from dabigatran to warfarin was the 
greatest. These findings could suggest two possibilities: 1) patients with high ischemic stroke 
risk may be more likely to persist with initial therapy because of the high possibility of stroke, or 
2) patients with high ischemic stroke risk may have been more likely to see a noticeable benefit 
in dabigatran altogether compared with patients with low ischemic stroke risk (and thus not 
experienced therapeutic failure leading to the need to switch). Either way, now that there are 
more treatment options for non-valvular atrial fibrillation, a significant number of patients are 
switching anticoagulation options within the first year of treatment, but there were equal 
proportions of patients switching their initial anticoagulants. 
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5.1.2. Aim 2: Comparative effectiveness and safety of anticoagulants 
 In Aim 2, in this large study of 64,935 patients with non-valvular atrial fibrillation, after 
multivariable adjustment using survival analysis, we found that patients initiating dabigatran 
were approximately 30% less likely to experience ischemic stroke, venous thromboembolism, or 
transient ischemic attacks compared with patients initiating warfarin. However, when examining 
the comparative safety of experiencing an adverse event, patients initiating dabigatran were 
equally likely to experience one of the harm outcomes (e.g., hemorrhage, bleeding, or 
hospitalization) with two notable exceptions. First, dabigatran patients were approximately 40% 
and 15% less likely to experience a hemorrhagic stroke and other bleeding event compared with 
warfarin patients. However, dabigatran patients were also 10% more likely to experience a 
gastrointestinal bleeding event after initiating anticoagulation. Notably, myocardial infarction 
risk also did not differ between the two anticoagulant groups. These results were also confirmed 
among a subset of patients who were newly-diagnosed with atrial fibrillation. Overall, these 
results suggest that dabigatran has better comparative effectiveness and safety compared with 
warfarin among non-valvular atrial fibrillation patients in real-world clinical practice in the US. 
 We also found some potential areas of treatment effect heterogeneity among patients 
receiving different strengths of dabigatran. The comparative effectiveness in preventing ischemic 
stroke or VTE did not differ between warfarin initiators and dabigatran 75mg initiators; however, 
patients using the lower dabigatran dose were more likely to experience harmful outcomes 
compared with warfarin initiators. By contrast, when stratifying on dose, the comparative 
effectiveness and safety of dabigatran 150mg was even more pronounced compared with 
warfarin initiators. 
Certain characteristics known to be associated with comparative effectiveness in the real-
world were also noted in this aim. For instance, medication adherence and refill patterns were 
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also seen to notably differ across the anticoagulant groups. Patients initiating dabigatran had a 
20% lower likelihood of refilling dabigatran after the initial prescription compared with warfarin 
initiators. Overall medication adherence was also low in this study (<50% PDC in the 12-months 
post-anticoagulation initiation). Even though they were less likely to refill initially, patients 
filling dabigatran were found to have 45% higher likelihood of being adherent (PDC ≥ 80%) 
compared with warfarin initiators, even after adjustment for patient baseline characteristics. 
However, patients with high ischemic stroke risk were more likely to be adherent compared with 
those with low ischemic stroke risk.  
 
5.1.3. Aim 3: Clinical effects of switching anticoagulants 
 In Aim 3, the goal was to examine whether patients who switched anticoagulants were at 
a higher risk of adverse events compared with patients who remained on one medication. We 
were particularly interested in isolating patients who switched for reasons unlikely to be 
associated with therapeutic failure, motivating the use of a time-varying exposure design that 
censored patients if they had experienced a clinical outcome prior to the switch.  
In this study, we found notable differences in clinical outcomes among patients who 
switched anticoagulants (and had not experienced an outcome prior to the switch) compared with 
those who did not switch anticoagulation. After adjustment for patient baseline characteristics, 
we also found that patients who switched from warfarin to dabigatran were 32% less likely to 
experience ischemic stroke, VTE, or TIA compared with non-switchers. However, these warfarin 
switchers were also 32% less likely to experience a harm outcome, including bleeding, 
hemorrhage or hospitalization. Overall, these results suggest the risk of switching between 
anticoagulants is unlikely to result in any clinically-significant increases in clinical effectiveness 
or harm outcomes.  
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5.2. IMPLICATIONS OF FINDINGS 
These results concur in part with previous research suggesting that some selection (or 
channeling) away from dabigatran has occurred, particularly away from patients with high 
ischemic stroke and bleeding risk.
40,241
 Specifically, patients at higher risk of clinical outcomes 
like ischemic stroke or bleeding were much more likely to initiate the standard of care, warfarin. 
While these studies were generally small in sample size or limited to younger patients, they too 
found that patients who were newly-initiating dabigatran had lower bleeding risk and fewer 
comorbidities. However, in contrast to a recent study published by Steinberg et al, we found that 
bleeding risk was more strongly associated with initial anticoagulant selection than ischemic 
stroke risk.
242
 In our study, we found that patients with higher bleeding risk initiated dabigatran 
more often than warfarin. Moreover, the associations with initial anticoagulation selection were 
higher in magnitude for the risk of bleeding compared with the risk of ischemic stroke in our 
study. Their study found an overall lack of familiarity with bleeding risk guidelines by 
physicians for patients enrolled in the ORBIT-AF registry; however, the study was limited by 
participants enrolling through October 2011 and did not examine either rivaroxaban or the 
contribution of patients’ prescription benefits. By comparison, the results in our study suggest 
that there may be selective use of dabigatran for patients at lower risk of bleeding. Concerns over 
lack of a bleeding antidote may indeed prevail in this risk-benefit paradox.
40,241
  
Our findings suggest that clinicians may be differentially choosing warfarin in real-world 
clinical practice for patients with both high stroke risk and bleeding risk, which may indicate 
possible concerns about the complications with the lack of a convenient reversal agent for the 
NOACs in general. In addition, these findings are in contrast to some other studies examining 
newly-approved pharmaceuticals. In other contexts, patients using newly-approved 
pharmaceuticals have tended to be sicker than those on the comparator medication; our findings 
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were opposite, which may have implications for studying comparative effectiveness.
181,243
 If 
patients using the newly-approved therapies are more likely to be sicker (and these confounders 
are not properly controlled for), then the new therapy is more likely to appear inferior to the 
standard of care. For our study, the patients using the newly-approved therapy were healthier, in 
which case the new therapy is more likely to appear superior. These observations could have 
implications for the process and outcomes of treatment decision-making in clinical practice in 
that researchers should strive to consider which way their estimates are likely to skew and 
control for confounding using the best possible methodologies. 
Further, providers appear to base anticoagulant selection on factors other than predictions 
of treatment benefit, which has implications for studying the anticoagulants’ comparative 
effectiveness. At the time of this research, clinical guidelines had recommended continuing with 
warfarin in currently-treated patients but have been less clear with anticoagulant selection in 
treatment-naïve patients, which were the focus of this dissertation.
2-4
 Until early 2014, warfarin 
was still considered the preferred agent in the US; however, as early as 2012, European 
guidelines had begun to prefer the novel agents for anticoagulant-naïve patients with non-
valvular atrial fibrillation.
3
 On the other hand, recent guidelines from the American Heart 
Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) 
published in March 2014 suggested that clinical equipoise may exist between all the 
anticoagulants for patients at high risk of stroke.
5
  
These guidelines also recommend that clinicians weigh the balance of benefit with the 
risk of harm of available treatment options, but also consider that treatment selection may be in 
large part influenced by clinicians through preferences or other factors unrelated to patient 
clinical or prognostic characteristics.
244
 In our study, while both ischemic stroke risk and 
bleeding risk were associated with overall anticoagulant selection, other clinical and 
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demographic factors, including prescription benefits’ generosity were also strongly associated 
with selection. Because there is some clinical equipoise in our study, this finding may be 
exploited when assessing the comparative effectiveness of these anticoagulants. Because factors 
not clinical and prognostic may be related to initial anticoagulant selection and may lessen 
potential bias, we can have more faith in our estimates.  
Comorbidity and co-medications may also play a role in anticoagulation switching. We 
saw in this study that patient comorbidity burden may play a role in lessening the likelihood of 
switching in that patients with more cardiovascular comorbidities were less likely to switch. 
Moreover, using antiarrhythmic or beta-blocker medications at baseline was also associated with 
switching from warfarin but not dabigatran. These factors together suggest that patients who are 
frailer are less likely to switch anticoagulants. It is also possible that patients using warfarin may 
have higher comorbidities at baseline and be more cautious with switching to avoid side effects, 
as has been seen in previous studies.
40,41,245
 All in all, switching anticoagulants does not appear 
to be consistent across anticoagulants and may be due to the underlying reasons why the patients 
were initially placed on those medications to begin with.
224
 Most recent guidelines and 
commentaries have recommended maintaining patients on warfarin if they were previously 
stabilized using warfarin, and these findings can be reassuring that indeed most patients are 
remaining on their initial anticoagulant as is recommended.
5
 Either way, switching medications 
generally requires more time from the provider, pharmacist, and health care system to ensure the 
patient has the adequate knowledge to manage the new medication, which is enough reason to be 
cautious to avoid unnecessary switching.
224
 
When considering the anticoagulants’ clinical effectiveness, the large randomized-
controlled trials used for initial approval of dabigatran and the other NOACs broadly found 
similar or better efficacy in preventing ischemic stroke and systemic embolism compared with 
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warfarin but significantly better safety, particularly in reducing intracranial bleeding and 
hemorrhagic stroke.
13,15,18
 The results of this study concur with the RE-LY trial, in that 
dabigatran appears to be more effective than warfarin in preventing ischemic stroke and systemic 
embolism.
13
 Just as in the RE-LY trial, gastrointestinal bleeding was higher among dabigatran 
patients compared with warfarin patients, but there were otherwise no general differences in the 
risk of harm or adverse outcomes. A very recent report by the FDA of a very large cohort of 
Medicare patients with atrial fibrillation found similar associations with lower risk of clot-related 
strokes, intracranial bleeding and death compared with warfarin.
246
  
Our study also found a similar risk for AMI compared with warfarin and an increased 
risk of major gastrointestinal bleeding. Overall, while the use of dabigatran should be cautioned 
in patients at high bleeding risk, high risk of gastrointestinal bleeding or in renal insufficiency, 
dabigatran should otherwise be considered a safe and effective alternative to warfarin, even in 
real-world clinical practice.
17,122
 We did note some underlying treatment effect heterogeneity 
among certain characteristics of AF patients, particularly patients with prior VTE and higher 
bleeding risk, which warrants further exploration. In addition, sensitivity analyses on the 
outcome definition and the subgroups yielded similar associations with slightly differing 
magnitudes, but the overall conclusions were robust to these modifications. Either way, insurers 
and policy-makers alike can have some reassurance that dabigatran users are no more likely to 
have worsened clinical outcomes compared with warfarin users, even outside the tightly-
monitored clinical trials, particularly once underlying comorbidity differences are controlled for, 
as in this study. 
Unlike the RE-LY trial, patients in our study were not regularly followed up as part of a 
protocol; in our study, these were patients in real-world practice. Some have felt that the clinical 
efficacy in the RE-LY trial was largely due to the regular monitoring of dabigatran that would 
 163 
 
not necessarily take place in the real world but was done in the study to maintain blinding with 
warfarin, and a recent article by the BMJ in July 2014 raised some concerns about the trial’s 
conduct and possible underrepresentation of bleeding events.
247,248
 In addition, the rates of 
adverse events submitted to the FDA have also been higher for dabigatran compared with 
warfarin since dabigatran’s market availability, but the FDA has since found that more events 
were likely to be reported, because dabigatran is a newer medication.
138
 For both these concerns, 
the results of Aim 2 could be used to reassure patients and providers, because the results do 
indicate that dabigatran can be considered a safe and possibly more effective alternative to 
warfarin, even in patients outside clinical trials. Moreover, the fact that in Aim 1b, there were no 
differences in the rates of switching away from dabigatran compared with switching away from 
warfarin bolsters this assumption. Had there been major differences in switching, one could 
attribute those differences in switching to differences in therapeutic failure or adverse 
complications, but this was not the case in our study. 
Due to the dependence on adherence and persistence to warfarin and dabigatran for the 
prevention of ischemic stroke and thrombosis, the low rate of adherence to both warfarin and 
dabigatran is concerning. Dabigatran patients were less likely to refill their medication again, but 
warfarin patients were less likely to be adherent over a 12-month period (even taking into 
account switching to a different anticoagulant). In this way, discontinuation would not be 
inappropriately attributed to not continuing anticoagulation altogether. While this study did not 
specifically examine persistence or discontinuation to warfarin, the low overall rate of adherence 
(less than 50%) to anticoagulation is troubling. Indeed, Tsai et al recently found that 40% of 
beneficiaries discontinued dabigatran within 6 months among a cohort of 17,000 US 
beneficiaries, most of whom did not continue any anticoagulation.
248
 Our finding of adherence 
less than 50% at 12-months post-initiation concur with their results. These results continue to 
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suggest a need for healthcare professionals to provide additional support with these medications, 
particularly if the need for weekly face-to-face interactions through INR monitoring is no longer 
necessary in the novel oral anticoagulants. In addition, dabigatran is also dosed twice-daily, 
compared with warfarin’s once-daily dosing, which could play a role in medication adherence 
and potential adverse events with a missed dosed.   
Further, the findings from Aim 3 could possibly be attributed to physiologic differences 
between the agents. Warfarin’s half-life is much longer than dabigatran’s half-life..5 As a result, 
switching from warfarin to dabigatran could be less problematic for both clinical effectiveness 
and harm outcomes compared with switching from dabigatran to warfarin. Indeed, switching to 
dabigatran was associated with similar (or lower) risk of harmful outcomes compared with 
remaining on warfarin. By comparison, switching to warfarin from dabigatran resulted in no 
clinically-significant differences in risk for the outcomes studied. While guidelines are clearer 
about how to bridge to dabigatran from warfarin (initiate dabigatran once INR<2.0) compared 
with vice versa, neither switching direction resulted in clinically or statistically significant 
increases in outcomes, which is generally the largest concern in switching medications. While 
guidelines recommended maintaining prevalent users of warfarin on warfarin, these findings can 
be reassure that switching anticoagulants is unlikely to results in any large risk of outcomes.  
Further, the analysis of switching anticoagulants also poses an interesting question. In 
Aim 2, we found that the comparative effectiveness of dabigatran was superior to warfarin. 
However, how can one adequately measure the actual “risk” of switching anticoagulant 
altogether compared with the advantages in comparative safety of switching to the new agent? 
Indeed, we found that the clinical effects of switching from warfarin to dabigatran were superior 
to staying on warfarin – at least unilaterally in terms of reducing ischemic stroke and systemic 
embolisms. Had we been only measuring the comparative effectiveness of the agents (and not 
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the effects of switching), we would have seen a corresponding increase in the risk of adverse 
outcomes when switching from dabigatran to warfarin. However, we saw no difference in the 
risk of outcomes when examining switching from dabigatran to warfarin. 
We know that incident user designs are usually preferred when measuring comparative 
effectiveness and safety, because prevalent user designs are more fraught with biases such as 
survivor bias and confounding by indication.
189,199,249
 However, in the real world, patients are not 
always incident users, and warfarin has been thought to have major issues with switching 
between manufacturers – let alone different agents. The design employed in Aim 3 is intended to 
disentangle this question and point to why examining “switching” – as compared with just 
prevalent or incident use – can be useful in its own right. Indeed, studying prevalent users is not 
the same as examining switching between medications. Despite the comprehensive literature 
search for this dissertation, there was a  relative lack of literature examining methods to address 
medication switching itself as an exposure and resulting outcomes. More attention should be paid 
towards developing methods to try to better assess medication switching.  
 
5.3. STRENGTHS AND WEAKNESSES 
As previously described in the Chapter 3 (Methods), our study has several limitations. 
First, prescription refill records from commercial claims databases may not fully reflect 
medication use. However, prescription refill records have been shown to have good validity, 
correlation, and similar sensitivity and specificity as other measurements, including self-report, 
pill counts, and electronic records.
209,250
 Some warfarin prescriptions may also not be captured 
due to concomitant market influences, such as the low-cost generic prescription programs 
available in community pharmacies; however, these patients would merely not be included in 
this study.
201
 The ATRIA score has also been used less frequently in research; however, it has 
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shown to be better validated in administrative claims data compared with other measures of 
bleeding risk.
107,113
 In addition, the use of a 12-month baseline period for covariate identification, 
while standard in the literature and avoids unnecessary sample size truncations, may have led to 
some underidentification of covariates, although this was unlikely to be differential between the 
anticoagulant groups.
251
 While this study could not measure mortality, the recent findings from 
the FDA and the sensitivity analyses help reduce the likelihood this impacted the study results.
246
 
 In addition, as previously discussed, unmeasured confounding, especially healthy user 
biases, may impact the study’s findings. While underlying characteristics were adjusted for in the 
regression analyses, warfarin patients may be sicker (or frailer) in other confounding 
characteristics that could not be measured. The fact that the unadjusted analyses were down and 
away from the null and adjusting through multivariate analyses and propensity scores move the 
estimates closer to the null indicates that some residual confounding may exist. Provider-level 
and health-system level covariates could also not be measured due to the limitations of the 
database.  
The findings from Aim 3 may also be impacted, because technically the “switcher” 
follow-up time may have led to some survivor bias, as the switchers had to avoid an outcome in 
order to be considered an anticoagulant switcher. While this censoring may also have impacted 
generalizability of the findings, it also limited confounding by indication. Ideally, marginal 
structural models could be an approach to address this issue and could be considered in future 
research to address issues of time-varying exposure and time-varying covariates.  
In addition, in Aim 3, by virtue of the design and the intention-to-treat approach, patients 
were not removed from the cohort if they discontinued medications or had poor medication 
adherence. Our study found that patients who switched medications were no less likely to 
experience a harm outcome compared with patients who did not switch. If patients had actually 
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discontinued the medication, they would have contributed exposure time to the “non-switching” 
group. In theory, that could have actually made the “non-switching” group slightly less at risk of 
a harmful outcome; however, it also could have left the “non-switching” group at higher risk of 
ischemic stroke and systemic embolism (because of the discontinuation). In actuality, this 
finding was only noted in the warfarin switcher group and not in the dabigatran switcher group. 
If this assumption was to have hugely biased the study, it likely would have biased both the 
warfarin switchers and the dabigatran switchers.  
There are, however, also several strengths of this study. This research used a large 
database of nationally-representative commercially-insured patients, including some Medicare 
beneficiaries in the United States. To our knowledge, most previous research examining the use 
of the novel anticoagulants has been conducted in Europe, in smaller, less representative 
databases, or by synthesizing results from randomized-controlled trials in meta-analyses. In 
addition, this study assessed general patterns of use and effectiveness of dabigatran a full two 
years after NOACs have been available, which have not been previously published. Lastly, while 
the clinical prediction risk scores have been thought to be only moderately associated with true 
risk of the outcomes in atrial fibrillation, the use of the CHA2DS2-VASc in particular has been 
thought to have better real-world concordance than the CHADS2 and could also be considered a 
strength of our study compared with previous analyses. 
 
5.4. RECOMMENDATIONS FOR FUTURE RESEARCH 
First and foremost, due to the availability of data, this dissertation focuses on dabigatran. 
While dabigatran is now just one of the (currently) three FDA-approved NOACs for the 
prevention of stroke and systemic embolism, rivaroxaban and apixaban have more recently been 
available. Much work will be needed in general in this growing area – examining not just 
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dabigatran but the other NOACs as well. Early evidence indicates that each of the NOACs could 
have slightly different advantages and disadvantages. Dabigatran, in particular, may lead to more 
gastrointestinal side effects, and may be more problematic for patients with renal insufficiency. 
On the other hand, dabigatran may have fewer drug-drug interactions than either rivaroxaban or 
apixaban, because it is not metabolized via CYP3A4 and may be better for patients with hepatic 
disease.  Either way, the clearest recommendation for future research lies in the need to 
disentangle the advantages and disadvantages of the NOACs, as most research to date in the real-
world setting has examined dabigatran exclusively.  
Relatedly, another trend worth noting is that the number of patients initiating warfarin 
decreased somewhat over time, while the number of patients initiating dabigatran increased from 
baseline in late 2010 and peaked in early 2012. Beginning in the 1
st
 quarter of 2012, dabigatran 
initiation too began to decline. The introduction of rivaroxaban in late 2011 for the prevention of 
ischemic stroke and systemic embolism may have affected trends in anticoagulation use over the 
study time period. Future research should examine how utilization patterns of rivaroxaban (and 
other NOACs such as apixaban and edoxaban) have influenced medication selection and how 
they fare in comparative effectiveness and safety. Head-to-head studies are unlikely due to cost 
and feasibility issues, and salient and sound observational research studies in a variety of 
populations will be needed to ascertain not only how these medications are really being used 
clinically but also how safe and effective they are for different populations. Beyond the need to 
generalize the study of NOACs beyond dabigatran, when examining dabigatran specifically, this 
dissertation research points to a few other clear directions for future research.  
First of all, this research was not designed to directly examine heterogeneity in 
effectiveness and safety of the differing dabigatran strengths, and these doses were FDA-
approved with different target populations in mind. Dabigatran 75mg is intended for patients 
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with renal insufficiency; however, dabigatran 110mg was actually studied in clinical trials. Even 
if it was not our intention, some secondary findings in our research have several implications for 
patients with renal insufficiency. First, in Aim 1a, this research found that almost 10% of patients 
receiving dabigatran 150mg had diagnosed chronic kidney disease for whom the 150mg dose is 
neither FDA-approved nor recommended per clinical guidelines, and 22% of patients were using 
the 75mg dose without an indication of any kidney disease. Both groups of these patients could 
be subject to additional adverse events or harmful outcomes, because of the inappropriate doses; 
however, this has not yet been examined. In Aim 2, this research suggested that dabigatran 75mg 
was similarly effective as warfarin in the prevention of ischemic stroke and systemic embolism 
but that it was slightly more harmful. By contrast, patients using the dabigatran 150mg strength 
were less likely to experience an ischemic stroke or systemic embolic event without any 
increased risk of a harmful outcome. Even less work has been done examining how 
anticoagulation should be managed in patients undergoing dialysis, and none of the new oral 
anticoagulants are currently recommended. In sum, further examining this sub-population and 
the utilization patterns and comparative effectiveness and safety is highly relevant.  
Secondly, this research was not originally designed to examine other types of treatment 
effect heterogeneity, including the comparative effectiveness and safety among patients with 
different types of comorbidity patterns. Before the application of propensity-score weighting, the 
largest absolute differences between baseline characteristics of warfarin and dabigatran initiators 
were renal impairment, anemia, venous thromboembolism, and congestive heart failure. These 
clinical comorbidities are known to be associated with ischemic stroke risk in patients with atrial 
fibrillation. While this research did explore some heterogeneity among subgroups, further 
examining the comparative effectiveness among strata of patients with atrial fibrillation 
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combined with one of these comorbidities may yield some potential areas for treatment effect 
heterogeneity and patients who may benefit more or less from certain anticoagulants. 
Similarly, this study was not designed to specifically examine how medication adherence 
differed between the different users of anticoagulants, to some degree because a previous study 
undertaken by the authors had noticed potential missing warfarin prescription in the 
MarketScan® database.
201
 Because dabigatran, the comparator, is a brand-name medication and 
more expensive for patients, prescriptions are likely to be less frequent in the warfarin group, 
resulting in differences in fill rates between the groups affecting the relative medication 
adherence calculations. Medication adherence has been known to be disentangled with 
comparative effectiveness, because medications traditionally work better in patients who take 
them regularly. Initiating an appropriate “as-treated” analysis in addition to the “intention-to-
treat” approach used here would be warranted in the examination of anticoagulants; however, 
using medication adherence as an “exposure” and measuring resultant outcomes can be difficult 
methodologically. 
Lastly, in addition to assessing the comparative effectiveness and safety of these new oral 
anticoagulants, which was one of the primary purposes of this dissertation, further work still 
needs to be done to examine and understand the cost implications of the agents. Particularly, 
analyses are needed that incorporate both the increased cost of the NOACs as well as the 
potential cost savings resulting from the prevention of outcomes and the avoidance of the need 
for INR measurements. Because of the current lack of an approved, affordable reversal agent in 
the event of a bleeding incident for the NOACs, these cost implications could also change over 
time once one does become available. Vigilance to developments in this area and the 
management of complications will also be an area where research will be much warranted. 
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5.5. CONCLUSION 
 In this large, nationwide cohort of non-valvular patients initiating anticoagulation from 
2010-2012, we found that the uptake and utilization of dabigatran since its market entry has 
differed drastically from warfarin. Despite the rapid uptake of dabigatran, patients initiating 
dabigatran were healthier than those initiating warfarin and had lower risk of adverse outcomes. 
When examining the comparative effectiveness and safety of the medications, dabigatran was 
found to equally safe and even more effective than warfarin, even after adjusting for these 
differences in comorbidities and risk of outcomes. These results can provide some reassurance 
for patients, clinicians, and policymakers that dabigatran may be considered a safe and effective 
alternative to warfarin, even when used in real-world clinical practice and outside tightly-
controlled clinical trials. 
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APPENDIX TABLES AND FIGURES 
Appendix Table 1. Sensitivity analyses: Bivariate associations of continuous 
 covariates with dabigatran and warfarin selection 
 
 New users Newly-diagnosed new users 
Baseline Characteristic 
(Assessed as continuous 
value) 
RR 95% CI RR 95% CI 
Age 0.99 0.98-0.99** 0.99 0.98-0.99** 
CCI 0.89 0.89-0.90** 0.90 0.89-0.90** 
CHADS2 0.85 0.84-0.86** 0.85 0.84-0.87** 
CHA2DS2-VASc 0.87 0.86-0.88** 0.87 0.86-0.88** 
ATRIA 0.88 0.87-0.88** 0.88 0.87-0.89** 
HAS-BLED 0.84 0.83-0.86** 0.84 0.83-0.86** 
Number of hospitalizations 0.77 0.76-0.78** 0.74 0.72-0.76** 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; CCI, Charlson comorbidity index 
  NOTE: Warfarin: referent group 
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Appendix Table 2. Multivariable associations between dabigatran compared  
with warfarin and other baseline covariates in the 12-month baseline period 
 
 New Users Newly-diagnosed new users 
Baseline Characteristic RR 95% CI RR 95% CI 
Demographic     
Region (ref: Northeast)     
  North Central 0.93 0.90-0.96** 0.89 0.85-0.93** 
  South 1.20 1.16-1.24** 1.14 1.10-1.19** 
  West 1.01 0.97-1.05 0.86 0.82-0.91** 
Insurance plan (ref: 
Comprehensive) 
    
  HMO 0.65 0.62-0.68** 0.59 0.55-0.63** 
  POS 1.00 0.95-1.05 0.95 0.89-1.01 
  PPO 0.99 0.97-1.02 0.96 0.93-0.99* 
  CDHP 0.89 0.82-0.95* 0.85 0.77-0.93** 
Prescription generosity 
(ref: None/Poor)     
  Fair coverage 9.18 7.18-11.74** 7.44 5.50-10.05** 
  Good coverage 10.30 8.07-13.21** 8.21 6.07-11.10** 
Clinical (ref: 0/None 
unless specified)     
VTE 0.32 0.30-0.35** 0.34 0.30-0.38** 
Hyperlipidemia 1.04 1.02-1.06* 1.07 1.04-1.11** 
Peptic Ulcer disease 0.93 0.78-1.11 0.87 0.67-1.12 
Sleep Apnea 1.06 1.03-1.10** 1.08 1.03-1.13* 
Cognitive deficiency 0.98 0.85-1.14 0.82 0.64-1.04 
CCI (ref: 0)     
  1-2 0.92 0.90-0.95** 0.95 0.92-0.98* 
  3-5 0.81 0.78-0.84** 0.84 0.80-0.88** 
  6-8 0.67 0.63-0.73** 0.71 0.64-0.79** 
  ≥ 9 0.71 0.63-0.79** 0.79 0.67-0.92* 
≥1 hospitalizations 0.87 0.85-0.89** 0.81 0.79-0.84** 
Catheter ablation 1.30 1.22-1.38** 1.28 1.05-1.56* 
Medication use     
Antiplatelet therapy 1.12 1.08-1.16** 1.02 0.97-1.07 
Gastroprotective agent 0.95 0.92-0.99* 0.93 0.89-0.98* 
Antiarrhythmic 1.04 1.01-1.06* 1.01 0.97-1.05 
Digoxin 0.91 0.88-0.94** 0.91 0.87-0.96** 
Beta-blocker 1.04 1.01-1.06* 0.97 0.94-1.00* 
Calcium channel blocker 1.01 0.99-1.03 0.96 0.93-0.98* 
ACEI/ARB 1.04 1.02-1.07* 1.03 1.00-1.06 
Statin 0.99 0.97-1.01 0.97 0.94-1.00 
Hormone 1.13 1.07-1.19** 1.09 1.02-1.17* 
  NOTE: For covariates not already included in ischemic stroke or bleeding risk scores 
  *p<0.05 
  **p<0.001 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS, 
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism; 
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker 
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Appendix table 3.  Ischemic stroke and bleeding risk score model predictor 
 options and associations with dabigatran use compared with warfarin use 
 
  New Users Newly-diagnosed new users 
Model Option: 
QIC 
Baseline Characteristic RR 95% CI RR 95% CI 
1: CHA2DS2-VASc (ref: 0)     
NU: 125,890.05   1 0.97 0.94-1.01 0.97 0.92-1.02 
Ndx: 71,272.10   ≥2 0.91 0.87-0.95** 0.92 0.87-0.98* 
 ATRIA (ref: 0-3)     
   4 0.86 0.82-0.89** 0.85 0.80-0.91** 
   ≥5 0.72 0.69-0.76** 0.71 0.67-0.76** 
2: CHA2DS2-VASc (ref: 0)     
NU: 126,253.76   1 0.97 0.93-1.00 0.97 0.92-1.02 
Ndx: 71,395.15
  
  ≥2 
0.91 0.87-0.95** 
0.93 0.87-0.99* 
 HAS-BLED (ref: 0-2)     
   ≥5 0.80 0.76-0.85** 0.78 0.73-0.85** 
3: CHADS2 (ref: 0)     
NU: 125,957.39   1 0.98 0.95-1.01 0.99 0.95-1.04 
Ndx: 71,272.46   ≥2 0.94 0.90-0.98* 0.98 0.92-1.03 
 ATRIA (ref: 0-3)     
   4 0.85 0.82-0.89** 0.85 0.80-0.90** 
   ≥5 0.72 0.69-0.76** 0.71 0.67-0.76** 
4: CHADS2 (ref: 0)     
NU: 126,227.92   1 0.97 0.94-1.01 0.99 0.95-1.03 
Ndx: 71,398.17   ≥2 0.94 0.90-0.98* 0.98 0.93-1.03 
 HAS-BLED (ref: 0-2)     
   ≥5 0.80 0.76-0.85** 0.78 0.73-0.85** 
    Abbreviations: RR, Relative risk; Ref, referent group; CI, confidence interval; QIC, Quasilikelihood under the Independence 
model Criterion; NU, new user; Ndx, Newly-diagnosed new user 
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Appendix table 4.  Sensitivity analyses: Multivariable associations between 
 dabigatran compared with warfarin and ischemic stroke and bleeding risk scores 
 
 New Users Newly-diagnosed new users 
 Commercial Medicare Commercial Medicare 
Baseline Characteristic 
RR  
(95% CI) 
RR  
(95% CI) 
RR  
(95% CI) 
RR  
(95% CI) 
Demographic     
CHA2DS2-VASc (ref=0)     
  1 0.99 (0.95-1.03) 1.01 (0.95-1.07) 0.99 (0.94-1.04) 1.04 (0.96-1.13) 
  ≥2 0.94 (0.89-0.99)* 0.98 (0.91-1.05) 0.95 (0.88-1.02) 1.04 (0.95-1.14) 
ATRIA (ref: 0-3)     
  4 0.80 (0.75-0.86)** 0.90 (0.85-0.95)** 0.80 (0.73-0.87)* 0.91 (0.84-0.99)* 
  ≥5 0.57 (0.50-0.65)** 0.75 (0.72-0.79)** 0.53 (0.43-0.64)** 0.75 (0.70-0.80)** 
  *p<0.05 
  **p<0.001 
  NOTE: By definition, Medicare supplement beneficiaries cannot have CHA2DS2-VASc=0. For these patients, CHADS2 was 
calculated and used in the relative risk estimations. Warfarin is the referent group. 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval 
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Appendix table 5. Patient prescription cost-sharing of index anticoagulation 
 and switching characteristics 
 
 All Warfarin New Users All Dabigatran New Users 
Index prescription 
generosity 
Switcher,  
N (%) 
Non-
Switcher, 
N (%) 
Absolute 
SD 
Switcher, N 
(%) 
Non-Switcher, 
N (%) 
Absolute 
SD 
  No coverage 1,023 (36.5) 7,247 (37.8) 3.3 3 (0.21) 30 (0.29) 2.5 
  Poor coverage 224 (8.0) 1635 (8.5) 2.5 1 (0.07) 7 (0.07) 0.0 
  Fair coverage 742 (26.5) 4,805 (25.0) 4.3 295 (20.8) 2,398 (23.3) 7.9 
  Good coverage 811 (29.0) 5,502 (28.7) 0.8 1,117 (78.9) 7,872 (76.4) 6.4 
 Prevalent Users    
 Switcher, N 
(%) 
Non-
Switcher, N 
(%) 
Absolute 
SD 
  
 
  No coverage 2,997 (28.4) 24,288 (34.7) 17.2    
  Poor coverage 572 (5.4) 4982 (7.1) 10.3    
  Fair coverage 3,671 (34.8) 24,689 (35.3) 1.3    
  Good coverage 3,321 (31.4) 15,969 (22.8) 23.4    
  Abbreviations: SD, Standardized Differenced 
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Appendix table 6. Multivariable associations between anticoagulant  
switching and the other baseline covariates in the 12-month follow-up period 
 
 Warfarin New Users Dabigatran New Users Prevalent Users 
Baseline Characteristic RR 95% CI RR 95% CI RR 95% CI 
Demographic       
Region (ref: Northeast)       
  North Central 0.95 0.86-1.06 0.99 0.85-1.15 0.80 0.75-0.84** 
  South 1.17 1.06-1.30* 1.09 0.95-1.26 1.23 1.17-1.29** 
  West 1.16 1.03-1.31* 1.13 0.96-1.34 1.17 1.10-1.24** 
Insurance plan (ref: 
Comprehensive) 
      
  HMO 0.54 0.46-0.62** 0.94 0.76-1.16 0.38 0.35-0.42** 
  POS 1.12 0.96-1.31 0.80 0.63-1.01 1.11 1.03-1.20* 
  PPO 1.09 1.01-1.18* 0.95 0.85-1.06 1.09 1.05-1.14** 
  CDHP 0.96 0.75-1.24 0.97 0.67-1.39 0.88 0.75-1.03 
Prescription generosity 
(ref: None/Poor) 
      
  Fair coverage 1.07 0.86-1.32 1.66 0.43-6.37 1.43 1.19-1.71** 
  Good coverage 1.24 1.00-1.53* 1.57 0.41-6.01 1.71 1.43-2.04** 
Clinical (ref: 0/None 
unless specified) 
      
VTE 0.56 0.48-0.66** 1.11 0.83-1.48 0.61 0.56-0.67** 
Hyperlipidemia 0.98 0.91-1.05 1.08 0.97-1.20 1.12 1.08-1.17** 
Peptic Ulcer disease 0.78 0.45-1.34 0.5 0.17-1.48 1.11 0.86-1.44 
Sleep Apnea 1.22 1.10-1.36** 1.12 0.97-1.30 1.24 1.18-1.31** 
Cognitive deficiency 0.93 0.58-1.50 0.98 0.51-1.89 0.99 0.80-1.24 
≥1 hospitalizations 0.95 0.88-1.03 0.84 0.75-0.93* 1.09 1.04-1.13* 
Catheter ablation 0.89 0.62-1.29 0.26 0.12-0.55** 1.31 1.16-1.48** 
Newly-diagnosed AF 1.29 1.20-1.39** 1.05 0.95-1.16 N/A N/A 
Medication use       
Antiplatelet therapy 1.06 0.95-1.18 0.93 0.80-1.09 1.12 1.05-1.20** 
Gastroprotective agent 1.01 0.91-1.13 1.06 0.90-1.24 1.02 0.96-1.07 
Antiarrhythmic 1.16 1.07-1.26** 1.11 0.99-1.25 1.23 1.18-1.28** 
Digoxin 1.02 0.93-1.12 0.97 0.84-1.12 0.98 0.94-1.02 
Beta-blocker 1.01 0.94-1.09 1.26 1.12-1.41** 1.09 1.05-1.14** 
Calcium channel blocker 1.04 0.97-1.12 1.06 0.96-1.18 1.13 1.09-1.17** 
ACEI/ARB 1.11 1.03-1.19* 0.91 0.82-1.01 1.07 1.03-1.12* 
Statin 1.06 0.99-1.15 0.9 0.81-1.00 1.05 1.01-1.09* 
Hormone 1.36 1.17-1.57** 1.06 0.85-1.31 1.12 1.03-1.22* 
  NOTE: For covariates not already included in ischemic stroke or bleeding risk scores; REF: Non-switching; *p<0.05 **p<0.001 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS, 
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism; 
AF, Atrial Fibrillation; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker 
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Appendix table 7.  Ischemic stroke and bleeding risk score model  
predictor options and associations with anticoagulant switching 
 
 
 
Warfarin New 
User 
Dabigatran New 
User 
Prevalent User 
Model Option: QIC Risk Score RR (95% CI) RR (95% CI) RR (95% CI) 
1: CHA2DS2-VASc (ref: 0)    
WNU: 19153.8948   1 1.01 (0.87-1.17) 1.07 (0.86-1.31) 1.12 (1.02-1.22)* 
DNU: 10000.1665   ≥2 0.88 (0.76-1.02) 1.35 (1.09-1.66)* 0.91 (0.84-0.99)* 
PU: 71836.1822 ATRIA (ref: 0-3)    
   4 0.95 (0.83-1.08) 0.91 (0.74-1.12) 0.96 (0.90-1.03) 
   ≥5 0.69 (0.61-0.79)** 1.12 (0.94-1.33) 0.82 (0.77-0.87)** 
2: CHA2DS2-VASc (ref: 0)    
WNU: 19215.4250   1 1.00 (0.86-1.16) 1.05 (0.85-1.30) 1.12 (1.03-1.22)* 
DNU: 9984.9208   ≥2 0.86 (0.74-0.99)* 1.32 (1.07-1.62)* 0.90 (0.83-0.98)* 
PU: 71903.7451 HAS-BLED (ref: 0-2)    
   ≥5 0.94 (0.85-1.05) 0.95 (0.82-1.10) 1.00 (0.95-1.05) 
3: CHADS2 (ref: 0)    
WNU: 19156.6780   1 0.92 (0.81-1.04) 1.06 (0.90-1.26) 0.94 (0.89-1.00) 
DNU: 9988.5815    ≥2 0.91 (0.80-1.03) 1.20 (0.99-1.44) 0.83 (0.78-0.88)** 
PU: 71825.2560 ATRIA (ref: 0-3)    
   4 0.95 (0.83-1.08) 0.91 (0.74-1.12) 0.97 (0.91-1.04) 
   ≥5 0.69 (0.61-0.78)** 1.11 (0.93-1.33) 0.83 (0.78-0.88)** 
4: CHADS2 (ref: 0)    
WNU:19220.4114   1 0.91 (0.80-1.02) 1.07 (0.90-1.26) 0.94 (0.88-1.00)* 
DNU:9980.0506   ≥2 0.99 (0.78-1.01) 1.21 (1.01-1.46)* 0.81 (0.76-0.87)** 
PU: 71884.1138 HAS-BLED (ref: 0-2)    
   ≥5 0.94 (0.85-1.03) 0.96 (0.82-1.11) 1.01 (0.96-1.06) 
  *p<0.05 
  **p<0.001 
  NOTE: REF: Non-switching 
  Abbreviations: QIC, Quasilikelihood under the Independence model Criterion; RR, Relative risk, ref, referent group; CI, 
confidence interval; WNU, Warfarin new user; D, Dabigatran new user; P, Prevalent user  
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Appendix table 8.  Sensitivity analyses: Multivariable associations  
between anticoagulant switching and ischemic stroke and bleeding risk scores 
 
 Warfarin New Users Prevalent Users 
 Commercial Medicare Commercial Medicare 
Risk Score 
RR  
(95% CI) 
RR  
(95% CI) 
RR  
(95% CI) 
RR  
(95% CI) 
CHA2DS2-VASc (ref=0)     
  1 1.04 (0.88-1.22) 0.83 (0.68-1.00)* 1.13 (1.03-1.25)* 0.85 (0.78-0.93)** 
  ≥2 1.10 (0.89-1.35) 0.83 (0.69-1.00)* 1.06 (0.93-1.20) 0.76 (0.69-0.82)** 
ATRIA (ref: 0-3)     
  4 0.87 (0.70-1.08) 1.00 (0.86-1.18) 0.78 (0.70-0.90)* 1.03 (0.95-1.11) 
  ≥5 0.51 (0.34-0.78)* 0.72 (0.63-0.83)** 0.81 (0.66-1.00)* 0.86 (0.80-0.91)** 
 Dabigatran New Users   
 Commercial Medicare   
 
RR 
(95% CI) 
RR 
(95% CI) 
  
CHA2DS2-VASc (ref=0)
§
     
  >0 1.09 (0.87-1.36) 1.05 (0.82-1.35)   
ATRIA (ref: 0-3)
§
     
  ≥3 0.75 (0.54-1.06) 1.10 (0.95-1.28)   
  *p<0.05 
  **p<0.001 
  §
Due to small cell size issues (and non-convergence of the original model), the risk score levels were combined and some non-
significant covariates omitted (e.g., prescription benefits generosity, peptic ulcer disease) 
  NOTE: By definition, Medicare supplement beneficiaries are unlikely to have CHA2DS2-VASc=0 (due to age). For these 
patients, CHADS2 was calculated and used in the relative risk estimations; REF: Non-switching 
  Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval 
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Appendix table 9. Propensity score assessments: Testing variables’ crude 
 associations with risk of effectiveness and harm outcomes in new users 
 
 
Exposure 
association 
Outcome association Variable classification 
Baseline Characteristic RR (95% CI) 
Effectiveness 
RR (95% CI) 
Harm 
HR (95% CI) 
X1 X2 X3 None 
Demographic        
Age (ref: <55 years)        
  55-64 years 0.90 (0.87-0.93) 1.05 (0.96-1.14) 1.13 (1.07-1.20)  -   
  65-74 years 0.76 (0.74-0.79) 1.16 (1.07-1.26) 1.27 (1.20-1.34)  -   
  ≥ 75 years 0.59 (0.57-0.61) 1.58 (1.46-1.70) 1.55 (1.48-1.63)  X   
Gender (ref: Female) 1.16 (1.13-1.19) 0.73 (0.70-0.76) 0.86 (0.84-0.88)  X   
Region (ref: Northeast)        
  North Central 0.92 (0.89-0.95) 1.01 (0.95-1.06) 1.04 (1.00-1.08)  -   
  South 1.27 (1.23-1.31) 0.92 (0.87-0.98) 0.95 (0.91-0.98)  -   
  West 0.96 (0.92-0.99) 0.98 (0.92-1.05) 0.89 (0.85-0.93)  X   
Insurance plan (ref: Comprehensive)       
  HMO 0.70 (0.67-0.73) 0.83 (0.78-0.88) 0.87 (0.83-0.90)  -   
  POS 1.25 (1.20-1.32) 0.74 (0.67-0.82) 0.83 (0.78-0.88)  -   
  PPO 1.20 (1.17-1.23) 0.84 (0.80-0.87) 0.81 (0.78-0.83)  -   
  CDHP 1.30 (1.21-1.39) 0.59 (0.49-0.71) 0.70 (0.63-0.78)  X   
Prescription generosity (ref: None/Poor)       
  Fair coverage 8.66 (6.77-11.09) 1.18 (1.04-1.34) 1.30 (1.18-1.43)  -   
  Good coverage 9.69 (7.57-12.40) 1.35 (1.18-1.53) 1.43 (1.31-1.58)  X   
Clinical (ref: 0/None 
unless specified)    
    
Ischemic Stroke 0.72 (0.69-0.76) 6.26 (6.01-6.53) 1.35 (1.30-1.41)  X   
Congestive Heart Failure 0.67 (0.65-0.69) 1.31 (1.26-1.37) 1.67 (1.62-1.72)  X   
VTE 0.26 (0.24-0.28) 7.83 (7.51-8.17) 1.35 (1.29-1.41)  X   
Hyperlipidemia 1.00 (0.98-1.03) 0.99 (0.95-1.03) 0.98 (0.95-1.00)    X 
Hypertension 0.88 (0.86-0.90) 1.35 (1.29-1.42) 1.21 (1.18-1.25)  X   
Myocardial infarction 0.61 (0.56-0.66) 1.40 (1.28-1.52) 1.50 (1.41-1.59)  X   
Coronary artery disease 0.83 (0.80-0.85) 1.14 (1.10-1.19) 1.40 (1.36-1.44)  X   
PVD 0.69 (0.58-0.83) 1.81 (1.71-1.92) 1.56 (1.49-1.63)  X   
Renal impairment 0.53 (0.50-0.56) 1.45 (1.37-1.53) 1.67 (1.61-1.74)  X   
Diabetes  0.84 (0.82-0.86) 1.05 (1.00-1.09) 1.27 (1.23-1.30)  X   
Major bleeding 0.74 (0.71-0.77) 1.69 (1.61-1.78) 1.47 (1.41-1.52)  X   
Anemia 0.59 (0.56-0.61) 1.70 (1.62-1.78) 1.61 (1.56-1.66)  X   
Peptic Ulcer disease 0.69 (0.58-0.83) 1.91 (1.59-2.30) 1.68 (1.46-1.94)  X   
Sleep Apnea 1.11 (1.08-1.15) 0.95 (0.91-1.00) 1.15 (1.10-1.20)   X  
Cognitive deficiency 0.69 (0.59-0.80) 4.15 (3.67-4.68) 1.35 (1.18-1.54)  X   
CCI (ref: 0)        
  1-2 0.82 (0.80-0.84) 1.79 (1.69-1.91) 1.37 (1.32-1.42)  -   
  3-5 0.61 (0.59-0.63) 2.91 (2.74-3.10) 1.99 (1.92-2.07)  -   
  6-8 0.43 (0.40-0.46) 4.11 (3.80-4.45) 2.69 (2.55-2.84)  -   
  ≥ 9 0.42 (0.37-0.47) 5.32 (4.78-5.91) 3.19 (2.94-3.46)  X   
CHA2DS2-VASc (ref: 0)        
  1 0.93 (0.90-0.97) 1.08 (0.96-1.21) 1.09 (1.03-1.17)  -   
  ≥2 0.63 (0.61-0.65) 2.24 (2.03-2.47) 1.67 (1.58-1.77)  X   
 181 
 
ATRIA (ref: 0-3)        
  4 0.73 (0.70-0.76) 1.58 (1.49-1.69) 1.37 (1.31-1.43)  X   
  ≥5 0.49 (0.47-0.51) 1.86 (1.78-1.95) 1.84 (1.79-1.90)  X   
  ≥1 hospitalizations 0.71 (0.69-0.72) 2.89 (2.76-3.02) 1.56 (1.52-1.60)  X   
Catheter ablation 1.68 (1.58-1.79) 0.48 (0.37-0.62) 0.72 (0.63-0.82)  X   
Medication use        
Antiplatelet therapy 0.98 (0.95-1.01) 1.49 (1.42-1.57) 1.50 (1.45-1.55)   X  
Gastroprotective agent 0.88 (0.85-0.91) 1.41 (1.33-1.48) 1.30 (1.25-1.35)   X  
Antiarrhythmic 1.10 (1.07-1.13) 0.88 (0.84-0.92) 1.09 (1.06-1.12)   X  
Digoxin 0.86 (0.83-0.89) 0.95 (0.90-0.99) 1.16 (1.12-1.20)   X  
Beta-blocker 0.99 (0.97-1.02) 1.00 (0.96-1.04) 1.16 (1.13-1.19)   XH XE 
Calcium channel blocker 0.96 (0.94-0.99) 1.04 (1.00-1.08) 1.17 (1.14-1.20)  X   
ACEI/ARB 0.98 (0.96-1.01) 1.00 (0.95-1.03) 1.15 (1.12-1.19)   XH XE 
Statin 0.96 (0.94-0.98) 1.15 (1.10-1.19) 1.11 (1.08-1.14)  X   
Hormone 1.15 (1.09-1.21) 1.05 (0.95-1.16) 1.00 (0.94-1.07) X    
  Abbreviations: HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred provider organization; CDHP, 
consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-enzyme inhibitor; ARB, 
angiotensin receptor blocker; VTE, venous thromboembolism; PVD, Peripheral vascular disease 
  NOTE: E: Effectiveness Outcome; H: Harm Outcome; X1: variable only associated with exposure; X2: variable associated with 
both exposure and outcome; X3: variable associated with only outcome; None: variable associated with neither exposure nor 
outcome 
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Appendix figure 1. Estimated propensity score kernel densities among 
 new users of anticoagulation 
 
A. New Users 
 
 
B. Newly-diagnosed new users 
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C. New Users excluding venous thromboembolism and prescription benefits generosity 
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Appendix table 10. Balance of covariates after applying the stabilized IPTW 
 propensity scores among new users of dabigatran and warfarin 
 
Baseline Characteristic Warfarin, % Dabigatran, % Absolute SD 
Demographic    
Age 
  < 55 years 10.51% 10.07% 1.9 
  55-64 years 25.57% 25.40% 0.5 
  65-74 years 22.55% 23.35% 2.4 
  ≥ 75 years 41.37% 41.18% 0.5 
Male Gender 59.91% 59.18% 1.7 
Region 
  Northeast 16.76% 17.10% 1.2 
  North Central 33.12% 33.11% 0.0 
  South 30.91% 31.43% 1.4 
  West 16.93% 16.92% 0.0 
Insurance plan 
  Comprehensive 34.43% 35.59% 3.0 
  HMO 12.39% 12.02% 1.5 
  POS 4.93% 4.78% 1.0 
  PPO 41.02% 41.49% 1.1 
  CDHP 1.80% 1.92% 1.3 
Benefits generosity 
  No/poor coverage 2.60% 3.13% 4.6 
  Fair coverage 48.00% 48.08% 0.2 
  Good coverage 49.41% 48.79% 1.4 
Clinical    
Ischemic Stroke 9.59% 10.30% 3.2 
Congestive Heart Failure 25.10% 26.69% 4.6 
VTE 9.13% 10.76% 7.6 
Hyperlipidemia 49.57% 49.65% 0.2 
Hypertension 71.82% 72.63% 1.9 
Myocardial infarction 3.86% 3.91% 0.4 
Coronary artery disease 32.32% 32.94% 1.6 
Peripheral vascular 
disease 7.79% 9.12% 6.7 
Renal impairment 10.36% 11.20% 3.7 
Diabetes  30.12% 30.88% 2.1 
Major bleeding 12.26% 13.31% 4.3 
Anemia 16.90% 17.90% 3.5 
Peptic Ulcer disease 0.64% 1.18% 9.5 
Sleep Apnea 10.95% 11.31% 1.5 
Cognitive deficiency 0.86% 0.89% 0.5 
CCI 
  0 26.37% 25.56% 2.3 
  1-2 41.13% 40.36% 1.9 
  3-5 24.49% 25.07% 1.7 
  6-8 5.93% 6.39% 2.7 
  ≥ 9 2.09% 2.62% 5.2 
CHA2DS2-VASc 
  0 8.26% 7.85% 2.0 
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  1 16.96% 16.69% 0.9 
  ≥2 74.78% 75.46% 1.7 
ATRIA 
  0-3 74.32% 73.19% 2.8 
  4 8.72% 8.83% 0.5 
  ≥5 16.96% 17.98% 3.5 
≥1 hospitalizations 53.35% 54.11% 1.7 
Catheter ablation 1.31% 1.31% 0.0 
Medication Use    
Antiplatelet therapy 13.03% 14.05% 4.0 
Gastroprotective agent 12.04% 11.72% 1.3 
Antiarrhythmic 23.68% 23.68% 0.0 
Digoxin 16.09% 16.71% 2.2 
Beta-blocker 67.22% 68.11% 2.1 
Calcium channel blocker 41.81% 42.19% 0.9 
ACEI/ARB 56.88% 57.09% 0.5 
Statin 54.18% 54.29% 0.3 
  Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred 
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin receptor blocker 
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Appendix figure 2. Kaplan-Meier curves of anticoagulant initiators 
 
A. Composite of clinical effectiveness outcomes 
 
 
B. Composite of risk of harm outcomes 
 
 
Dabigatran 
Warfarin 
Dabigatran 
Warfarin 
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C. Acute myocardial infarction outcome 
 
 
 
  
Dabigatran 
Warfarin 
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Appendix figure 3. Estimated treatment effects and 95% confidence  
Interval bounds for deciles of the estimated propensity scores for new users 
 
A. Effectiveness composites 
 
 
 
 
B. Harm composites 
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C. Acute myocardial infarction 
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Appendix Table 11. Estimated treatment effects comparing new users  
of dabigatran to warfarin on risk of outcomes: Inpatient outcomes only 
 
Outcome Type 
Original  
PS-IPTW 
HR (95% CI) 
Inpatient-only 
PS-IPTW  
HR (95% CI) 
Warfarin 
Events/1,000 
person-years 
(Inpatient-only) 
Dabigatran 
Events/1,000 
person-years 
(Inpatient-only) 
Effectiveness     
  Ischemic stroke 0.92 (0.87-0.98)* 0.91 (0.81-1.02) 35.6 17.3 
  TIA 1.07 (0.92-1.25) 1.07 (0.91-1.25) 11.3 9.2 
  VTE 0.51 (0.47-0.54)** 0.70 (0.60-0.80)** 20.4 9.1 
  Composite 0.70 (0.67-0.74)** 0.86 (0.79-0.93)** 48.6 30.2 
Harm     
  Hemorrhagic stroke 0.64 (0.54-0.75)** 0.51 (0.40-0.65)** 8.0 3.3 
  GI hemorrhage 1.19 (1.12-1.26)** 1.11 (1.02-1.22)* 32.1 21.8 
  Other bleeding 0.91 (0.86-0.96)** 0.76 (0.65-0.89)** 14.4 8.1 
  Hospitalization 1.00 (0.97-1.02) 0.99 (0.97-1.02) 343.4 295.8 
  Composite 1.02 (0.99-1.05) 0.99 (0.97-1.02) 343.4 295.8 
AMI 0.88 (0.77-1.00)* 0.88 (0.77-1.00)* 19.1 13.1 
*p<0.05; **p<0.001  
  Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse 
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous 
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction 
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Appendix table 12. Full multivariable survival analysis model results comparing 
dabigatran with warfarin use among new users of anticoagulation 
 
 Effectiveness Composite Harm Composite 
Acute Myocardial 
Infarction 
 HR 95% CI HR 95% CI HR 95% CI 
Dabigatran (ref: Warfarin) 0.62 0.59-0.66** 1.00 0.97-1.03 0.86 0.74-0.99* 
Baseline Demographic Characteristic     
Age (ref: <55 years) 
  55-64  years 
  65-74 years 
  ≥75 years 
 
0.99 
0.84 
0.94 
 
0.91-1.08 
0.77-0.92** 
0.86-1.03 
1.03 
1.01 
1.13 
0.98-1.09 
0.95-1.08 
1.06-1.21** 
 
1.39 
1.42 
1.62 
 
1.00-1.92* 
1.01-2.00* 
1.15-2.29* 
Male Gender (ref: Female) 0.91 0.87-0.95** 0.91 0.89-0.94** 1.00 0.97-1.13 
Region (ref: Northeast)       
  North Central 1.04 0.98-1.10 1.02 0.95-1.03 0.84 0.71-0.99* 
  South 1.01 0.95-1.07 0.99 0.95-1.03 0.83 0.69-0.98* 
  West 1.06 1.00-1.14 0.93 0.89-0.98* 1.02 0.84-1.25 
Insurance plan (ref: 
Comprehensive) 
      
  HMO 0.96 0.90-1.03 0.99 0.95-1.04 0.78 0.63-0.96* 
  POS 0.92 0.83-1.02 0.99 0.93-1.06 0.69 0.49-0.97* 
  PPO 1.02 0.97-1.06 0.93 0.90-0.96** 0.80 0.69-0.93* 
  CDHP 0.81 0.67-0.98* 0.91 0.81-1.01 0.89 0.50-1.56 
Prescription generosity (ref: 
None/Poor)     
  
  Fair coverage 0.95 0.84-1.09 1.07 0.97-1.17 0.68 0.46-1.01 
  Good coverage 1.01 0.89-1.15 1.11 1.01-1.22* 0.72 0.49-1.07 
Baseline Clinical Characteristic (ref: 0/None)     
Ischemic stroke 4.07 3.88-4.27** 1.02 0.97-1.06 0.93 0.76-1.12 
Congestive Heart Failure 0.81 0.77-0.85** 1.21 1.17-1.25** 1.38 1.20-1.59** 
Acute Myocardial infarction 0.87 0.80-0.96* 0.99 0.93-1.06 3.64 3.06-4.32** 
Coronary artery disease 0.89 0.85-0.93** 1.11 1.08-1.15** 1.44 1.25-1.66** 
Hypertension 1.06 1.00-1.12* 1.01 0.97-1.05 1.03 0.88-1.22 
Peripheral vascular disease 0.97 0.81-1.03 1.10 1.05-1.15** 0.96 0.79-1.17 
Diabetes Mellitus 0.80 0.76-0.84** 1.00 0.97-1.03 1.13 0.98-1.31 
VTE 5.82 5.56-6.09** 1.06 1.01-1.11* 0.83 0.68-1.02 
Renal insufficiency 0.90 0.82-0.96* 1.05 1.00-1.11 1.30 1.04-1.63* 
Hyperlipidemia 0.97 0.93-1.01 0.93 0.90-0.95** 0.82 0.72-0.93* 
Anemia 1.07 1.00-1.15 1.16 1.09-1.22** 0.92 0.74-1.14 
Peptic Ulcer disease 1.00 0.83-1.20 1.17 1.01-1.34* 1.13 0.60-2.11 
Sleep Apnea 1.02 0.96-1.09 1.13 1.08-1.18** 1.01 0.83-1.24 
Cognitive deficiency 1.22 1.08-1.38 1.02 0.89-1.17 1.32 0.78-2.26 
Major bleeding 1.05 0.99-1.11 1.18 1.14-1.23** 0.95 0.80-1.15 
CHA2DS2-VASc 
1 
≥2 
 
1.02 
1.25 
 
0.90-1.16 
1.10-1.42** 
 
0.97 
1.01 
 
0.91-1.05 
0.93-1.09 
 
1.40 
1.65 
 
0.85-2.28 
0.99-2.74 
ATRIA 
4 
≥5 
 
1.00 
0.92 
 
0.93-1.08 
0.84-1.01 
 
1.01 
1.06 
 
0.96-1.07 
0.99-1.13 
 
1.04 
1.02 
 
0.82-1.31 
0.77-1.34 
CCI (ref: 0)       
1-2 1.30 1.21-1.40** 1.16 1.11-1.21** 1.25 1.00-1.56 
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3-5 1.62 1.50-1.76** 1.41 1.34-1.48** 1.41 1.08-1.83* 
6-8 2.02 1.81-2.25** 1.59 1.47-1.71** 1.50 1.05-2.12* 
≥ 9 1.87 1.64-2.12** 1.87 1.70-2.05** 1.56 1.00-2.42 
≥1 hospitalizations 1.64 1.56-1.73** 1.18 1.15-1.22** 1.31 1.13-1.53** 
Catheter ablation 0.67 0.53-0.89* 0.80 0.70-0.92* 1.01 0.52-1.95 
Baseline Medication Use (ref: None)     
Antiplatelet therapy 1.05 1.00-1.11 1.16 1.12-2.21** 1.29 1.11-1.51* 
Gastroprotective agent 1.05 0.99-1.11 1.11 1.07-1.15** 1.11 0.94-1.31 
Antiarrhythmic 0.89 0.85-0.94** 1.05 1.01-1.08* 0.90 0.78-1.04 
Digoxin 0.88 0.83-0.93** 1.05 1.02-1.09* 1.05 0.90-1.22 
Beta-blocker 0.94 0.90-0.98* 1.03 1.00-1.06 1.14 0.98-1.33 
Calcium channel blocker 0.91 0.88-0.95** 1.08 1.05-1.11** 0.87 0.76-0.98* 
ACEI/ARB 0.94 0.90-0.98* 1.00 0.97-1.03** 1.08 0.84-1.24 
Statin 1.05 1.00-1.10* 0.96 0.93-0.98* 1.10 0.95-1.26 
  *p<0.05 
  **p<0.001 
  Abbreviations: HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS, 
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism; 
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker 
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Appendix table 13. Stratification by insurance status: Clinical effectiveness 
 and safety of dabigatran compared with warfarin  
 
 Commercially-insured (CCAE) Medicare Supplement (MDCR) 
 
Effectiveness 
Composite 
HR (95% CI) 
Harm Composite 
HR (95% CI) 
Effectiveness 
Composite 
HR (95% CI) 
Harm Composite 
HR (95% CI) 
New Users     
  Unadjusted 0.28 (0.25-0.31)** 0.87 (0.83-0.91)** 0.55 (0.52-0.58)** 0.89 (0.86-0.92)** 
  MV-adjusted 0.46 (0.41-0.50)** 0.99 (0.94-1.04) 0.72 (0.68-0.77)** 1.00 (0.97-1.04) 
  PS-IPTW 0.46 (0.42-0.51)** 0.98 (0.94-1.03) 0.77 (0.73-0.81)** 1.02 (0.98-1.05) 
  PS-SMRW 0.60 (0.53-0.67)** 0.99 (0.93-1.04) 0.81 (0.75-0.87)** 1.00 (0.96-1.05) 
Newly-diagnosed new 
users 
    
  Unadjusted 0.31 (0.27-0.35)** 0.89 (0.83-0.95)** 0.58 (0.54-0.64)** 0.91 (0.86-0.95)** 
  MV-adjusted 0.47 (0.41-0.54)** 1.00 (0.94-1.08) 0.76 (0.70-0.83)** 1.00 (0.95-1.05) 
  PS-IPTW 0.52 (0.46-0.59)** 1.00 (0.94-1.07) 0.72 (0.67-0.79)** 0.99 (0.94-1.04) 
  PS-SMRW 0.61 (0.52-0.71)** 0.99 (0.92-1.06) 0.83 (0.76-0.93)** 1.00 (0.94-1.06) 
  *p<0.05; p<0.001 
  Abbreviations: MV, Multivariable; IPTW, Inverse-probability treatment weighting; 
HR, Hazard Ratio; CI, Confidence interval; SMRW, Standardized Mortality Ratio Weighting 
 
 
 
  
 194 
 
Appendix table 14. Dabigatran strength subgroups: Association between 
 anticoagulation and outcomes compared with warfarin 
 
Outcome Type 
Unadjusted 
HR (95% CI) 
MV Adjusted 
HR (95% CI) 
PS-IPTW 
HR (95% CI) 
Dabigatran 75mg    
  Effectiveness Composite 0.80 (0.71-0.90)** 0.93 (0.82-1.05) 0.96 (0.86-1.08) 
  Harm Composite 1.17 (1.09-1.26)** 1.03 (0.96-1.12) 1.19 (1.10-1.28)** 
Dabigatran 150mg    
  Effectiveness Composite 0.40 (0.38-0.42)** 0.59 (0.56-0.63)** 0.67 (0.64-0.71)** 
  Harm Composite 0.83 (0.80-.0.85)** 0.99 (0.96-1.02) 1.00 (0.97-1.03) 
  *p<0.05; p<0.001 
  Abbreviations: MV, Multivariable; IPTW, Inverse-probability treatment weighting; 
HR, Hazard Ratio; CI, Confidence interval 
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Appendix Table 15. Estimated treatment effects among strata of new user  
AF patients with certain characteristics 
 
Patient Subgroups 
 Effectiveness  
HR (95% CI) 
Harm Outcome 
HR (95% CI) 
Original 0.86 (0.79-0.93)** 0.99 (0.97-1.02) 
Ischemic stroke 0.85 (0.70-1.02) 1.07 (0.97-1.17) 
VTE 0.50 (0.35-0.72)** 1.04 (0.91-1.20) 
CHF 0.88 (0.75-1.03) 0.98 (0.93-1.04) 
AMI 0.95 (0.63-1.43) 1.06 (0.91-1.22) 
ATRIA < 4 0.89 (0.80-0.99)* 1.01 (0.98-1.05) 
ATRIA = 4 0.84 (0.64-1.09) 0.97 (0.88-1.07) 
ATRIA ≥ 5 0.73 (0.60-0.90)* 0.93 (0.86-1.00)* 
CHA2DS2-VASc =1 1.01 (0.77-1.31) 1.00 (0.93-1.08) 
CHA2DS2-VASc ≥2 0.84 (0.77-0.92)** 0.96 (0.93-1.00)* 
Age <55 years 0.94 (0.70-1.26) 0.95 (0.86-1.05) 
Age 55-64 years 0.59 (0.57-0.84)** 1.01 (0.95-1.07) 
Age 65-74 years 0.79 (0.65-0.96)* 1.04 (0.98-1.11) 
Age ≥75 years 0.89 (0.79-1.01) 0.91 (0.87-0.95)** 
Fair prescription generosity 0.85 (0.75-0.96)* 1.02 (0.97-1.06) 
Good prescription generosity 0.91 (0.81-1.02) 0.98 (0.94-1.02) 
*p<0.05; **p<0.001  
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Appendix table 16. Full multivariable survival analysis model results comparing warfarin 
switchers to dabigatran versus warfarin non-switchers 
 
 
Effectiveness 
HR  
(95% CI) 
Harm 
HR  
(95% CI) 
AMI 
HR  
(95% CI) 
Switcher  
(ref: non-switcher) 
0.68 (0.66-0.71)** 0.68 (0.65-0.71)** 0.68 (0.66-0.70)** 
Demographic baseline characteristic  
Age (ref: <55 years) 
 55-64  years 
 65-74 years 
 ≥75 years 
 
1.06  (1.02-1.11)* 
1.01 (0.96-1.06) 
1.04  (0.99-1.09) 
 
1.07 (1.02-1.12)* 
1.01 (0.96-1.07) 
1.03 (0.97-1.08) 
1.06 (1.02-1.10)* 
1.00 (0.95-1.04) 
1.04 (1.00-1.09) 
Male Gender (ref: Female) 0.98 (0.96-1.00) 0.98 (0.95-1.00) 0.99 (0.97-1.01) 
Region (ref: Northeast)    
  North Central 1.03 (1.00-1.06) 1.03 (1.00-1.07) 1.04 (1.01-1.07)* 
  South 0.99 (0.96-1.03) 0.99 (0.96-1.03) 1.00 (0.97-1.03) 
  West 0.99 (0.96-1.02) 0.98 (0.94-1.02) 1.00 (0.97-1.03) 
Insurance plan (ref: 
Comprehensive) 
   
  HMO 1.13 (1.09-1.17)** 1.15 (1.11-1.20)** 1.11 (1.08-1.15)* 
  POS 1.06 (1.01-1.12)* 1.08 (1.02-1.14)* 1.06 (1.01-1.11)* 
  PPO 1.18 (1.15-1.21)** 1.20 (1.16-1.22)** 1.17 (1.14-1.20)** 
  CDHP 1.09 (1.00-1.19)* 1.12 (1.02-1.23)* 1.12 (1.03-1.21)* 
Prescription generosity (ref: 
None/Poor)    
  Fair coverage 0.88 (0.83-0.93)** 0.88 (0.83-0.94)** 0.89 (0.85-0.94)** 
  Good coverage 0.87 (0.82-0.92)** 0.86 (0.81-0.92)** 0.87 (0.83-0.92)** 
Clinical baseline characteristic (ref: 0/None) 
Ischemic stroke 1.00 (0.95-1.05) 1.05 (1.00-1.09)* 1.06 (1.03-1.10)* 
Congestive Heart Failure 1.05 (1.02-1.08)* 1.04 (1.01-1.08)* 1.05 (1.02-1.07)* 
Acute Myocardial infarction 1.04 (0.98-1.10) 1.07 (1.00-1.15)* 1.02 (0.97-1.08) 
Coronary artery disease 0.99 (0.96-1.01) 0.99 (0.97-1.02) 0.98 (0.96-1.01) 
Hypertension 1.08 (1.05-1.11)* 1.09 (1.05-1.12)* 1.08 (1.05-1.11)* 
Peripheral vascular disease 1.03 (0.99-1.07) 1.03 (0.95-1.08) 1.01 (0.97-1.04) 
Diabetes Mellitus 0.97 (0.95-1.00) 0.97 (0.94-1.00) 0.97 (0.95-1.00)* 
VTE 1.03 (0.98-1.07) 1.05 (1.01-1.09)* 1.06 (1.02-1.09)* 
Renal insufficiency 1.01 (0.96-1.06) 0.99 (0.93-1.04) 0.99 (0.95-1.04) 
Hyperlipidemia 1.09 (1.07-1.12)** 1.11 (1.08-1.14)** 1.10 (1.07-1.12)** 
Anemia 1.03 (0.99-1.08) 1.01 (0.96-1.06) 1.03 (0.99-1.07) 
Peptic Ulcer disease 1.00 (0.87-1.15) 1.02 (0.88-1.19) 0.98 (0.88-1.09) 
Sleep Apnea 1.03 (0.99-1.06) 1.01 (0.97-1.05) 1.01 (0.98-1.05) 
Cognitive deficiency 1.23 (1.08-1.41)* 1.26 (1.11-1.42)** 1.20 (1.09-1.33)** 
Major bleeding 1.00 (0.96-1.03) 1.02 (0.98-1.06) 1.00 (0.97-1.03) 
CHA2DS2-VASc 
1 
≥2 
 
0.95 (0.90-1.00)* 
0.94 (0.88-0.99)* 
 
0.95 (0.89-1.00) 
0.94 (0.88-1.01) 
 
0.95 (0.91-1.00) 
0.95 (0.90-1.00) 
ATRIA 
4 
≥5 
 
1.02 (0.97-1.06) 
1.04 (0.98-1.10) 
 
1.05 (1.00-1.11)* 
1.07 (1.00-1.14)* 
 
1.03 (0.99-1.07) 
1.03 (0.98-1.08) 
CCI (ref: 0)    
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1-2 1.06 (1.03-1.09)* 1.04 (1.01-1.08)* 1.05 (1.02-1.07)* 
3-5 1.11 (1.06-1.15)* 1.09 (1.04-1.14)* 1.10 (1.06-1.14)* 
6-8 1.16 (1.08-1.24)** 1.15 (1.06-1.24)* 1.18 (1.12-1.25)** 
≥ 9 1.46 (1.33-1.60)** 1.34 (1.21-1.48)** 1.42 (1.33-1.54)** 
≥1 hospitalizations 1.00 (0.98-1.03) 1.00 (0.97-1.03) 1.01 (0.99-1.03) 
Catheter ablation 0.88 (0.79-0.98)* 0.78 (0.69-0.88)** 0.86 (0.78-0.95)* 
Baseline Medication characteristic (ref: None) 
Antiplatelet therapy 1.00 (0.96-1.04) 1.00 (0.96-1.04) 1.00 (0.97-1.03) 
Gastroprotective agent 1.04 (1.00-1.07)* 1.04 (1.01-1.08)* 1.05 (1.02-1.08)* 
Antiarrhythmic 1.01 (0.99-1.04) 1.02 (1.00-1.06) 1.01 (0.99-1.03) 
Digoxin 0.97 (0.94-0.99)* 0.95 (0.92-0.98)* 0.97 (0.95-1.00)* 
Beta-blocker 1.04 (1.01-1.06)* 1.02 (0.99-1.04) 1.03 (1.01-1.06)* 
Calcium channel blocker 1.02 (1.00-1.04)* 1.03 (1.00-1.06)* 1.02 (1.00-1.04)* 
ACEI/ARB 0.97 (0.95-1.00)* 0.97 (0.95-1.00)* 0.98 (0.96-1.00)* 
Statin 0.99  (0.97-1.01) 0.99 (0.97-1.02) 0.98 (0.96-1.00) 
Hormone 0.98 (0.92-1.04) 0.97 (0.91-1.03) 0.99 (0.94-1.04) 
  *p<0.05 
  **p<0.001 
  Abbreviations: AMI, Acute Myocardial infarction; HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health 
maintenance organization; POS, point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; 
VTE, venous thromboembolism; CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker 
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Appendix table 17. Full multivariable survival analysis model results comparing 
dabigatran patients switching to warfarin versus dabigatran non-switchers 
 
 
Effectiveness 
HR  
(95% CI) 
Harm 
HR  
(95% CI) 
AMI 
HR  
(95% CI) 
Switcher  
(ref: non-switcher) 
1.02 (0.97-1.08) 1.06 (0.97-1.15) 0.99 (0.94-1.04) 
Demographic baseline characteristic  
Age (ref: <55 years) 
 55-64  years 
 65-74 years 
 ≥75 years 
1.04 (0.99-1.09) 
0.94 (0.88-0.99)* 
0.89 (0.83-0.95)* 
 
1.07 (1.01-1.12) 
0.98 (0.91-1.05) 
0.92 (0.86-1.00)* 
 
1.04 (1.00-1.09) 
0.95 (0.90-1.01) 
0.92 (0.86-0.98)* 
Male Gender (ref: Female) 0.96 (0.93-1.00)* 0.96 (0.92-0.99)* 0.96 (0.93-0.99) 
Region (ref: Northeast)    
  North Central 1.05 (1.01-1.10)* 1.05 (1.00-1.11)* 1.06 (1.02-1.10)* 
  South 0.90 (0.87-0.94)* 0.90 (0.86-0.94)* 0.91 (0.88-0.95)* 
  West 0.97 (0.92-1.02) 0.96 (0.90-1.02) 0.97 (0.93-1.02) 
Insurance plan (ref: 
Comprehensive) 
   
  HMO 1.19 (1.12-1.27)** 1.22 (1.14-1.31)** 1.18 (1.11-1.25)** 
  POS 0.98 (0.92-1.05) 0.99 (0.91-1.06) 0.99 (0.93-1.05) 
  PPO 1.07 (1.03-1.11)* 1.09 (1.04-1.13)* 1.07 (1.03-1.11)* 
  CDHP 1.12 (1.01-1.24)* 1.14 (1.01-1.28)* 1.09 (0.99-1.20) 
Prescription generosity (ref: 
None/Poor)    
  Fair coverage 1.07 (0.85-1.36) 1.05 (0.81-1.37) 1.08 (0.84-1.38) 
  Good coverage 1.08 (0.85-1.37) 1.06 (0.81-1.38) 1.08 (0.84-1.39) 
Clinical baseline characteristic (ref: 0/None) 
Ischemic stroke 0.99 (0.92-1.07) 1.01 (0.94-1.08) 1.01 (0.95-1.07) 
Congestive Heart Failure 1.05 (1.00-1.09)* 1.06 (1.01-1.12)* 1.05 (1.01-1.10)* 
Acute Myocardial infarction 1.02 (0.92-1.13) 1.04 (0.92-1.17) 1.01 (0.92-1.12) 
Coronary artery disease 1.01 (0.98-1.05) 1.01 (0.97-1.05) 1.00 (0.97-1.04) 
Hypertension 1.06 (1.02-1.11)* 1.09 (1.03-1.14)* 1.06 (1.02-1.10)* 
Peripheral vascular disease 0.99 (0.92-1.05) 0.96 (0.88-1.04) 1.00 (0.94-1.06) 
Diabetes Mellitus 0.98 (0.94-1.02) 0.97 (0.93-1.02) 0.99 (0.95-1.03) 
VTE 0.88 (0.80-0.97)* 0.89 (0.79-1.00)* 0.93 (0.85-.101) 
Renal insufficiency 0.95 (0.87-1.04) 1.01 (0.90-1.13) 0.97 (0.89-1.05) 
Hyperlipidemia 1.05 (1.02-1.09)* 1.08 (1.04-1.12)* 1.05 (1.02-1.09)* 
Anemia 1.04 (0.96-1.12) 1.04 (0.95-1.14) 1.04 (0.97-1.11) 
Peptic Ulcer disease 0.98 (0.76-1.26) 1.00 (0.79-1.28) 0.99 (0.78-1.23) 
Sleep Apnea 1.03 (0.98-1.07) 1.02 (0.96-1.07) 1.01 (0.97-1.05) 
Cognitive deficiency 1.15 (0.89-1.48) 1.24 (0.98-1.57) 1.18 (0.97-1.43) 
Major bleeding 0.92 (0.87-0.97)* 0.95 (0.89-1.02) 0.92 (0.87-0.97)* 
CHA2DS2-VASc 
1 
≥2 
 
0.99 (0.93-1.05) 
1.00 (0.92-1.08) 
 
0.97 (0.91-1.04) 
0.94 (0.86-1.03) 
 
0.99 (0.92-1.06) 
0.98 (0.90-1.05) 
ATRIA 
4 
≥5 
 
1.00 (0.93-1.08) 
1.09 (0.99-1.20) 
 
0.99 (0.91-1.09) 
1.07 (0.95-1.21) 
 
0.99 (0.92-1.06) 
1.07 (0.97-1.17) 
CCI (ref: 0)    
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1-2 1.02 (0.98-1.06) 1.03 (0.98-1.08) 1.03 (0.99-1.07) 
3-5 1.08 (1.02-1.14)* 1.07 (1.00-1.14) 1.09 (1.03-1.15)* 
6-8 1.14 (1.02-1.28)* 1.14 (1.00-1.30)* 1.14 (1.02-1.26)* 
≥ 9 1.37 (1.18-1.59)** 1.21 (1.02-1.44)* 1.44 (1.26-1.65)** 
≥1 hospitalizations 1.04 (1.01-1.07)* 1.04 (1.00-1.08)* 1.04 (1.01-1.07)* 
Catheter ablation 1.02 (0.93-1.12) 1.21 (1.02-1.44)* 1.03 (0.94-1.13) 
Baseline Medication characteristic (ref: None) 
Antiplatelet therapy 0.89 (0.85-0.94)* 0.89 (0.84-0.94)* 0.90 (0.86-0.94)* 
Gastroprotective agent 1.01 (0.97-1.06) 1.01 (0.95-1.07) 1.01 (0.97-1.06) 
Antiarrhythmic 1.01 (0.98-1.05) 1.00 (0.96-1.04) 1.01 (0.98-1.04) 
Digoxin 0.98 (0.94-1.02) 0.96 (0.91-1.10) 0.97 (0.93-1.01) 
Beta-blocker 1.04 (1.00-1.07)* 1.02 (0.99-1.06) 1.03 (1.00-1.06)* 
Calcium channel blocker 1.01 (0.98-1.05) 1.01 (0.98-1.05) 1.01 (0.98-1.04) 
ACEI/ARB 0.98 (0.95-1.01) 0.98 (0.95-1.02) 0.98 (0.95-1.01) 
Statin 0.95 (0.92-0.99)* 0.94 (0.90-0.97) 0.95 (0.92-0.98)* 
Hormone 0.95 (0.89-1.02) 0.93 (0.86-1.01) 0.95 (0.89-1.02) 
  *p<0.05 
  **p<0.001 
  Abbreviations: AMI, Acute Myocardial infarction; HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health 
maintenance organization; POS, point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; 
VTE, venous thromboembolism; CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker 
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Appendix table 18. Stratification by insurance status: Clinical effectiveness 
 and safety of switching anticoagulants  
 
Outcome Type 
Effectiveness Composite 
HR (95% CI) 
Harm Composite 
HR (95% CI) 
AMI HR (95% CI) 
Commercially-insured (CCAE)  
Warfarin switchers (ref: non-switchers)
 §
  
Unadjusted 0.71 (0.67-0.75)** 0.71 (0.67-0.76)** 0.71 (0.67-0.74)** 
MV-adjusted 0.70 (0.67-0.74)** 0.70 (0.66-0.75)** 0.71 (0.67-0.74)** 
Dabigatran switchers (ref: non-switchers)
 §
 
Unadjusted 1.04 (0.95-1.14) 1.03 (0.90-1.18) 0.99 (0.91-1.07) 
MV-adjusted 1.03 (0.94-1.12) 1.02 (0.90-1.17) 0.97 (0.90-1.06) 
Medicare Supplement (MDCR)  
Warfarin switchers (ref: non-switchers)
 §
  
Unadjusted 0.65 (0.62-0.68)** 0.64 (0.60-0.68)** 0.64 (0.62-0.66)** 
MV-adjusted 0.67 (0.64-0.70)** 0.66 (0.63-0.70)** 0.66 (0.64-0.69)** 
Dabigatran switchers (ref: non-switchers)
 §
  
Unadjusted 1.03 (0.95-1.10) 1.09 (0.98-1.21) 1.01 (0.94-1.07) 
MV-adjusted 1.02 (0.95-1.09) 1.08 (0.97-1.19) 1.00 (0.94-1.07) 
   §
 Warfarin switchers: patients who switched from warfarin to dabigatran; Dabigatran switchers: patients who 
switched from dabigatran to warfarin 
  NOTE: REF: Non-switching 
  *p<0.05; p<0.001 
  Abbreviations: MV, Multivariable; HR, Hazard Ratio; CI, Confidence interval 
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